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ABSTRACT 
Ovarian cancer is the second leading cause of death among women in the gynaecological 
category of cancers. The current post surgery treatment which involves the use of platinum-
based therapy with its attendant adverse drug-resistance often results in the return of the 
cancer. This research work, explored the role of natural products as the major source of new 
drugs by the evaluation of the anti-ovarian cancer activities of three selected medicinal plants 
and the semi-synthesis of analogues of an anti-cancer agent; thymoquinone from Nigella 
sativa. Using a bioassay-guided approach, an investigation of the cell growth inhibition of the 
extracts/fractions of these plants on four human ovarian cancer cell lines, A2780, OVCAR 4, 
OVCAR 8, and CIS-A2780 showed that Acalypha wilkesiana, Margaritaria discoidea and 
Rutidea parviflora had promising anti-ovarian cancer activities. This is the first report of the 
anti-cancer activities of M. discoidea and R. parviflora. The bioactive compounds of the 
plants were isolated by HPLC, identified by mass spectrometry/NMR spectroscopy and 
investigated for cytotoxicity. Gallic acid, (IC50 range of 6.2±0.3 – 26.9±4.1 µM) was the active 
compound in A. wilkesiana. The significantly bioactive compounds of M. discoidea were 
securinine, (IC50 range of 2.7±0.7 – 8.7±0.1 µM), betulinic acid, (IC50 of 16.0±1.9 µM) and 
gallic acid. While palmatine, (IC50 range of 5.5±0.9 – 7.9±0.5 µM) was the major active 
compound in R. parviflora. Twenty-one thymoquinone analogues including eleven semi-
synthetic ones were evaluated for cytotoxicity. A synthetic 2-dimethylamino-5-methyl-1,4-
benzoquinone demonstrated optimum activity (IC50 range of 4.7±0.5 – 11.2±1.9 µM) and 
superior aqueous solubility. Palmatine, securinine and 2-dimethylamino-5-methyl-1,4-
benzoquinone showed induction of apoptosis via increased caspase 3/7 activity. Palmatine 
demonstrated PAPR cleavage by western blot analysis. 2-dimethylamino-5-methyl-1,4-
benzoquinone showed synergy with carboplatin and paclitaxel. These studies have provided 
scientific evidences for the potential treatment of ovarian cancer with these traditional 
medicinal plants and hit compounds for future optimization towards clinical trials. 
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Chapter One  
Introduction 
1.1 Cancer 
Cancer is a health burden of global dimensions as it ranks amongst the deadliest diseases 
and is the leading cause of death in both developed and developing nations today. Cancer-
related deaths claimed 8.2 million lives globally in 2012. The current global estimate of new 
cancer diagnosis made was 14 million in 2012. There is an immense cancer burden 
observed from the cancer statistics report for African, Asian, Central and South American 
populations; where about 70% of the cancer deaths reportedly occurred in these regions 
(Ferlay et al., 2017). 
Cancer could be defined as a disease condition which is characterised by the uncontrollable 
proliferation of cells in any part of the body, leading to the destruction of tissues and organs. 
There are over 200 different types of cancer (UICC, 2017), of which ovarian cancer is the 
second most common gynaecologic cancer among women. Current treatment involves the 
use of radiotherapy, surgery and chemotherapy which usually poses some adverse effects to 
the patient. 
1.2 Ovarian Cancer 
In the England, about 6000 women are diagnosed with ovarian cancer annually with a 
mortality of about 4000 deaths recorded (Trent Cancer Registry, 2012). This cancer is the 
fifth commonest cancer that affects women in the UK. In the United States, it was estimated 
that there would be about 22,000 new cases and 14,000 deaths from ovarian cancer in 2013 
(NCI, Progress Report, 2012).  
Ovarian cancer is the ninth most prevalent cancer in the US, and is classed under the 
gynaecologic cancers where it is the second major cause of death in this category of cancers 
in the UK and US (Siegel et al., 2012).  
2 
 
The symptoms of ovarian cancer include abdominal and pelvic pain, frequent urination, 
abdominal blotting, a feeling of fullness /loss of appetite, swollen abdomen, back ache, 
irregular menstruation and post-menopausal bleedings. This cancer forms in tissues of the 
ovary and there are several types of ovarian cancers, such as ovarian epithelial carcinoma 
and malignant germ cell tumours. The most prevalent of the ovarian cancers is the ovarian 
epithelial carcinoma with a prevalence of about 90% (Jelovac et al., 2011). 
 
Figure 1.1 An Illustration of Ovarian cancer 
The high mortality rate of ovarian cancer is largely due to poor diagnosis because the cancer 
lacks early detectable symptoms and thus there are no screening tests available for the 
cancer. About 70% of cases are not diagnosed until they have reached advanced stages due 
to ovarian cancer’s ability to invade other surrounding tissues such as the bladder, bowel and 
uterus. These cancer- invaded tissues eventually develop new tumours; compounding the 
situation, whilst the cancer is yet undetected, thus making ovarian cancer poorly treatable 
(Jayson et al., 2014). Presently, the standard treatment for ovarian cancer entails surgical 
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cytoreduction aimed at removing most of the cancerous cells, followed by the administration 
of paclitaxel and carboplatin resulting in multiyear survival. However, use of platinum-based 
chemotherapy introduces drug resistance, which could result in ovarian cancer relapse 
leading to the death of the cancer patients (Petty et al., 1998; Xu et al., 2012).  Thus, the 
investigations into the discovery and identification of new drug leads  that may offer 
therapeutic benefits in ovarian cancer therapy is compelling and urgent in the light of the 
ovarian cancer menace.  
1.3 Medicinal Plants-A Proven Source of Cancer Drugs 
The use of plants in the treatment of cancer, is not new, as there are documented evidences 
of the use of medicinal plants by indigenious communities for the treatment of cancer in 
several countries such as Nigeria (Sowemimo et al., 2010), Malaysia and Thailand (Lee et 
al., 2005). Hence, research into medicinal plants has once again aroused global attention 
and significance. 
Historically, Mankind have long benefitted from the efficacy of medicinal plants, even before 
the advent of orthodox medicine. In the indigenous communities, it is still a common practice 
to use decoctions of medicinal plants for the treatment of diseases, which often has offered 
useful leads to the discovery of new drugs. For instance, the medicinal uses of the cinchona 
bark from which quinine was derived were first discovered by the Quechua people of Bolivia 
and Peru, who used the plant in the treatment of fever, before its antimalarial properties was 
validated (Motley et al., 2010). Similarly, Artemisia annua, from which artemisinin, a 
renowned antimalarial drug which has recently been shown to possess anticancer activity, 
has been in use in the traditional Chinese medicines (TCM) for a very long time (Tu1981).  
Numerous drugs have been derived from plants. The discovery of the Vinca alkaloids 
(vinblastine and vincristine) in the 1950s marked the beginning of the search for anti-cancer 
agents from plants (Cragg et al., 2005). This was followed by the epipodophyllotoxin lignans 
(teniposide and etoposide), then the discoveries of paclitaxel and the camptothecins. These 
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four classes of plant derived antineoplastic agents are currently in use for various cancers 
(DeVita et al., 2008). An inventory of the anticancer drugs in use from 1981-2006 showed 
that 47% of the 155 clinically approved oncological drugs were derived from natural products, 
either as unmodified compounds, or semi-synthesised analogues, or synthesised based on 
natural product leads (Cragg et al., 2007). Interestingly it has been observed that secondary 
metabolites from natural products often have diverse structures with a high degree of 
biological suitability than compounds produced from chemical synthesis (Bindseil et al., 
2001; Balunas et al., 2005). This unique quality of natural product-derived compounds have 
immense potentials as leads which could be further optimized by synthesis to obtain more 
potent analogues, which again underscores the importance of natural product as a rich 
source of drug remedies. Semi-synthesis offers several obvious advantages which makes it 
an indispensable tool in the drug discovery and production processes. Typically, the stem 
barks of about 2,000- 3,000 trees were required for the isolation of 1 kg of Taxol (paclitaxel), 
(Runowicz et al., 1993; Suffness et al., 1995). But through semisynthetic methods, comes 
the commercial production, which is geared towards meeting the herculean demand for the 
drug which otherwise would not be met by the natural sources. Paclitaxel is commercially 
produced based on semi-synthesis.  
Another advantage of semi-synthesis is in the optimization of potent drugs. This use of semi-
synthesis has been widely exploited in the development of analogues of a potent drug 
candidate, with a higher degree of potency, such as digitoxigenin, a synthetic analogue of 
digitoxin which has enhanced anticancer activity (Langenhan et al., 2005) and Vinorelbine a 
semi-synthetic analogue of the Vinca alkaloids (Goa et al., 1994).  Also, the employment of 
semi-synthesis has been utilised in overcoming the problem of poor solubility and adverse 
reactions of potent drugs. For example, due to the low solubility and high toxicity of 
Camptothecin, semi-synthethic derivatives such as topotecan and irinotecan, with enhanced 
solubility and far-less toxicity were developed (Oberlies et al., 2004). 
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1.3.1 Natural Products Derived and Platin-derived Drugs Clinically Used in the 
Treatment of Ovarian Cancer 
 
 
1.3.1.1 Camptothecin 
Camptothecin (Figure 1.2) is a cytotoxic compound isolated from the Chinese tree 
Camptotheca acuminate (family; Cornaceae) (Li et al 2005), by Drs’ Monroe E. Wall and 
Mansukh C. Wani of Research Triangle Institute (Wall et al., 1966). The compound exhibited 
significant cytotoxicity against breast, pancreas, lung, stomach and ovarian cancers. The 
drug’s mechanism of action is by the inhibition of DNA relaxation mediated by DNA 
topoisomerase I, through the formation of a complex between DNA and topoisomerase I 
(Thomas et al., 2004). Camptothecin is very hydrophobic, which have led to the semi-
synthesis of some analogues of the drug. Two of these analogues; Hycamtin (topotecan) and 
Camptosar (irinotecan or CPT-11) (Figure 1.2) are clinically used in the treatment of ovarian 
and colon cancers and are marketed by GlaxoSmithKline and Pfizer respectively. The side 
effects of these drugs include severe myelosuppression, diarrhoea and increased 
susceptibility to infections (Oberlies et al., 2004). 
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Figure 1.2 The chemical structures of some natural products derived drugs and platin-derived 
drugs clinically used in the treatment of ovarian cancer. 
1.3.1.2 Paclitaxel 
Paclitaxel (Figure 1.2) was originally discovered from the bark of the pacific yew tree, Taxus 
brevifolia, Nutt.  in 1964 by Drs’ Monroe E. Wall and Mansukh C. Wani of Research Triangle 
Institute (Wani et al., 1971). The use of paclitaxel in the treatment of cancers has been on for 
more than two decades. The mechanism of action of Paclitaxel involves the ability of the 
drug to bind onto beta-tubulin subunits of microtubule, thus stabilizing the microtubule and 
preventing a disassembly, causing defects in mitotic spindle assembly, segregation of 
chromosomes and cell division (Suffness et al., 1995; Lowe et al., 2001). Paclitaxel has been 
approved in the UK for use in the treatment of breast, lung, non-small cell lung and ovarian 
cancers. Paclitaxel is used in the first-line and second-line treatment of ovarian cancer (NICE 
2003). The drug has a number of side effects which have necessitated its use in combination 
with other agents, such as carboplatin which are less toxic. These side effects include: 
shortness of breath, severe exhaustion, unusual bleeding, painful joints and vomiting 
(Ozcelik, et al., 2010). Several derivatives of paclitaxel have been developed. One of which 
is Abraxane; an albumin nano-particle-paclitaxel water-soluble formulation, with less side 
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effects, approved by the FDA in 2005 for the treatment of metastatic breast cancer (Chen et 
al., 2015). Another water soluble conjugate of paclitaxel and poly(L-glutamic acid); Paclitaxel-
poliglumex has been assessed in pre-clinical pharmacokinetic studies and in phase I/II 
clinical trials for ovarian cancer. However the drug showed no significant advantage over the 
use of taxane-based regimen (Galic et al., 2011). 
1.3.1.3 Cisplatin 
Cisplatin is one of the platinum-based drugs used in the treatment of cancers. This synthetic 
agent was the lead compound for the synthesis of other platin-based drugs. The mechanism 
of action (MOA) of cisplatin is by alkylation of the DNA. The drug is very toxic and could 
cause damage to kidneys, and nerves. Other adverse effects of cisplatin include loss of 
hearing, vomiting and bone marrow suppression resulting in anaemia. Cisplatin is used in the 
treatment of several cancers, such as testicular, small cell lung and ovarian cancers. The 
major drawback in the use of cisplatin is the adverse side effects, so it is used mainly in 
conjunction with other chemotherapeutic agents (Loehrer et al., 1984; Milosavlievic et al., 
2010; CNRS 2010).  
1.3.1.4 Carboplatin 
Carboplatin is another platinum-based drug in the treatment of some cancers. The 
compound is also a DNA alkylating agent but unlike cisplatin, carboplatin is less toxic and 
thus has fewer side effects compared with cisplatin. However, carboplatin is less effective 
than cisplatin. The drug is used in the treatment of lungs, ovarian, head and neck cancers. 
Also, as with all platinum drugs, there is the development of platinum resistance which may 
cause the cancer to re-emerge (Stordal et al., 2007; Wheate et al., 2010). 
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1.3.2 Plant natural products in Clinical Trials 
1.3.2.1 The Epipodophyllotoxin Lignans: Etoposide and Teniposide 
The lignans, epipodophyllotoxin and podophyllotoxin (Figure 1.3) were isolated from the 
roots of the poisonous North American May Apple (Mandrake) plant, Podophyllum peltatum 
L. (family: Berberidaceae). The plant is highly toxic when consumed in large quantities but in 
small amounts has been used in folklore medicine for the treatment of a vast array of 
ailments such as typhoid fever, cholera, dysentery, venereal diseases, worm expulsion, 
prostate problems and cancer. The decoction has a strong purgative activity (Ernest et al., 
1999). Podophyllotoxin is available as Podofilox (trade name is Condylox); an extract of the 
plant and is used for the treatment of genital warts (Xu et al., 2009).   Podophyllotoxin’s 
mechanism of action is through the formation of tubulin complex to forestall the production of 
microtubules, (Canel et al., 2000). The glycosidic derivatives; etoposide and teniposide 
possess anti-tumour activities, as topoisomerase II inhibitors. Both drugs are in clinical use 
with etoposide (VP-16) employed in the treatment of non-lymphocytic leukaemia, lymphoma, 
Kaposi sarcoma, Ewing’s sarcoma, testicular and lung cancers (Hande 1998). Teniposide 
(Vumon) is used in the treatment of some brain tumours, Hodgkin’s lymphoma and acute 
lymphocytic leukaemia in children (Jasek 2007).  
Four clinical trials of etoposide in the treatment of ovarian cancer have been conducted. In 
the first study, the drug demonstrated activity in recurrent ovarian cancer previously treated 
with cisplatin, but showed a relatively short response and survival periods (Moosavi et al., 
2004). Another trial observed positive outcomes from an alternating use of 50mg/day dose of 
orally administered etoposide and blotecan (a synthetic derivative of camptothecin) in 
platinum-resistant ovarian cancer patients, (Hwang et al., 2012). Other clinical trials for 
combinations of oral etoposide and irinotecan on recurrent ovarian cancers previously 
treated with platinum and taxane drugs were inconclusive, as one group observed high 
response rate in the combination but with significant un-anticipated haematological toxicity 
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recorded.A second group reported an insignificant moderate response rate in a study of 60 
patients (Gronlund et al., 2005; Matsumoto et al., 2012, 2015). Further clinical trials are 
required to establish the potency and safety of etoposide in ovarian cancer treatment.  
 
Figure 1.3 Phytochemicals and their derivatives currently in clinical trials for the treatment of 
ovarian cancer. 
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1.3.2.2 Vinca Alkaloids Derivatives 
Two vinca alkaloids; vinblastine and vincristine (Figure 1.3) were obtained from Catharanthus 
roseus (L.) G. Don (Family: Apocynaceae), a Chinese plant. The compounds are microtubule 
inhibitors similar to podophyllotoxin (Capasso 2012) and are used as anti-leukaemic agents.  
The overexpression of folate receptor (FR) is exhibited by ovarian cancer cells and has been 
explored as a diagnostic biomarker for the targeting of these cells by the development of a 
derivative of vinblastine; Vincafolide (EC145), which is a folic acid and desacetyvinblastine 
conjugate, (i.e. a FR-targeted vinca alkaloid agent) is being optimised for the treatment of 
epithelial ovarian cancer (Vergote et al., 2015). 
 Additionally, EC20, a radiopharmaceutical was developed for use as a non-invasive 
detection agent for active FR. The combined use of these two agents have demonstrated 
promise in ovarian cancer clinical trials, with vincafolide shown to possess a good safety 
profile in phase I trials. A comparative study involving the combination of vincafolide and 
pegylated liposomal doxorubicin (PLD) against the single use of PLD in a phase II trial of 
participants with platinum-resistant ovarian cancer observed statistically significant outcomes 
in progression-free survival in the drug combination group of participants. The Phase III Trial 
is currently on-going (Graybill et al., 2014). 
1.3.2.3 Combretastatins 
Combretastatins (Figure 1.3) were isolated from the South African bush willow tree, 
Combretum caffrum (Eckl. And Zeyh) Kuntze, (family: Combretaceae), (Petit et al., 1995). 
The compounds are stilbenoid phenols with antitumour activities against leukaemia, colon 
and lungs cancers. Combretastatins inducetumour necrosis by binding to the micro-tubulins 
(Tozer et al., 2002).An analogue, Combretastatin A-4 could be considered the most cytotoxic 
of the isolated combretastatins, (Petit et al., 1995; Ohsumi et al., 1998).  
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A Phase II clinical trial of a combination of combretastatin A4 phosphate, carboplatin and 
paclitaxel in the treatment of patients with platinum-resistant ovarian cancer, showed 
improved responses with an increase in tolerance compared with the administration of the 
chemotherapeutic agents in the absence of combretastatin A4 phosphate (Zweifel et al., 
2011). 
1.3.2.4 Perillyl Alcohol 
Perillyl alcohol (Figure1.3) is a monoterpene derived from lavender, sage, peppermint, 
spearmint, lemon grass, cherries and celery seeds (Belanger et al., 1998; Crowell et al., 
2001). The anti-cancer mechanism of action of perillyl alcohol may involve blocking signal 
transduction by the inhibition of post-translational isoprenylation of small G proteins, (Azzoli 
et al., 2003). A phase II clinical study of the compound  in advanced ovarian cancer patients 
for a duration of six months observed no increase in the time-to-progression of  the disease 
in the patients at a dose of 1200 to 1500mg/m2 (Bailey et al., 2008). The recent development 
in inhalation chemotherapy has been applied in the treatment of recurrent malignant glioma 
with perillyl alcohol and shown to be an effective and safe strategy (CO et al., 2013). There 
are several applications in clinical trials involving malignant brain tumour patients in Brazil 
(Chen et al., 2015). 
1.3.2.5 Phenoxodiol 
Phenoxodiol (Figure1.3) is a derivative of genistein, an isoflavone found in soybean, [Glycine 
max (L.) Merr; Fabaceae]. Recent findings seem to point to an inverse relationship between 
the dietary intake of isoflavones and the occurrence of cancer. Thus, investigations into the 
anti-cancer activities of these compounds have become necessary. Preclinical studies of 
phenoxodiol, indicated cytotoxic activities, with chemotherapeutic potentials in the treatment 
of solid carcinomas such as breast carcinoma, head and neck squamous carcinomas, 
(Constantinou et al., 2002; Aguero et al., 2005) and haematological-related cancers, (Patries 
et al., 2009). 
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The agent was shown to induce apoptosis in ovarian cancer cells and also act as a 
chemosensitizer, for many drugs, such as carboplatin, gemcitabine, paclitaxel, topotecan and 
docetaxel in chemo-resistant ovarian cancer cells, (Alvero et al., 2006). 
Clinical trials of phenoxodiol on cervical, ovarian and prostate cancers have demonstrated 
that the agent is a promising drug candidiate for cancer treatment (Mor et al., 2006; Silasi et 
al., 2009).  Further clinical evaluation of a combination of phenoxodiol and either cisplatin or 
paclitaxel on gynaecological cancers such as cancers of the ovary, fallopian tube and 
primary peritoneal cancer which have developed resistance to cisplatin or paclitaxel showed 
that a combination of phenoxodiol and cisplatin was the most active of the drug 
combinations. However a very recent study observed a lack of activity in the oral 
administration of phenoxodiol in combination with a weekly dose of AUC2-carboplatin in 
platinum-resistant ovarian cancer, (Fotopoulou et al., 2014).Further investigations on the 
drug candidate are relevant (Kelly et al., 2011). 
1.3.3 Natural Products Derived Drugs in Pre-Clinical Trials for the Treatment of 
Ovarian Cancer 
1.3.3.1 Baicalin and Baicalein 
Baicalin and baicalein (the aglycone of baicalin) (Figure 1.4), are flavones isolated from the 
Chinese medicinal plants; Scutellaria baicalensis Georgi (family; Lamiaceae) and 
Scutellariae radix. The anti-inflammatory, anti-cancer and neuroprotective activities of these 
compounds have recently being reported, (Ye et al., 2002). The compounds demonstrated 
cytotoxic activities in vitro on two ovarian cancer cell lines; OVCAR 3 and CP-70, at an IC50 
range of 25-40µM for baicalein and 45-55µM for baicalin, with mild toxicity on normal ovarian 
cancer cells, (Chen et al., 2013). 
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1.3.3.2 Betulinic Acid 
Betulinic acid (Figure 1.4) a lupane-type pentacyclic triterpene was first isolated from the 
white birch, (Betula pubescens), is found in several plants, such as Crossopteryx febrifuga 
(family: Rubiaceae), Diospros Leucomelas (family: Ebenaceae) and Ziziphus mauritiana 
Lam. (family: Rhamnaceae), (Cichewicz et al., 2004; Zhang et al., 2015). Betulinic acid is a 
topoisomerase inhibitor, (Chowdhury et al., 2002).The compound has demonstrated 
cytotoxicity in leukaemia, (Ji et al., 2002) ovarian carcinoma and malignant brain tumour cell 
lines, (Zuco et al., 2002). The anti-cancer activities of betulinic acid has been reported in 
ovarian cancer in vitro, and the compound exhibited significant synergism with 5-fluorouracil 
on ovarian cancer cells, (Ying-Jian et al., 2015). 
 
 
1.3.3.3 Tetrandrine 
Tetrandrine (Figure 1.4) is a bis-benzylisoquinoline-type alkaloid, isolated from the Chinese 
herb, Stephania tetrandra S Moore (family: Menispermaceae). The compound has been 
obtained from other Chinese and Japanese herbs. Tetrandrine, a known calcium channel 
 
Figure 1.4 Some plant-derived natural products in pre-clinical trials. 
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blocker has a broad range of bioactivities, which include anti-inflammatory, anti-allergenic, 
and anti-tumour activities, (Zhang et al., 2009) with the potentials for use in liver cancer 
treatment, (Liu et al., 2011). The in vitro and in vivo studies of combinations of cisplatin and 
tetrandrine on ovarian cancer demonstrated significant increase in cytotoxicity, in both 
studies compared to the single use of the agents (Zhang et al., 2011). 
1.3.3.4 Quercetin 
Quercetin (Figure 1.4) is a naturally occurring flavonoid obtained from vegetables like 
watercress, radish, fennel leaves, dill, red onion and capers. Quercetin has a wide range of 
pharmacological activities, such as anti-inflammatory, anti-allergic and anti-tumour activities. 
The compound’s activity on ovarian cancer cell lines has been documented with the 
compound exhibiting synergism in combination with cisplatin, (Scambia et al., 1990). 
Quercetin has been shown to activate caspase 3 and 9 with the induction of apoptosis on 
A2780 ovarian cancer cell. Also, in xenograft studies of A2780 ovarian cancer tumour, the 
intravenous administration of a nano-formulation of quercetin encapsulated in mono-methoxy 
poly(ethylene glycol)-poly(ƹ-caprolactone) particles demonstrated a significant reduction in 
tumour growth (Gao et al., 2012). Further studies have examined the safety of quercetin and 
shown that the compound is less toxic and potentiates the therapeutic activity of cisplatin and 
paclitaxel in the treatment of ovarian cancer at low doses. The same effect was observed in 
a xenograft mouse model of ovarian cancer, involving the use cisplatin and quercetin (Yang 
et al., 2015). Quercetin’s ability to reverse multi-drug resistance has been demonstrated in in 
vitro experiments (Maciejczyk et al., 2013). 
1.3.3.5 Thymoquinone 
Thymoquinone (TQ, Figure 1. 4), is a promising anticancer agent isolated from the volatile oil 
of Nigella Sativa L. (Family: Ranunculaceae) (El-Dakhakhany 1963; Schneider-Stock et al., 
2014). The compound is a 2, 5-di-substituted benzoquinone and thymoquinone has shown 
activity against numerous cancers, which include leukaemia, osteosarcoma, breast 
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adenocarcinoma, lungs, colorectal, pancreatic, prostate and ovarian cancers (Gali-Muhtasib 
et al., 2006; Woo et al., 2011; Schneider-Stock et al., 2014).The compound has been shown 
to hinder the proliferation of ovarian cancer cells in vitro, with minimal toxicity on normal cells 
(Shoieb et al., 2003). Further studies on the mechanism of action of thymoquinone in breast 
cancer in vitro observed the induction of apoptosis and the activation of caspases 7, 8 and 9 
(Woo et al., 2011).  In a prostate cancer xenograft study, some researchers have reported 
the inhibition of tumour angiogenesis by thymoquinone. Further inhibition of tumour growth 
with minimal toxicity was also reported (Yi et al., 2008). More details about thymoquinone are 
discussed in later sections. 
1.3.4 Recent Plant-Derived Compounds with Activities on Ovarian Cancer Cell 
Lines 
About 200,000 secondary metabolites have been reported in plants. Some of the important 
phytochemical constituents, found in plants, include alkaloids, flavonoids, tannins, terpenes, 
steroids, glycosides, saponins, fatty acids, and quinones. The bio-activities of medicinal 
plants have been linked to the presence of one or more of the various classes of 
phytochemicals. Alkaloids, phenolics and terpenes rank amongst the commonest class of 
biosynthesised compounds (Kinghorn et al., 2011). 
During the time-frame 1981-2010, about 50 anti-cancer drugs have been developed from 
natural products, with 5 drugs approved in 2010: romidepsin from the bacteria 
Chromobacterium violaceum and used in the treatment of T-cell lymphomas and peripheral 
T-cell lymphomas(NCI 2009); cabazitaxel a derivative of paclitaxel used in the treatment of 
prostate cancer [Jevtana (cabazitaxel) Injection](Sanofi-Aventis. 2010); eribulin, a synthetic 
macrocyclic analogue of halichondrin B which was obtained from species of Halichondria- a 
sea sponge and is used in the treatment of breast cancer (Towle et al., 2001; Yu 2005);  
mifamurtide, a synthetic derivative of muramyl dipeptide (MDP), isolated from Mycobacterium 
species used in the treatment of osteosarcoma (Bin et al., 2016); and vinflunine , a derivative 
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of vinca alkaloids used in the treatment of metastatic transitional cell cancer of the urothelial 
tract (Kruczynski et al., 1998). This underscores the importance of natural products as 
sources of new cancer chemotherapeutic (Newman et al., 2012). 
However, no new plant-derived drug has been approved for ovarian cancer. In this review, 
some of the recently plant-derived anti-ovarian cancer compounds from 2001-2014 with IC50≤ 
10µM are presented in Tables 1.1.
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Table 1-1 A list of novel and potent plant natural products against ovarian cancer cells discovered between 2001 and 2014 (the order 
of the compound is arranged according to the year in which they were reported). 
Compound name Structure Plant name (family) IC50 (A2780 
ovarian 
cancer cell 
line) 
Reference 
trihydroxyalkylclohexenones 
 
Pleiogynium timoriense 
(A. DC) Leenh 
(Anacardiaceae) 
0.8, 0.7, and 
0.8µM, 
respectively 
Eaton et al., 
2015a 
securinine 
 
Margaritaria discoidea 
(Baill.) G. L. Webster 
(Euphorbiaceae) 
3.16 µM 
(OVCAR8, 
A2780 and 
A2780cisa 
Johnson-
Ajinwo et 
al., 2015 
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3-β-[O-aG55lpha-L-
rhamnopyranosyl-(1-2)-
αarabionopyranosyl)oxy]-16-
α-hydroxyolean-12-en-28-oic 
acid 
 
Polyscias duplicate 
(Thouars ex Bail.) 
Lowry and G.M. 
Plunkett (Araliaceae) 
2.8µM Eaton et al., 
2015b 
(+)-1.2-dehydrotelobine and 
(+)-2’-norcocsuline 
 
(+)-1.2-dehydrotelobine  
 
(+)-2’-norcocsuline 
 
Anisocycla grandidieri 
Baill. 
(Menispermaceae) 
4.1±0.3µM, 
respectively 
Liu et al., 
2013 
19 
 
bufatrienolidesb 
 
 
 
Urginea depressa 
Baker (Asparagaceae) 
24.1, 11.2, 
111, and 40.6 
nM 
respectively 
Dai et al., 
2013b 
randianin, 2”-O-
acetylrandianin 
 
 
 
Nematostylis 
anthophylla (A. Rich. ex 
DC.) Baill (Rubiaceae) 
1.2, 1.7, and 
2.2 µM, 
respectively 
Dai et al., 
2013a 
20 
 
10-desoxygochnatiolide A 
 
Gochnatia polymorpha 
(Less) Cabr. Ssp. 
Floccose Cabr. 
(Compositae) 
2µM (OVCAR 
3) 
Strapasson, 
R., et al., 
2012 
tavinin A and epi-tavinin A 
 
 
Sterculia taiva Baill. 
(Malvaceae) 
EPI-TAVINI A 
5.5 and 6.7 
µM, 
respectively 
Dai et al., 
2012 
madagascarensilide A and 
madagascrensilide B 
 
 
Leptadenia 
madagascariensis 
Decne. (Apocynaceae) 
0.18 and 0.29 
µM 
respectively 
Pan et al., 
2011a 
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sampangine 
 
 
Ambavia gerrardii 
(Baill.) Le Thomas 
(Annonaceae) 
 
0.58 µM Pan et al., 
2011b 
athrolide D 
 
 
 
Athroisma proteiforme 
(Humbert) Mattf. 
(Compositae) 
0.6 µM Pan et al., 
2011c 
16,18-dihydroxykolavenic 
acid lactone 
 
 
Cyphostemma 
greveana Desc. 
(Vitaceae) 
0.44 µM Cao et al., 
2011 
22 
 
2’-(R)-O-
acetylelaucarubinone 
 
Quassia gabonensis 
Pierre [Syn. 
Odyendyea gabonensis 
(Pierre) Engl.] 
(Simaroubaceae) 
<18 nM 
(MSPC1, 
2774-C10. 
HeyA8 Hoc7) 
Usami et al., 
2010 
terminaliaside A 
 
 
Terminalia tropophylla 
H. Perrier 
(Combretaceae) 
1.2µM Cao et al., 
2010 
cardenolide glycosides 
 
 
Elaeodendron 
alluaudianum H. Perrier 
70nM Hou et al., 
2009 
23 
 
 
isomahubannolide-23 
 
Machilus wangchiana 
Chun (Lauraceae) 
2.66µ Cheng, W., 
et al., 2009 
dodoneasides A and B 
 
 
Dodonaea wiscosa (L.) 
Jacq. (Sapindaceae) 
0.79 and 0.70 
µM, 
respectively 
Cao et al., 
2009 
parthenolide 
 
 
Magnolia kobus DC. 
(Magnoliaceae) 
9.7 µM 
(SK.OV-3) 
Park et al., 
2010 
24 
 
 
xanifolia-Y0  Xanthoceras sorbifolia 
Bunge (Sapindaceae) 
4.2±0.7 µM 
(OVCAR3) 
Chan et al., 
2008 
caseanigrescens A-D 
 
 
Casearia nigrescens 
Tul. (Salicaceae) 
0.83-1-4 µM Williams et 
al., 2007 
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atractyligenin 15 keto and 
atractyligenin 2,15-diketo 
 
 
 
Atractylis gummiferaL. 
(Asteraceae) 
0.3 and 0.2 µM 
(1A9), 
respectively 
Rosselli et 
al., 2007 
boivinide A 
 
 
Roupellina 
(Strophanthus) boivinii 
Baill. (Apocynaceae) 
0.17 µM Karkare et 
al., 2007 
vedelianin, achweinfurthin E 
 
Macaranga alnifolia 
Baker (Euphorbiaceae) 
0.26 and 0.13 
µM, 
respectively 
Yoder et al., 
2007 
26 
 
 
glaucolides M 
 
 
Vernonia pachyclada 
Baker (Compositae) 
3.3µM Williams et 
al., 2005 
lpomoeassin D 
 
Lpomoea squamosal 
Choisy 
(Convolvulaceae) 
35nM Cao et al., 
2005 
Isomundulinol 
 
 
 
Mundulea chapelieri 
(Baill.) Du Puy and 
Labat (Leguminosae) 
1.2µM Cao et al., 
2004 
27 
 
molvizarin 
 
Annonaceous plants 1.2 pM (1A9 
cell) 
Nakanishi et 
al., 2003 
celastrol and pristimerin 
 
Reissantia buchananii 
(Loes.) N. Hallé 
(Celastraceae) 
0.17 and 0.22 
µM (1A9), 
respectively 
Chang et 
al., 2003 
chlorojanerin 
 
Centaurothamnus 
maximus (Forssk.) 
Wagenitz and Dittrich 
(Compositae) 
15 µM (SK-
OV-3) 
Muhammad 
et al., 2003 
cycloviolacin O2 Cyclic peptide Viola odorata L. 
(Violaceae) 
1.32 µM 
(OVCA) 
Lindholm et 
al., 2002 
28 
 
Methyl (10S)-
hydroxypheophorbide a 
 
Clerodendrum 
calamitosum L. 
(Lamiaceae) 
 
0.43 µM (1A9) Cheng et 
al., 2001 
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1.3.5 Some Other Compounds with Anti-cancer Activities 
There are some recently discovered compounds which have shown promise on other 
cancers and have not being investigated on ovarian cancer cell lines. Some of these 
compounds are discussed in this review. 
1.3.5.1 Curcumin 
Curcumin (Figure 1. 5) is a polyphenol isolated from the South Asian plant Curcuma longa L. 
(Zingiberaceae). This plant is also called turmeric and has been shown to possess a host of 
bio-activities such as, anti-inflammatory, anti-microbial, anti-oxidant immunomodulatory and 
anti-tumour effects. Curcumin has been subjected to phase II trial in patients with advanced 
pancreatic cancer at the M.D. Anderson Cancer Centre in Houston, Texas (Dhillon et al., 
2008). Currently, a Phase III Trial of Gemcitabine, Curcumin and celebrex in patients with 
advance or inoperable pancreatic cancer is on-going at the National Cancer Institute (NCI 
Clinical Trials 2013). 
 
 
 
Figure 1.5 Structures of some novel anti-cancer compounds with activities on other 
cancer cell lines. 
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1.3.5.2 Phenylquinolones and Naphthyridinones: NSC-656158 
Three naturally-occurring flavonoids with anti-leukemic activities were isolated from 
Wikstroemia indica. These are tricin (Figure 1.5), kaempferol-3-O-B-D-glucopyranoside and 
the lignin, (+)-nortrachelogenin. Synthetic modifications of 2-phenyl-4-quinolones which are 
structurally linked to the flavonoids had very active anti-mitotic and anti-tumour fluorinated 
quinolones. One of the fluorinated quinolone (NSC-656158) (Figure 1.5), at µM dose 
significantly inhibited hepatocyte growth factor-induced invasion of SK-Hep-1 human 
hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression. An 
analogue of these quinolones derived by the replacement of methylenedioxy with pyrolidine 
ring had the greatest activity with an in vitro tubulin inhibitory IC50 of 0.46 µM (Lee 2010). 
1.3.5.3 Protopanaxadiol 
Protopanaxadiol (Figure 1.4) is derived from the hydrolysis of specific saponins from ginseng 
[Panax ginseng C.A. Mey.; Araliaceae]. The agent’s MOA is by the induction of apoptosis in 
cancer cells through signalling pathways such as caspases 3, 8 and 9 (Saklani et al., 2008; 
Shin et al., 2015). 
1.3.5.4 Schischkinnin and Montamine 
Schischkinnin (Figure 1.5) and montamine are alkaloids isolated from the seeds of 
Centaurea schischkinii and Centaurea Montana, that have demonstrated moderate 
cytotoxicity against human colon cell lines (Shoeb et al., 2005; 2006). 
1.3.5.5 Silvestrol 
Silvestrol (Figure 1.5) is a derivative of a relatively recently discovered class of plants 
secondary metabolites called the rocaglate.  Rocaglamide was the first member to be 
discovered in 1982 (King et al., 1992). Silvestrol was obtained from Aglaia foveolata, Pannell 
(Meliaceae), a tropical plant. The compound’s anti-cancer activity competes favourably with 
that of paclitaxel and Camptothecin (Hwang et al., 2004). Silvestrol also showed β-cell 
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selectivity in both chronic lymphocytic leukaemia in vitro and acute lymphocytic leukaemia in 
in vivo models, (Lucas et al., 2009). Preclinical testing for silvestrol as an anti-leukemic agent 
is on-going (Pan et al., 2012). 
1.4 Literature Survey of the Medicinal Plants Investigated in this 
study 
1.4.1 Acalypha wilkesiana- A Plant with Potential Chemotherapeutic Activities 
Acalypha wilkesiana (AW), a specie of the genus Acalypha, belongs to the Euphorbiaceae 
family. This family is referred to as the ‘spurge family’ as a result of purgative use of these 
plants. Euphorbiaceae comprises of approximately 300 genera with 7500 species. Notable 
genera in the family are Jatropha, Manihot and Acalypha. The family is widely distributed in 
tropical climates; mainly in Indo-Malayan zones, North America, and some parts of Africa. 
Numerous species are found in the other non-tropical regions, which include the South of 
America, South Africa, Mediterranean basin and the Middle East. 
 
Figure 1.6 A picture of AW (Marginata Cultivar), taken at a Bioreserve. 
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Acalypha is the fourth largest genus in Euphorbiaceae family, with about 450-570 species. A 
number of these species have long being used in ethno medicine by Africans and locals of 
Mauritius, Réunion and Rodrigues (Mascarene Islands). Most species of the genus are found 
in America and about 30% in Africa.  
Ethnopharmacological Uses of AW 
AW is used in the treatment and management of various disease conditions, such as 
diabetes mellitus, malaria, hypertension and stomach problems in some indigenous 
communities (Quds et al., 2012). The plant is reputedly useful in the treatment of a wide 
range of skin infections in Nigeria (Oyelami et al., 2003) and the seeds are used for breast 
tumours in the western parts of Nigeria (Bussing et al., 1999). Other uses of the plant include 
the use of the aerial part as an abortifacient in Papua New Guinea (Kumar et al., 2012), the 
leaves for inflammations in Rodrigues, and the treatment of asthma, dysentery and diabetes 
mellitus in Mauritius (Gurib-Fakim et al., 1996). 
Research-Validated Bioactivities 
AW has being investigated for pharmacological activities to validate the traditional uses of 
the plant. There is relatively little research into this area and these are presented in this 
review. A clinical study of the ointment formulation of AW demonstrated significant anti-
fungal activities, with the achievement of a cure rate of 100% for infections of Candida 
intetrigo, Pityriasis versicolor and Tinea pedis (Oyelami et al., 2003).  Similarly, the extracts 
of AW showed significant inhibition of MRSA (methicillin resistantStaphylococcus aureus), 
validating the plant’s anti-bacterial activities (Akinyemi et al., 2005). The anti-malaria, 
analgesic (Udobang et al., 2010), cytotoxic and immunomodulatory activities of AW have 
also being reported (Bussing et al., 1999).  The anti-emetic activity of AW was investigated in 
an in vivo study with chicks (Quds et al., 2012).  
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Phytochemistry of the Plant 
The phytochemical investigations of AW revealed the presence of a broad range of 
compounds, such as anthroquinine, alkaloids, saponin, tannin, and cardiac glycosides 
(Oladunmoye 2006). The isolation of corilagin, gallic  acid and geraniin has been carried out 
in AW, (Adesina et al., 2000). The structures of these isolated compounds are shown in 
Figure 1.6. 
 
Figure 1.7 The chemical structures of three compounds isolated from AW. 
 
1.4.2 Margaritaria discoidea- An unexplored plant for Anti-cancer Activities 
M. discoidea (MD) also referred to as the pheasant berry or the bushveld peacock-berry is an 
average-growing tree, reaching about 30m in height. The plant is native to the tropics and 
sub-tropical climates, where it is often found in forests and near rivers. The stem is usually 
straight with a grey-brown to-red colour and the leaves in alternating positions. The plant is a 
flowering plant, with fragrant male and female flowers borne on separate plants, producing 
three-lobed fruit capsules which are brown in colour (Pooley 1993). 
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Figure 1.8 Pictures of M. discoidea; showing a closer view of the leaves (Left) and M. 
discoidea with a height of about 30m (Right), taken at a bioreserve, Enugu state, 
Nigeria. 
M. discoidea has had a complicated taxonomy, with the plant being formerly placed in the 
Phyllanthus genus which is in the Phyllanthaceae family. The Phyllanthaceae family had 
previously being submerged into the Euphorbiaceae family together with Pandaceae, 
Picrodendraceae and Putranjivaceae families. Presently, these families have now being 
segregated from the larger family - Euphorbiaceae. Phyllanthaceae is rich in diversity with 60 
genera and nearly 2000 species (Samuel et al., 2005). The largest genus of the 
Phyllanthaceae family is Phyllanthus which has 1270 species, and have been the focus of 
intense phytochemical and pharmacological research for decades with numerous 
pharmacologically important compounds isolated from the species (Peter 2001). 
Presently, M. discoidea is a species of the genus Margaritaria, which belongs to the 
Euphorbiaceae family. The plant remains a species in the Phyllanthaceae family. M. 
discoidea is also named Phyllanthus discoideus (the name of the plant while it was place in 
the Phyllanthus genus) (Hoffmann et al., 2005). The plant is has a wide variety of uses, such 
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as medicinal, aphrodisiacs, pesticides and for domestic purposes. Additionally, the tree is 
used for shades in most farmlands. The pictures of MD are shown in Figure 1.8.  
The genus Margaritaria is the smallest genus in the Phyllanthaceae family with thirteen 
species distributed in tropical and sub-tropical countries, such as Congo, Cuba, Ghana, 
Nigeria, India, Mexico, and Zaire. Most of the species in this genus have scanty mention in 
literature and are yet to be evaluated for biological activities. MD is of immense 
ethnopharmacological importance, as the plant has found uses in many indigenous 
communities. The commonly used parts of the plant are the stem bark and the leaves. MD is 
used in the treatment of infections of the skin and wounds in Ghana (Abbiw 1990). In 
Guinean traditional medicine, MD is used in the management of diabetes mellitus (Diallo et 
al., 2012), diarrhoea and stomach problems, worm infections, impotence (Carriere 2000), 
malaria (Traore et al., 2013) and wounds (Basilevskaia 1969). The stem bark is used in the 
treatment of inflammations in Malawi (Irvine 1961), and in Congo the plant is used in the 
treatment of kidney problems and stomach upsets.  Again it is used in pregnancy to aid 
delivery and ease post-partum pains (Adedapo et al., 2009). Some indigenous communities 
in Zaire use the leaves and the roots in the treatment of blennorrhoea. While in some parts of 
West Africa the plant has been used as a purgative (Kerharo et al., 1974). Other uses of MD 
include the use of the dry leaves as a supplementary diet for sheep (Osakwe et al., 
2004).The hard wood of the plant has been employed in furniture-making. Also, the plant’s 
rapid growth and extensive height may be beneficial in agro forestation (Pooley 1993). 
Research-validated Bioactivities 
A few reports about the bioactivities of MD have been documented. The plant has 
demonstrated significant anti-inflammatory activities in two independent studies (Adedapo et 
al., 2009; Dickon et al 2010).  The antibacterial and anti-oxidant activities of MD have been 
reported (Dickson et al., 2010) and the plant shown to exhibit moderate anti-microbial and 
anti-protozoal activities in vitro. An investigation of the anti-HIV activities of MD, observed 
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that the plant had no measurable anti-HIV activities (Diallo et al., 2015). The free-radical 
scavenging activities (Ekuadzi et al., 2013) and the filaricidal activities (Cho-Ngwa et al., 
2010) have also being reported. Additionally, MD possesses acaricidal properties, which 
have been investigated on farm animals (Kaaya et al., 1995). This suggested that MD would 
be a rich source from which novel medicinal compounds might be identified. 
Median lethal dose (LD50) studies of orally administered aqueous extract of MD, in mice 
recorded a lack of acute toxicity in all the doses used. Additionally, the treated mice were in 
stable behavioural conditions post-treatment, a demonstration of the high safety profile of MD 
(Adedapo et al., 2009). 
Phytochemistry of the plant 
Earlier phytochemical studies on MD have reported the presence of alkaloids, triterpenes 
and lignans as the active constituents in the plant. The alkaloids in MD belong to the 
securinega-type of alkaloids characterised by a complex tricyclic back bone with anα, β-
unsaturated-γ-lactone ring. The securinega alkaloids are divided into two classes.  The first 
class is the securinane class, which derive their names from securinine and possess an 
indolizidine skeleton. The second class is the norsecurinane class with their parent name as 
norsecurinine and contains a pyrrolizidine skeleton (Snieckus 1975; Weinreb 2009).  
The presence of eleven alkaloids has been established in the leaves of MD. These alkaloids 
are allo-securinine, 14, 15-dihydroallo-securinine-15-β-ol, dihydrosecurinine, norsecurinine, 
phyllabine, phyllocristine, phyllanthine, phyllanthidine, phyllantidine, securinine and viro-allo-
securinine (Mensah et al., 1988; Calixto et al., 1998). Most of these alkaloids correspond to 
the securinega-type of alkaloids. Securinine is the first of the securinega alkaloids isolated 
from a Phyllanthus species, some fifty years ago (Quevauviller et al., 1959). 
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The presence of a triterpene, betulinic acid and a lignan-phyllanthin has been reported in the 
aerial part of the plant (Calixto et al., 1998). The rootbark of MD has also been investigated 
for the presence of secondary metabolites. Five alkaloids, namely, allo-securinine, (Janot et 
al., 1958; Parello et al., 1963a; Bevan et al., 1964a; Rich 1973), phyllalbine, (Parello et al., 
1963b), phyllanthidine, phyllanthine (Parello et al., 1965; Parello 1968; Horii et al.,1972) and 
securinine (Parello et al. 1963a; Parello 1966; Bevan et al., 1964b) were contained in the 
root bark. The Nigerian species of MD have been phytochemically investigated. Securinine 
has been documented as the major alkaloid present in these species. The presence of a 
small amount of allosecurinine was detected. A comparison of the amount of securinine 
obtained from the leaves, stembark and rootbark of the Nigerian species of MD, showed that 
the leaves had 0.06% securinine, the stembark had 0.2% securinine and rootbark had 0.4% 
securinine (Oliver-Bever 1986). Recently a flavonoid glycoside with significant anti-bacterial 
and free-radical scavenging activities has been isolated from MD (Ekuadzi et al., 2013). 
 
Figure 1.9 Some securinega alkaloids and a lignan found in MD. 
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1.4.3 Rutidea Parviflora- An un-researched Plant with Potentials for Cancer 
Treatment 
Rutideaparviflora D.C. (RP) belongs to the genus Rutidea in the Rubiaceae family.  
Rubiaceae referred to as the coffee family or bedstraw family is the fourth largest family of 
the angiosperms. Rubiaceae has 611 genera and approximately 13500 species distributed in 
different regions of the world, but with greater diversity in the sub-tropical areas. Two 
important genera of this family are Cinchona L., from which the drug quinine used in the 
treatment of malaria was derived and Coffea L., which have provided the world with the most 
consumed beverage-coffee. Other genera are Rubia, a collection of dye plants used for 
decorative purposes, Pavetta L., Uncaria schreb, Tarenna Gaertn, Oldenlandia L., and 
Galium L. (Angiosperm Phylogeny). 
 
Figure 1.10 A picture of Rutidea parviflora taken in a Bioreserve, with an arrow 
indicating the plant. 
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Ethnopharmacological Uses of RP 
The plant has a variety of medicinal uses. The sap is used in the treatment of eye infections. 
The fruits are taken to induce vomiting and for the treatment of convulsions, epilepsy, spasm 
and paralysis (http://plants.jstor.org). 
Research-Validated Bioactivities 
Presently, there is no report evaluating the pharmacological activity of RP. Thus there is a 
dire need for scientific investigations of the potential pharmacological activities of this plant to 
be carried out.  
Phytochemistry of the Plant 
A phytochemical study of RP has not been reported so far. Also the phytochemistry of other 
species in the genus has not been investigated. Recently, the in vitro anti-ovarian cancer 
activities of Tarenna grevei (Drake) Homolle (Rubiaceae), obtained from Madagascar, on 
A2780 cell line was reported (Kingston et al., 2012). Further investigation of the ethanol 
extract of the fruit and leaves led to the isolation of two novel antiproliferative saponins; 23-
hydroxylongispinogenin 3-ᴑ-β-D-glucpyranoside and longispinogenin 3-ᴑ-β-D-glucopyranosyl 
(1→2)-β-D-glucopyranoside with moderate activities. 
1.5 Thymoquinone - A Potential Anticancer Lead 
Nigella sativa, a plant in the Ranunculaceae family is a popular Mediterranean herb. The 
genus Nigella is encomprised of about 14 species among which are N. hispanica, N. 
integrifolia, N. orientalis, N. damascene, N. arvensis and N. cilliaris (Aggarwal et al., 2008).   
N. sativa is the most important specie of the Nigella genus and has been employed by many 
indigenous communities for the treatment of various diseases such as diabetes, 
hypertension, fever, arthritis, inflammation, gastrointestinal disturbances, and cancer, 
(Padhye et al., 2008). The plant has a rich historical significance, which have paved the way 
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for scientific investigations into the pharmacological activities of the herb. Nigella sativa is 
popularly referred to as black cumin seeds (Figure 1.11) and kalonji seeds. The black seed 
oil (Figure 1.11) is well-known for its medicinal use and thus is a commercially available 
phytopharmaceutical product majorly used in the Mediterranean and other parts of the world 
including Europe. The most bioactive compound contained in the black cumin seed oil was 
found to be thymoquinone. 
 
Figure 1.11 The Seeds and oil of Nigella Sativa 
Thymoquinone (TQ), a promising anti-cancer agent is one of the compounds isolated from 
the volatile oil of Nigella Sativa (NS), in 1963 (El-Dakhakhny 1963), alongside two other 
compounds: thymol (THY), and dithymoquinone (DTQ) (Figure 1.12). It was discovered that 
the compound is a 2, 5-di-substituted benzoquinone. 
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Figure 1.12 Structures of dithymoquinone, thymohydrodquinone, and thymoquinones of 
Nigella sativa. 
Several investigations have shown that TQ inhibits the proliferation of a wide range of 
cancers such as breast adenocarcinoma, colorectal cancer, leukaemia, lung cancer, 
pancreatic cancer, prostate cancer and osteosarcoma  (El-Mahdy et al., 2005; Rooney et al., 
2005; Richards et al., 2006; Kaseb et al., 2007; Roepke et al., 2007;Alhosin et al., 2010; Jafri 
et al., 2010; Koka et al., 2010; Effenderger-Neidnicht et al., 2011; El-najjair  et al., 2011;  
Woo et al. 2011). Studies on the mechanism of action showed that the agent exhibited 
antiproliferative activities, a reduction in cell viability and inhibition of DNA synthesis in 
prostate cancer cells while non-cancerous cells were apparently unaffected (Kaseb et al., 
2007).  
A 2009 study by Kimmel Cancer Centre in Philadelphia, Pennsylvania showed that TQ is 
both an antiproliferative and a chemopreventive agent. The study observed that TQ exerted 
significant cytotoxicity on pancreatic cancer cells, and also prevented the occurrence of this 
cancer, by increasing DNA acetylation which induces epigenetic changes in the cells (kimmel 
Cancer Centre 2009).The implication of this finding is that TQ could be exploited in 
chemoprevention. 
Toxicity of TQ  
Studies on the LD50 of TQ in mice and rats showed that the compound is relatively safe as 
reported from the intraperitoneal and oral administration of more than 15 and 150 times the 
doses investigated for in vivo antioxidant, anticancer and antiinflammation activities by 
intraperitoneal and oral routes respectively. The researchers reported that upon 
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intraperitoneal administration of TQ to mice and rats, LD50 was determined to be 104.7mg/kg 
(95% CL) and 57.5mg/kg (95% CL) respectively. The LD50 for oral administration was 
870.9mg/kg (95% CL) and 794.3mg/kg (95% CL), respectively (Al-Ali et al., 2008).Also, a 
phase I study conducted on 21 cancer patients recorded no toxicities for doses of TQ ranging 
from 75 mg/day to 2600 mg/day (Al-Amri et al., 2009).  
 
Combinational Uses of TQ and Other Drugs 
TQ has been found useful in ameliorating the adverse effects of other anti-cancer drugs from 
a number of studies on various combinational anti-cancer therapies. 
Thymoquinone and Cisplatin Combinational Therapy 
A combination of 100 µMTQ and 5µM Cisplatin (the most active chemotherapeutic agent in 
lung cancer), was employed in a drug combination study for non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC), in vitro. The researchers observed significant 
synergism in the combination of both drugs, than in either TQ or cisplatin on cell proliferation. 
Furtherxenograph study was conducted by use of a mouse model.  Reduction of tumour 
volume was reported from a combination of 20mg/kg TQ and 2.5mg/kg of cisplatin, which 
was significant in comparison to the effects of the agents singly and minimal toxicity was 
observed (Jafri et al., 2010). 
TQ and Doxorubicin Combinational Therapy 
Doxorubicin is one of the main cancer drugs with observed cardiotoxicity and a high 
incidence of multi-drug resistance. A recent study showed that an equimolar mixture of TQ 
and doxorubicin boosted the anticancer effect of doxorubicin in certain cancer lines. Also, 
cardiotoxicity and multi-drug resistance were greatly reduced by combination with TQ 
(Effenberger-Neidnicht et al., 2011). 
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TQ and Gentamicin Combinational therapy 
An in vivo investigation into the chemoprotective effect of TQ when co-administered with 
gentamicinin rats showed that the compound ameliorated the nephrotoxicity of gentamicin, 
with minimal changes observed in the kidney tissues of the rats (Sayed-Ahmed et al, 2007). 
Furthermore, the compound has demonstrated synergistic effect with cisplatin and oxaliplatin 
in ovarian cancer cells (Nessa 2011; Huq 2014; Wilson 2015). 
1.6 Research Design 
This research work on ‘Identification, Semi-synthesis and Evaluation of Anti-Ovarian cancer 
Compounds from Plants used in Traditional Medicines’ was undertaken to identify novel 
therapeutics to treat ovarian cancer by investigation of three selected plants for in vitro anti-
ovarian cancer activities and the semisynthesis of more potent analogues of thymoquinone; 
an anti-cancer compound from Nigella sativa. The selected plants were chosen based on the 
researcher’s observation of the use of these plants in the treatment of cancer by some 
indigenous communities in Nigeria. This curiosity was further aided by the existing 
ethnopharmacological data on the uses of these plants for other disease conditions, except 
for A. wilkesiana, which had documented use in the treatment of cancer. Additionally, the 
scarcity of research-validated bioactivities (importantly anti-cancer activities) of the plants 
was also a reason for the selection of these medicinal plants. In this research work, two 
approaches were explored in the search for anti-ovarian cancer compounds.  
Firstly, the selected medicinal plants; Acalypha wilkesiana Müll. Arg. (AW), Margaritaria 
discoidea (Baill.) G. L. Webster (MD) also called Phyllanthus discoideus and 
Rutideaparviflora D.C. (RP) were screened for cell growth inhibitory activities on the ovarian 
cancer cell lines. Further bioassay-guided fractionation and isolation of anti-ovarian cancer 
compounds from the medicinal plants were conducted. The active compounds from the most 
active extracts were isolated and identified by both gas and liquid chromatography mass 
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spectrometry (GC-MS, LC-MS) and additionally by nuclear magnetic resonance (NMR) 
spectroscopy.  
Secondly, semi-synthesis of eleven analogues of thymoquinone (TQ) was undertaken. Ten 
additional analogues were procured to enable the development of a SAR for the anti-ovarian 
cancer activities for TQ. These analogues were evaluated for cell growth inhibition on the 
ovarian cancer cell lines. Although a lot of studies on thymoquinone have been undertaken, 
there has been fewer studies on the synthesis of more potent analogues of TQ with anti-
cancer activites despite the compound’s in vitro and in vivo anti-cancer activities and good 
safety profile (Al-Ali et al., 2008; Al-Amri et al., 2009; Schneider-Stock et al. 2014). 
Additionally, thymoquinone, an anti-cancer agent is a small molecule with a molecular mass 
of 164, which makes it suitable as a lead compound for further modification (Schneider-Stock 
et al. 2014). Thus, there is a dire need for this unique compound with numerous bioactivities 
to be explored more closely, by semi-synthesis to obtain more potent analogues in order to 
harness the compound’s vital benefits in the treatment of cancer. 
The significantly active compounds obtained from the investigated medicinal plants and the 
most potent synthetic TQ analogue would be jointly administered with clinically used drugs in 
drug combination experiments. This is due to the increased clinical use of a combination of 
antineoplastic agents employed in the treatment of many cancers. The main benefits in this 
approach have been the need to increase the theraupectic effect, with an expected reduction 
in the side effects and the administered dose. Also, the prevention or minimization of the 
development of resistance is another therapeutic benefit offered by this approach (Chou 
2006).  A key factor in drug combination is the determination of synergy, which could 
potentially be explored in further studies. Synergy may not be predicated on the mechanism 
of action of the agents in the drug combination, as the MOA of many clinically used drugs, 
such as aspirin have not been clearly elucidated. Again most drugs tend to possess several 
mechanisms which would be difficult to investigate (Chou 2010). The current therapy for 
ovarian cancer involves a combination of paclitaxel and carboplatin, which have different 
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MOA, but have produced beneficial synergism in clinical outcome. Hence, investigations of 
the potential synergy of bioactive compounds with clinically used drugs by in vitro drug 
combination studies are worthwhile even though the MOA of these compounds are yet to be 
elucidated. Such studies hold promise in the early detection of the potential benefits of these 
compounds, which may spur further investigations. 
The bioactive compounds from this research were investigated for potential synergy with 
carboplatin firstly. Further investigation of the combination of these compounds with 
paclitaxel were carried out, when significant synergy was demonstrated in the combination 
with carboplatin. 
1.7 Aims and Objectives 
The main aim of this research is to characterize the anti-ovarian cancer activity and to 
identify the bioactive compounds of the three medicinal plants through bioassay-guided 
isolation, and to search better analogues of anti-cancer thymoquinone from Nigella sativa.  
In the achievement of the aims of this research, three research questions were generated to 
assist the research. 
The research questions were: 
Could new compounds with potentials for the treatment of ovarian cancer be obtained from 
medicinal plants? 
Could new compounds with potentials for the treatment of ovarian cancer be obtained semi-
synthetically? 
Could the Stable Isotope Dilution Gas Chromatography Mass Spectrometry method of 
quantification be developed for the quantification of Thymoquinone in Botanicals? 
The following hypotheses were tested in this research: 
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a) These bioactive compounds would have single agent growth inhibition in a 
concentration-dependent manner 
b) The growth inhibition activities of these agents would be due to apoptosis  
c) Some of these agents may sensitize ovarian cancer cells to carboplatin or paclitaxel 
potentially. 
The following objectives would be achieved in this research work:  
(i) To investigate the in vitro anti-cancer activities of the selected medicinal plants 
(ii) To obtain the bioactive fractions of the plant with optimum activity 
(iii) To isolate the pure compounds with anti-cancer activities 
(iv) To characterize the structure of the compounds using GC-MS, NMR and LC- 
 MS 
(v) To determine the selectivity index of these bioactive compounds 
(vi) To investigate the route of cancer cell death exhibited by the potent bioactive  
 Compounds 
(vii) To investigate the synergistic potentials of these potent bioactive compounds with 
carboplatin firstly and with paclitaxel where significant synergy is demonstrated in the 
combination with carboplatin 
(viii) To synthesise analogues of TQ with improved anti-cancer activities and obtain a SAR 
for the anti-ovarian cancer activity of TQ 
(ix) To develop a stable isotope dilution method for the quantification of thymoquinone in 
commercially available Nigella sativa oils 
(x) To investigate the cytotoxicity of some Gallic acid derivatives on human ovarian 
cancer cell lines 
To  test the hypotheses, the cell growth inhibition activities of the plants extracts, obtained 
fractions and the bioactive compounds were evaluated on the ovarian cancer cell lines. 
Similarly, the determination of the Selectivity index (SI) was by comparison of the obtained 
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IC50s of the bioactive compounds on the cancer cell lines with the IC50s of the respective 
compounds on a normal ovarian epithelial cell line in the cell growth assay. Two cell growth 
assays were employed; the Sulfordamine B (SRB) assay, (for determination of cell growth 
inhibition) and Trypan blue assay (TBA), for the determination of cell viability. Apoptosis 
studies were carried out by the evaluation of the Caspase3/7 activity of the bioactive 
compounds. Further investigations by Flow cytometry analysis of Annexin V/Propidium iodide 
labelling of cells pre-treated with these compounds respectively were undertaken. Western 
blot Immunochemistry assay was carried out where additional investigation was required. 
The synergistic potentials of the compounds were investigated by drug combination studies 
of the agents in combination with carboplatin firstly, then with paclitaxel, when significant 
synergism is demonstrated with carboplatin in the SRB and caspase 3/7 assays. 
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Chapter Two  
General Materials and Methods 
2.1 Materials 
2.1.1 Reagents 
Ethyl acetate, methanol, n-hexane, n-butanol, and dichloromethane were purchased from 
Fischer Scientific, UK. N,O-Bis(trimethylsily) trifluoroacetamide (BSTFA) and pyridine were 
purchased from Sigma Aldrich. 
2.1.2 Plant Materials 
The following plants: Acalypha wilkesiana (Leaves), Margaritaria discoidea (Stem bark), and 
Rutidea parviflora (stem bark) were sourced from a bio reserve in Nigeria. The plants were 
authenticated by a botanist, Mr Alfred O. Ozioko (INTERCEDD) with expert advice offered by 
Prof. J. F. Bamidele of the Department of Plant Biology and Biotechnology, University of 
Benin, Nigeria. The voucher specimen numbers of the plants were: 
Acalypha wilkesiana      INTERCEDD/1571 
Margaritaria discoidea   INTERCEDD/1579 
Rutideaparviflora           INTERCEDD/1588 
The voucher specimens were deposited at the International Centre for Ethno medicine and 
Drug Development (INTERCEDD), Nsukka, Nigeria. 
The plants materials were dried under a shade at 25°C for 7-10 days before pulverization. 
2.1.3 Cancer assay materials 
Roswell Park Memorial Institute (RPMI)  1640  Media, L-gluthamine, 10% fetal bovine serum 
(FBS), PENSTREP (50 µg/ml penicillin/streptomycin), and phosphate buffered saline (PBS) 
were purchased from Lonza; trypsin-EDTA solution, trizma base, sulfordamine B sodium salt, 
glacial acetic acid (GAA), dimethyl sulfoxide (DMSO), trypan blue, carboplatin, and paclitaxel 
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were purchased from Sigma Aldrich; trichloroacetic acid (TCA)  was purchased from Fischer 
Scientific, UK and Caspase-Glo 3/7 assay kit from Promega, UK.                                             
Other requirements include: NAPCO water jacketed incubator (Precision Scientific), Grant JB 
Series water bath (Grant Instruments), Neubauer haemocytometer, Thermo Scientific 
Heraeus Megafuge 8 Centrifuge, Olympus CKX41 light microscope, BioTek Synergy 2 multi-
mode microplate reader, Nuaire -86°C Ultralow freezer, pipettes, pipette gun, Industrial 
Methylated Spirit (IMS), Test-tubes, T-25 tissue culture Flasks, T-75 tissue culture flasks, 
multi-channel pipette, biological safety cabinet, 15 ml and 50 ml polypropylene tubes 
(Sarstedt), 6-wells, 12-wells and 96-wells plates (Sarstedt), 2 ml cryovials (Triple Red), “Mr 
Frosty” freezing container (Nalgene), liquid nitrogen storage tanks. 
2.1.4 The ovarian cancer cell lines 
The cell lines were ordered from America Tissue Culture Collection (ATCC). The cell lines 
A2780 was obtained from the ovarian carcinoma of a patient about to commence 
chemotherapy treatment (Eva et al., 1982).  CIS-A2780 was derived by the exposure of 
A2780 cells to graded doses of cisplatin to render the cells cisplatin-resistant (Godwin et al., 
1992).  
The OVCAR 4 and OVCAR 8 cell lines were derived from human carcinoma of patients that 
were resistant to cisplatin and carboplatin, respectively (Hamilton et al., 1984).  
2.1.5 The Human Ovarian Epithelial (HOE) Cell Line 
HOE was ordered from Applied Biological Materials (ABM) Inc, Canada. The cells were from 
normal ovarian epithelium. The selectivity indexes of the drugs were investigated using HOE.  
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2.2 Methods 
2.2.1 Cell Growth Conditions 
The ovarian cancer cell lines and the HOE were grown in a growth medium of RPMI 1640 
supplemented with 10%  fetal bovine serum (FBS), 2 mM glutamine and 50 µg/ml 
penicillin/streptomycin (Pen strep). The CIS-A2780 cells were exposed to 1 µM cisplatin for 7 
days every month to maintain chemo-resistant properties of the cells.  The cell cultures were 
kept in the incubator at 37oC under 5% CO2 for 24h in a humidified atmosphere. 
2.2.2 Resuscitation of cryopreserved cells 
The preserved cells were collected from the liquid nitrogen storage tanks and thawed quickly 
in a water bath at 37oC. Upon thawing, the cells were slowly added to 5 ml of media (pre-
warmed in the water bath at 37oC) in a 15 ml polypropylene tube. The cells were centrifuged 
at RT at a speed of 150g for 3 min, followed by removal of the media. The cell pellet was re-
suspended in 8ml of growth media and transferred into a T25 tissue culture flask and kept in 
the incubator at a temperature of 37ᴑC, for 24h. The growth media was changed to ensure 
the elimination of residual DMSO and dead cells and to enable the adherent live cells 
multiply to an appropriate number for experiments. 
2.2.3 Trypsinization of Cells 
Trypsinization was routinely carried out, when the cells were about 90% confluent as 
observed from a microscopic examination. The media was removed and the cells washed 
with 1 ml of phosphate buffered saline, PBS before exposure to 1ml of 0.01% trypsin in PBS 
to detach the cells. To facilitate detachment of cells, the T25 culture flask containing the cells 
was maintained at 37oC in the incubator for 10 min, followed by gentle agitation of the flask. 
Once the cells were detached, the trypsin was neutralized by the addition of 1ml of growth 
media, and transferred into a 15 ml polypropylene tube for centrifugation at RT at a speed of 
150g for 3 min. The media was gently aspirated and the cell pellet re-suspended in fresh 
growth media and transferred into T25 or T75 tissue culture flask as required for incubation. 
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Cells for experimentation were counted using the haemocytometer, to determine the number 
of cells, which was used in calculating the required volume of media and cell density required 
for each experiment. 
2.2.4 Cryopreservation of Cells 
Cryopreservation was carried out to preserve cells for further experiments without allowing 
the cells undergo much passage which could result in changes in their morphology and thus 
affect the results of the experiments. Typically, cells of passage <20 were cultured in T75 
tissue culture flask to ensure 50% confluence.  The cells were trypsinized, centrifuged and 
re-suspended in a 2 ml growth medium made of 1.8 ml of 10% FBS and 10% DMSO (0.2 
ml). Aliquots of 0.5 ml were transferred into 2 ml cryovials and kept in a Mr Frosty freezing 
container (Nalgene), containing 200 ml isopropanol. The container was stored at -80oC for 
24h in a Nuaire -86oC ultralow freezer before transfer into compartments in a liquid nitrogen 
tank for lasting storage until when required for experiments. 
2.3 Cell Growth Assay 
Two cell growth assays were carried out; the Sulfordamine B (SRB) assay to determine 
inhibition of cell proliferation and the Trypan Blue Assay (TBA) to determine whether the 
effect in the cell growth assays reflected inhibition of proliferation or cell death. 
The SRB protocol was used in the cancer assay of the plant extracts and the semi-
synthesised compounds. This assay is one of the widely used assays for the determination 
of in vitro cytotoxicity and is also the method adopted by the American National Cancer 
Institute, NCI (Rubinstein et al., 1990; Monks et al., 1991; Boyd 1995; Vanicha et al., 2006). 
The SRB assay was utilised for the evaluation of cell growth inhibition in the cell growth 
assays. OVCAR 4, OVCAR 8, A2780, CIS-A2780 and HOE were grown in RPMI, 
supplemented with 10% FBS, L-glutamine (2 mM) and penicillin-streptomycin (50 U/ml). 
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100 mg/ml concentrations of the plant extracts were prepared using 100% DMSO (organic 
extracts) and media (aqueous extracts) as stock solutions. 20 mM of thymoquinone and its 
analogues were prepared in 100% DMSO and used in the assay. Paclitaxel and carboplatin 
(the positive controls) in 100% DMSO were employed in the assays. The 0.1% DMSO in 
growth media was added to the cells; referred to as vehicle-treated cells (control). Nine 
concentrations of the drugs were prepared by using a two-fold serial dilution.   
In the SRB assay, each well of the 96-well plates were seeded with 80µl of the ovarian 
cancer cells at a density of 2000 cells/well, except for OVCAR 4 which was plated at  a 
density of 5000 cells/well. After 24h, 20 µl of plant extracts (1 mg/ml) after further 100-fold 
dilution of the stock solution in the medium or semi-synthetic quinones were added at the 
indicated concentrations and the cell cultures were kept in the incubator at 37oC under 5% 
CO2 for 72h in a humidified atmosphere. The medium was decanted and the cells fixed with 
10% TCA on ice for 30 min and dried. The dried plates were stained with 0.4% SRB for 30 
min, washed with 1% acetic acid and dried. 100 µL of Tris-base (10mM) were added to the 
plates and shaken for 10 min to solubilise the protein-bound SRB dye. The absorbance at 
570 nm was measured using a spectroscopic plate reader. The recorded data was analysed 
by non-linear regression using the Graph pad PRISM software to fit a 4 parameter sigmoidal 
dose-response curve to determine IC50 values and the Hill coefficient (Vidot et al., 2010).  
Significant cytotoxicity was considered to be <10 µM; moderate cytotoxicity was in the range 
of 10-30 µM and low cytotoxicity was considered to be >30 µM. 
Calculation of Selectivity Index  
Based on the Mean IC50s obtained the selectivity index (SI), was calculated for each 
bioactive compound using the formula: 
 
(Koch et al., 2005). 
53 
 
The SI value obtained is an indication of the preferential selectivity in the cytotoxicity of the 
compound for cancer cells. A large value suggests that the compound would be more 
cytotoxic to cancer cells than normal cells. 
2.3.1 Drug Combination Experiments 
The drug combinations were carried out by a simultaneous exposure of the cells to a range 
of concentration of carboplatin (maximum dose of 100 µM) or paclitaxel (maximum dose 50 
nM) obtained by two-fold serial dilution combined with a fixed concentration (indicated in the 
results chapters) of the potent compounds. At this fixed concentration, the test compounds 
were expected from IC50 determination experiments with the single agents, to achieve a 5% 
cell growth inhibition on the OVCAR 4 cell line. The agents were also tested singly in this 
assay. The vehicle-treated cells were used as the negative control. The cells were incubated 
for 72h, followed by removal of supernatant and fixing in TCA for 30min. The cells were 
stained with SRB and same protocol repeated as described above. The combined effect of 
the drug combinations were evaluated by the calculation of the Combinational index (CI). 
The method employed for the determination of the CI was first described by Chou and 
Talalay (Chou et al., 1984). 
The CI was calculated from the following equation: 
                                                 CI = (D)1/(Dx)1 + (D)2/(Dx)2 
Where D1 and D2 are the respective concentrations of drug 1 and drug 2 used in the 
combination that cause x% inhibition of cell growth, while (Dx)1 and (Dx)2 are the individual 
concentrations of drug 1 and drug 2 when used as single agents that cause cell growth 
inhibition by x%. The sum of the two drug fractions gave an indication of the effect.   
The CI is a quantitative estimation of the drug combination effect, to determine whether the 
combined drugs produce synergistic, additive or antagonistic effect. Where a CI<1 is 
synergistic effect, CI=1, is additive and CI>1 is antagonism.  
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In this research work, a slight modification of this classification described by Giovanni and his 
co-researchers was used (Giovanni et al., 2011). In this classification, combinational index CI 
was classed as follows; CI <0.9, CI=0.9–1.2 and CI>1.2 indicated synergistic, additive, and 
antagonistic effect, respectively. The obtained CI results were compared to deviation from 
unity with a paired t-test. 
2.3.2 Trypan Blue assay 
The viability of the compounds was assessed by trypan blue assay. The cells were plated in 
12 well plates at a seeding density of 1 x105 cells/well in 1 ml of media. The drugs were 
prepared at an initial concentration of 20 mM and diluted to a working concentration of 2mM. 
The cells were exposed to 40 µM (20 µl of drug), 20 µM (10 µl) and 10 µM (5 µl) 
concentrations of the drugs. 40 µM (10 µl) of carboplatin was the positive control, while 0.1% 
DMSO in growth media was the control. A combination of 40 µM carboplatin and the three 
drug concentrations was also carried out to investigate the combined effect of both 
compounds. The cells were incubated for 72h in the incubator at 37°C under 5% CO2. The 
supernatant was removed, followed by detachment of the adherent cells with trypsin. The 
cells in the supernatant and the cells collected by trypsinization were combined, centrifuged 
at 150 x g for 3 min, and re-suspended in 0.2% trypan blue in PBS. The live and dead cells 
were counted by the haemocytometer.  
The expected effect (R) of the drug combinations was calculated by the Bliss independence 
criterion (Goldoni et al., 2007; Yeh et al., 2009). 
                                   R(x, y) = [R (x) + R (y)] – [R (x) * R(y)] 
Where R (x) = the effect of drug x, and R(y) = the effect of drug y 
2.4 Apoptosis Studies 
Three apoptosis assays were carried out in this research to investigate the possible route of 
cell killing demonstrated by these drugs. The Caspase 3/7 activity was measured, as these 
55 
 
were the executor caspases involved in apoptosis. Flow cytometry analysis of cells stained 
with Annexin V and propidium iodide to investigate the effect of apoptosis were carried out.  
Also the measurement of PARP [Poly (ADP-Ribose) Polymerase] (which is a DNA repair 
nuclear enzyme) cleavage by western blot immuno-staining was investigated.  
2.4.1 Caspase 3/7 Assay 
The cells were plated in 96 well plates at the same density used in the SRB assay, and 
exposed to 10µM concentration of the potent compounds or 10nM of paclitaxel/10µM 
carboplatin, supplemented with 10µl of growth media. A combination of 10µl of the potent 
compounds and paclitaxel or carboplatin respectively was also utilised in another 
simultaneous experiment. After 36h/48h incubation, 25 µl of Caspase 3/7 Glo-reagent 
(Promega) was added and the cells incubated in the dark at RT for 30min on a gentle rocker. 
The luminescence was measured by a BioTek Synergy 2 multi-mode microplate reader. 
The expected effect (R) of the drug combinations was calculated by the Bliss independence 
criterion described above. 
2.4.2 Flow Cytometry 
The use of laser beam to analyse the characteristics of single cells in liquid suspensions has 
been employed clinically as a diagnostic tool for some diseases such as leukaemia 
(www.cancer.org) and is an important technique for studying apoptosis in cells, with the 
added benefit of quantification of the apoptosis. This technique involves the labelling of 
organelles and DNA with a fluorescent probe, for the detection of active mitochondria, which 
in this experiment was Annexin V. To further distinguish the activities of the cells, propidium 
iodide was added prior to analysis on the flow cytometer, to stain the DNA and RNA. 
OVCAR 4 cells were seeded into 12-well plates at a density of 5 x 104 cells/well and 
incubated for 24h at 37oC under 5% CO2. The indicated drug concentrations were used 
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singly and in combination with 40 µM carboplatin. The control was 0.1% DMSO in growth 
media.  
After 48h post-drug addition incubation, the supernatant was retrieved and the adherent cells 
were trypsinized. The cells obtained by trypsinization was combined with the supernatant, 
and then centrifuged for 3 min at a speed of 300g. The pellets were now ready for further 
preparative steps as directed by the Annexin V manufacturer’s instructions. 
Annexin V and Annexin V binding buffer were purchased from Miltenyibiotec. The 
manufacturer’s instruction was adhered to in the sample preparation. The obtained pellets 
were re-suspended in 1ml of annexin V binding buffer and re-centrifuged for another 10min 
at the same speed. The supernatant was completely aspirated and the cells re-suspended in 
100 µl of 1 X Annexin V binding buffer, followed by the addition of 10 µl of Annexin V 
fluorochrome. The solution was carefully mixed by pipetting and incubated in the dark for 15 
min at RT. At the end of the incubation period, the cells were washed by an addition of 1ml of 
1 X Annexin V binding buffer and centrifuged for 10 min at 300g. The supernatant was 
aspirated completely and the cells re-suspended in 500 µl of annexin V binding buffer. 
1µg/ml of propidium iodide dissolved in PBS was added prior to flow cytometry analysis on a 
Beckman Coulter Cytomics 500 flow cytometer, equipped with CXP software for data 
acquisition. 
The cell population was identified and gated by the forward scatter (FS) and side scatter 
(SS). The data was distributed in the FL1 (annexin V staining) and FL3 (propidium iodide 
staining) channels. The obtained data was analysed by the use of flowing software 
developed by Perttu Terho, Turku Centre for Biotechnology, University of Turku, Finland. The 
Bliss independent effect was calculated by the equation described above. 
 
 
57 
 
 
2.4.3 Methodology for Western Blot Assay 
The measurement of PARP cleavage was carried out. Six wells plates seeded with OVCAR 
4 cells at a density of 300,000/well and treated with 10 µM or 20 µM of palmatine (isolated 
from RP, see Chapter 5) or 40 µM of carboplatin and a combination of both agents for 
48hr.The cells were collected, trypsinized, washed with cold PBS and lysed with RIPA buffer 
(3 ml) consisting of 2 mM EDTA, 150mM NaCl, 20 mM Herpes, 0.05 mM pepstatin, 0.12 mM 
leupeptin, 1 mM phenylmethylsulfonyl fluoride, 0.5 % sodium deoxycholate and 1 % Nonidet-
P40.  
The protein concentrations were evaluated by the Bicinchoninic acid (BCA) Assay. The BCA 
protein kit obtained from Sigma-Aldrich was prepared by the addition of 4% copper (II) 
sulphate pentahydrate solution (CuSO4•5H2O), to a solution of BCA in 0.1 M sodium 
hydroxide, supplemented with sodium bicarbonate, sodium carbonate and sodium tartate in a 
ratio of 1:50. Bovine serum albumin (BSA) standards were prepared for a range of 
concentrations 0.1 to 2 mg/ml. 
A 100 µl of BCA was added to 10 µl of each concentration of the BSA standard or 5 µl of 
sample of cell lysate diluted with 5 µl of RIPA buffer, and then incubated at 37 oC for 30 min, 
before the measurement of the absorbance at 570 nm by a spectrophotometer. The protein 
standard calibration curve was derived from the absorbance measurement and utilised in the 
calculation of the protein concentration for each sample of the lysate. 
About 10 µg protein of each cell lysate sample was carefully added to NuPAGE sample 
buffer (obtained from Invitrogen) made up with 5% β-mercaptoethanol, before 
electrophoresis using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), for 15 min at a temperature of 70 oC to denature the proteins. The denatured 
proteins were added to a 4-20% Nuview Tris-Glycine polyacrylamide gradient gel (NUSEP) 
in a Xcell surelock mini cell (the stationary phase) to fractionate the proteins from the cell 
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lysates. The mobile phase consisted of Hepes running buffer prepared from 100 mM Hepes, 
100 mM Tris and sodium dodecyl sulphate (1%).  
For the detection of the immunodetected proteins, pageruler plus pre-stained protein ladder 
was included on the gels to indicate the molecular weights of the separated proteins from the 
gels. These separated proteins were later transferred to Amersham Hybond P 0.45 µm 
polyvinylidene difluoride membrane and incubated in transfer buffer with a composition of 
200 mM glycine, 25 mM Tris, 10% methanol and 0.075% SDS for 1.5hr. The membrane was 
again incubated in Tris Buffered Saline with Tween buffer (TBST) prepared by the addition of 
150 mM NaCl, 5% skimmed milk powder and 0.1% Tween 20 to 50 mm Tris hydrochloride at 
pH 7.4, for 1.5h on a rocker at RT  to achieve blocking of the membranes. The membrane 
was subsequently incubated at 4 oC in the buffer with primary antibody and placed on a 
rocker overnight. The membrane was washed several times with TBST, before incubation in 
the buffer with secondary antibody for 1h at RT on a rocker. Following several washes in 
TBST, the membrane was analysed on a FluorChem M Imager, for the visualization of the 
protein bands using the UptiLight HRP chemiluminescent substrate according to the 
manufacturer’s instructions (Uptima). 
2.5 Extraction of Plant Materials 
The plant materials were extracted according to the NCI method of extraction (Thomas, G., 
2010). Typically, 200g of 1 Kg of the pulverized plant material was macerated in a 1:1 
mixture of 750 ml of dichloromethane and 750ml of methanol for 24h. The ratio of plant 
material to solvent used was 1:5. This ratio was maintained for all weighed amount of plant 
materials used.  
The obtained solution containing the extracts was decanted off and 500 ml of methanol was 
added to the residue and allowed to stand for another 24h. The solution of the extract was 
collected by filtration and 1 litre of deionised water was added to the residue. The aqueous 
extract was collected after 24h of maceration. The methanol extraction was combined with 
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the 1:1 dichloromethane and methanol extraction to yield the organic extract. This extraction 
solution was evaporated to dryness on a rotary evaporator at a temperature of <40 °C. The 
obtained dry extracts were further dried in a desiccator to remove any trace of solvent. The 
aqueous extraction was dried on the lyophilizer after being solidified in a stream of liquid 
nitrogen. The percentage yields of the crude extracts of these plants were calculated as 
follows:   Yield (%) = [extract obtained (g) × 100]/[Sample (g)] 
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Figure 2.1 A schematic representation of the extraction procedure of the plant materials to obtain 
the aqueous and organic extracts. Based on preliminary in vitro screening results, the organic 
extracts were subsequently fractionated as described in the diagram. 
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2.5.1 Bioassay-guided fractionation of Plants 
The organic extracts of the plants (typically 4-5g) with the potent anti-ovarian cancer activity 
were subsequently partitioned based on increasing polarity in n-hexane, ethyl-acetate, and n-
butanol consecutively. The extracts were first dissolved in 90 % methanol in water (300 ml) 
and partitioned with n-hexane (150 ml × 3). The combined hexane solvent was evaporated to 
yield the n-hexane fraction. The 90% methanol fraction was evaporated and the resulting 
residue was dissolved in 300 ml water and partitioned with ethyl acetate (150 ml × 3), which 
upon evaporation, the ethyl acetate extract was obtained. Finally, partitioning in n-butanol 
(150 ml × 3) was carried out. After evaporation of the solventsthe n-butanol fraction and 
aqueous fraction were obtained respectively. These 4 fractions were investigated for growth 
inhibitory activities and the significantly active fractions were further fractionated; firstly by 
column chromatography and further purification by HPLC was carried out as described in the 
results sections of the chapters to yield the pure compound(s) responsible for the potential 
anti-ovarian cancer activity.  
2.5.2 TMSi Derivatization of the Bioactive Fractions 
1.0 mg of the bioactive fraction of these plant extracts were added to 10 µl of pyridine and 50 
µl of N,O-Bis (trimethylsily) trifluoroacetamide (BSTFA). The obtained solution was incubated 
in the oven at a temperature of 37oC for 2h to prepare the trimethylsilyl (TMSi) derivatives 
which were subsequently analysed on gas chromatography mass spectrometry (GC-MS) 
(Paulo de Andradea et al., 2012).  
2.6 Gas chromatography Mass Spectroscopy 
The GC-MS system consisted of an Agilent 7890 A gas chromatography systems, coupled to 
an Agilent MS model 5975C MSD with triple axis detector (Agilent Technologies, US). The 
instrument’s column is a HP5-MS column. 
The gas chromatography began with an oven temperature of 60°C for 2 min, which 
increased to 300°C at the rate of 10°C/min, which was held at 300°C for 9 min to yield a total 
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run of 30 min under a constant helium pressure (10 psi). The mass spectrometry utilized an 
electron impact (EI) source at 70eV with an ion source temperature of 230°C. The mass 
spectra data were acquired in the scan mode in m/z range 16-600. The compounds were 
identified by GC-MS which is often used for identification as well as relative quantification 
and is comparable to GC-FID (Doddsa et al., 2005). These identified compounds were 
compared with standard compounds directly without measuring Kovat's indices. 
2.7 High Performance Liquid Chromatography (HPLC) Analysis 
The bioactive plant fractions and semi-synthesised TQ analogues were firstly purified by 
column chromatography which utilized various solvent systems as specified in the chapters. 
The obtained sub-fractions with significant activities were subjected to preparative HPLC on 
the Agilent 1220 LC, USA instrument. A mobile phase composition made up of a mixture of 
solution A (0.1% TFA) and solution B (80% acetonitrile acidified with 0.1% TFA) was utilised 
on an Eclipse XDB-C18 reverse phase column with specifications 9.4 x 250 mm, particle size 
of 5 µm and pore size 300Å, (Agilent, UK)  at a flow rate of 4 ml/min. The gradient and run 
times for the isolated compounds are specified in the preceding chapters.  The purity of the 
isolated compounds were analysed using analytical HPLC C18 column (Phenomenex, UK). 
The flow rate was maintained at 1 ml/min. The column specifications were 4.6 x 250 mm, 
particle size of 5 µm and pore size 300Å. 
2.8 Liquid chromatography mass spectrometry (LC-MS) Analysis 
The isolated compounds were analysed by LC-MS, to determine their molecular mass, and 
their retention times compared with purchased standard compounds. The Agilent 
technologies 1260 Infinity coupled to Agilent technologies 6530 Accurate mass Q-TOF LC-
MS system was used. The gas temperature was 320 oC, with a dry gas flow rate of 11 L/min. 
ESI was operated at a voltage of 4000V, an m/z range of 100-2000. The samples were 
injected at a volume of 5 µl and the run time was <3 min. The solvent systems were 20 % 
solvent A (a solution of 5 mM of ammonium formate and 0.1% formic acid in water) and 80% 
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solvent B (acetonitrile).The data was analysed by the Agilent mass-hunter qualitative 
analysis software. 
2.9 NMR Spectroscopy 
1H NMR spectra were obtained at 300 or 400 or 500 MHz with a Bruker 1D (DPX-300) NMR 
spectrometer, for 300 MHz; Bruker 1D (DPX-400) for 400 MHz and Bruker 1D (DPX-500) for 
500 MHz. 13C and DEPT NMR spectra were obtained at 75 or 100 or 125 MHz with a Bruker 
NMR spectrometer and either Chloroform-D or Methanol-D was used as the solvent. 
Tetramethylsilane (TMS) served as the reference (δ=0 ppm) at a temperature of 25 ᴑC. The 
obtained chemical shifts were expressed downfield from the reference, TMS. 
 ACD/Labs 10 Freeware (Advanced Chemistry Development Inc., Ontario, Canada) was 
used in the Analysis of the NMR Spectra. 
2.10 Statistical analysis and Diagrams 
The absorbance at 570 nm for SRB assay was measured using a spectroscopic plate reader. 
The recorded data was analysed by non-linear regression using the Graph pad PRISM 
software to fit a 4 parameter sigmoidal dose-response curve to determine IC50 values and the 
Hill coefficient. The IC50 values of the extracts/pure compounds analogues were obtained 
from a plot of absorbance versus log of concentration in µg per ml/µM. The mean IC50s were 
obtained from mean calculations using IC50 values of three determinations of each plant 
extract. The standard error of the mean (SEM) was also determined. 
Statistical significance of results was determined by one-way ANOVA and paired t-test using 
the Graph pad PRISM. 
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2.11 The Diagrams 
The chemical structures and Figure 2.1 were drawn using the ChemBioDraw Ultra 13.0 
software, while the illustration of ovarian cancer, Figure 1.1 was drawn using Photoshop cc 
2015. The pictures in the thesis were camera snapshots taken by the researcher. 
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Chapter Three  
Anti-Ovarian Cancer Compounds from Margaritaria Discoidea 
(Baill.) G. L. Webster 
3.1 Introduction 
Margaritaria discoidea (MD) is a plant in the Margaritaria genus. This genus has just thirteen 
species and is the smallest genus in the Phyllanthaceae family. Literatures on the scientific 
investigations of most of these species are lacking. Despite the rich Ethnopharmacological 
uses of MD in many indigenous communities the plant has received less-research attention 
and thus is a relatively un-explored species for identifying novel compounds with biological 
activities. Previous researchers have documented the anti-bacterial, anti-inflammatory and 
anti-oxidant activities of MD (Adedapo et al., 2009; Dickon et al 2010). However, there are no 
reported studies on the anti-cancer activities of the specie which has necessitated this 
research work on investigation of the anti-ovarian cancer activities of MD. 
The research in this chapter aims to investigate the anti-cancer activities of MD on ovarian 
cancer cell lines.  Through bioassay-guided fraction, the active compounds were isolated and 
characterised. Further growth inhibition evaluation using cell-growth assay were carried out 
to validate the antiproliferative activities of the bioactive compounds. Selectivity index (SI), of 
the bioactive compounds with potent activitieswas undertaken. Through the apoptosis 
studies, the possible route, by which the potent bioactive compound kills cancer cells, was 
investigated. Drug combination studies were carried out to identify potential synergy between 
the bioactive compounds and clinically used ovarian cancer drugs both in cell growth assays 
and in the apoptosis studies.  
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3.2 Results and Discussion 
3.2.1 Extraction of plant materials 
The pulverised stembarks of MD were extracted using a combination of dichloromethane and 
methanol to obtain the organic extract, followed by extraction with deionised water to yield 
the aqueous extract, according to the procedures (Figure 2.1) used by National Cancer 
Institute (NCI, USA). The amounts of the extracts and their yields were obtained (Table 3.1). 
Table 3-1 Percentage Yield of the MD Extracts obtained from the extraction with 
dichloromethane/methanol (organic extract) and extraction with deionized water (aqueous 
extract). 
SAMPLE 
AMOUNT (G) 
ORGANIC 
EXTRACT (G) 
AQUEOUS 
EXTRACT (G) 
% YIELD OF TOTAL 
EXTRACT OF PLANT 
1000 9.8 1.3 1.11 
 
From the data in Table 3.1, it was observed, that the stembarks of MD yielded relatively low 
amounts of solid extract. Also, the organic extract was more than the aqueous extract. This 
may be due to the method of extraction, which was sequential; organic extraction, followed 
by aqueous extraction. 
3.2.2 Screening of anti-ovarian cancer activity of the plant extracts 
The organic and aqueous extracts of MD were screened for their inhibition of cell growth on 
OVCAR 8 and A2780 ovarian cancer cell lines using a cell growth assay in which cell 
number was estimated by staining with SRB. The results of the IC50 values of the preliminary 
anti-cancer investigations of the plant extracts (Table 3.2). 
The IC50 values of organic extracts of MD had the most significant growth inhibitory activity, 
as observed from the plant extracts’ IC50 values of 14.2 and 14.4 μg/mL on the A2780 and 
OVCAR 8 ovarian cancer cell lines, respectively, (Table 3.2).  This IC50 is below the threshold 
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which is considered to be significant from the perspective of the American national Cancer 
institute criteria, which from a screening of about 20,000 plant extracts, identified 452 
cytotoxic extracts with IC50<50µg/mL (Thomas 2010). Thus, the organic extract of MD with 
IC50s <50µg/mL on the two cell lines tested warranted further purification and investigation for 
anti-cancer activity.  
Table 3-2 Results of Preliminary Screening of the Extracts of MD on ovarian cancer cell lines in 
cell growth assays. The cells were treated for 72h with the indicated extract, followed by an 
estimation of the number of surviving cells by SRB staining. The results are expressed as 
mean ±SEM, n=3 experiments. 
EXTRACT IC50 OF A2780 (µg/ml) IC50OFOVCAR8 (µg/ml) 
ORGANIC EXTRACT 14.2±3.0 14.4±1.2 
AQUEOUS EXTRACT 35.3±1.8 66.3±0.6 
 
These findings are consistent with the reported observations of several studies that have 
shown that some related species of Margaritaria, such as Phyllanthus pectinatus inhibited 
ovarian cancer cells, (Sujatha et al., 2011). Phyllanthus amarus has been shown to retard 
the proliferation of liver cancer in vitro (Jeena et al., 1999). Also, from an in vivo study of 
Phyllanthus urinaria, the reduction of tumour growth in lung carcinoma has been reported 
(Huang et al., 2006). Phyllanthus emblica has demonstrated cytotoxic activities on gastric 
and uterine cancers in vitro (Zhang et al., 2004), and the cytotoxic activites of Phyllanthus 
polyphyllus on breast, colon and liver cancer cells has also been documented (Rajkapoor et 
al., 2007). 
3.3 Bioassay-guided fractionation of M. discoidea 
Further solvent fractionation of 4.0 g of the crude organic extract of MD, using various 
solvents was perfomed (mass of solid compound recovered is shown in parentheses: n-
hexane (0.5 g), ethyl acetate (0.8 g), n-butanol (1.5 g) and aqueous (0.9 g) fractions 
respectively. These fractions were further evaluated in cell growth assays (Table 3.3). 
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Table 3-3 The Results of the growth inhibition evaluation of the fractions of MD on ovarian 
cancer cell lines in cell growth assays. The cells were treated for 72h with the indicated 
fraction, followed by an estimation of the number of surviving cells by SRB staining. The 
results are expressed as mean ±SEM, n=3 experiments. 
Fraction Abbrev IC50 of OVCAR8 
(µg/ml) 
IC50 of A2780 
(µg/ml) 
n-Hexane MD-N-HEX 33.7±2.2 27.0±1.3 
Ethyl Acetate MD-EA 11.6±1.5 7.3±0.7 
n-Butanol MD-N-BU 95.4±15.2 68.2±0.9 
Aqueous MD-AQ 63.9±7.2 91.2±0.9 
 
 
Figure 3.1 Mean concentration-response curve of the ethyl acetate fraction of Margaritaria 
discoidea on the OVCAR 8 ovarian cancer cell line. The cells were treated for 72h with the 
indicated compound, followed by an estimation of the number of surviving cells by SRB 
staining. The results were expressed as mean IC50 ± SEM, n=3 experiments. 
The ethyl acetate fraction showed lower IC50 values both in the OVCAR8 and A2780 cell 
lines and was the most potent of the fractions. Thus, ethyl acetate fraction merited further 
chemical characterization. 
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A similar finding has also been observed in a study on the growth inhibition of human 
gynaecologic and colon cancer cells, which showed that the anti-cancer activity of 
Phyllanthus watsonii specie, a related specie of the M. discoidea plant family was in the 
middle range polarity phase of the solvent system as reported by the authors (Ramasamy et 
al., 2012). 
3.4 Chemical characterization of active fraction of M. discoidea 
In order to find out the anti-cancer components in the ethyl acetate fraction, their TMSi 
derivatives were prepared and analysed by GC-MS. 
The TMSi derivatives of the ethyl acetate fraction of M. discoidea was obtained by the 
treatment of BSTFA and pyridine and subjected to further analysis on the GC-MS to 
determine the potential bioactive compounds that could be responsible for the activity of the 
fraction. 
 
Figure 3.2 GC Chromatogram of TMSi derivatives of Ethyl Acetate Fraction of M. discoidea 
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The GC chromatogram of the ethyl acetate fraction of M. discoidea is displayed in Figure 3.2. 
Twenty-nine compounds were detected; some of them could be identified by comparison of 
their mass spectra with those in the NIST library. For example, Figure 3.3 shows the 
identification of a peak at 19.37 min as securinine, an alkaloid. There were also many 
unknown compounds. As a result, many compounds such as 2-(2-hydroxyphenyl)acetic acid, 
4-hydroxybenzoic acid, 4-hydroxy-3-methoxybenzoic acid, 4-(2-hydroxyethyl)-2-
methoxyphenol, (E)-3-(4-hydroxy-3-methoxyphenyl) acrylaldehyde, 3,4-dihydroxybenzoic 
acid, ethyl 2-hydroxy-2-(2-hydroxyphenyl)acetate, 3-(4-hydroxy-3-methoxyphenyl)propane-
1,2-diol, 3,4,5-trihydroxybenzoic acid (gallic acid), nonanedioic acid (azelaic acid), and 
securinine could be identified (Table 3.4) and their chemical structures are shown in Figure 
3.4. 
 
Figure 3.3 Mass spectrum of a peak at 19.372 min for securinine in the ethyl acetate fraction of 
M. discoidea (top) and mass spectrum of securinine from NIST library (bottom). 
Securinine, an indolizidine alkaloid (Figure 3.4) is the major alkaloid of Securinega 
suffruticosa, plant. Securinega suffruticosa, yī yè qiū (presently known as Flueggea 
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suffruticosa) is one of the fifty important herbs used in the traditional Chinese Medicine 
(TCM). The shrub is a dioecious plant, belonging to the Phyllanthaceae family as MD, but 
classed under the genus; flueggea (Wong et al., 1976). The plant is rich in pharmacologically 
important alkaloids, such as securinine, which was isolated in 1956 by the Russian scientist- 
Muraveva and Bankovski; and its analogues, allosecurinine, virosecurinine and viro-
allosecurinine.  F. suffruticosa had historically been used in the treatment of a wide range 
diseases and ailments, such rheumatism, neuroparalysis, impotence and infant paralysis 
(Kee 1999). Similarly, another anti-tumour compound, corilagin, has been reportedly found in 
Phyllanthus niruri, a related specie of M. discoidea (Jia et al., 2013).      
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Chemical structures of some compounds found in the ethyl acetate fraction of 
M.discoidea by GC-MS. 
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Table 3-4 TMSi derivatives detected in the ethyl acetate fraction of M. discoidea by GC-MS. 
peak retention 
time (min) 
TMSi derivatives parent molecules in plants area of peak 
(%) (n =3) 
1 10.94 glycerol, tris(trimethylsilyl) ether glycerol 0.47 ± 0.07 
2 11.49 butanedioic acid, bis(trimethylsilyl) ester butanedioic acid 0.44 ± 0.07 
3 12.13 nonanoic acid, trimethylsilyl ester nonanoic acid 0.11 ± 0.03 
4 14.61 3-hydroxy-4-methoxy benzaldehyde, trimethylsilyl 
ether  
3-hydroxy-4-methoxy benzaldehyde 0.21 ± 0.03 
5 15.02 acetic acid, [o-(trimethylsiloxy)phenyl]-, 
trimethylsilyl ester 
2-(2-hydroxyphenyl)acetic acid 0.37 ± 0.08 
6 15.72 benzoic acid, 4-[(trimethylsilyl)oxy]-, trimethylsilyl 
ester 
4-hydroxybenzoic acid 0.17 ± 0.01 
7 15.87 Benzene acetic acid, 4-[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 
4-hydroxybeneacetic acid 0.16 ± 0.03 
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8 15.95 dodecanoic acid, trimethylsilyl ester dodecanoic acid 0.43 ± 0.03 
9 17.37 benzoic acid, 3-methoxy-4-[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 
4-hydroxy-3-methoxybenzoic acid 
(vanillic acid) 
0.31 ± 0.06 
10 17.67 azelaic acid, bis(trimethylsilyl) ester azelaic acid 0.24 ± 0.09 
11 18.01 benzoic acid, 3,4-bis[(trimethylsilyl)oxy], 
trimethylsilyl ester 
3,4-dihydroxybenzoic acid  0.37 ± 0.06 
12 18.09 D-(-)-Fructofuranose, pentakis(trimethylsilyl) ether  D-(-)-fructofuranose 0.46 ± 0.06 
13 18.19 D-(-)-Fructopyranose, pentakis(trimethylsilyl) ether D-(-)-fructopyranose 0.89 ± 0.11 
14 18.99 beta.-D-Glucopyranose, 1,2,3,4,6-pentakis-O-
(trimethylsilyl)- 
beta-D-glucopyranose 1.04 ± 0.11 
15 19.22 2-hydroxymandelic acid, ethyl ester, di-TMS ethyl 2-hydroxy-2-(2-
hydroxyphenyl)acetate 
0.06 ± 0.02 
16 19.34 securinine securinine 2.06 ± 0.76 
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17 19.55 benzoic acid, 3,4,5-tris(trimethylsiloxy)-, 
trimethylsilyl ester 
3,4,5-trihydroxybenzoic acid (gallic acid) 0.20 ± 0.06 
18 19.63 3-vanil-1,2-bis(trimethylsilyloxy)propane 3-(4-hydroxy-3-methoxyphenyl)propane-
1,2-diol 
0.12 ± 0.01 
19 19.86 D-(+)-galactopyranose, pentakis(trimethylsilyl) 
ether 
D-(+)-galactopyranose 1.32 ± 0.09 
20 20.13 Benzeneacetic acid, 3-methoxy-alpha,4-
bis[(trimethylsilyl)oxy]-, trimethylsilyl ester  
3-methoxy-4-hydroxybeneneacetic acid 0.92 ± 0.18 
21 20.27 hexadecanoic acid, trimethylsilyl ester hexadecanoic acid 1.42 ± 0.04 
22 21.89 9,12-octadecadienoic acid (Z,Z)-, trimethylsilyl 
ester 
(Z,Z)-9,12-octadecadienoic acid  2.05 ± 0.17 
23 22.08 2,2-bis(4-trimethylsioxy)phenyl]propane 2,2-bis(4-hydroxyphenyl]propane 0.25 ± 0.09 
24 22.15 octadecanoic acid, trimethylsilyl ester octadecanoic acid 0.41 ± 0.06 
25 25.97 sucrose, octakis(trimethylsilyl) ether sucrose 7.16 ± 1.06 
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26 27.59 2H-1-benzopyran, 3,4-dihydro-2-[3,4-
bis[(trimethylsilyl)oxy]phenyl]-3,5,7-
tris[(trimethylsilyl)oxy]-, (cis)- 
cis-catechin 1.23 ± 0.14 
27 27.79 2H-1-benzopyran, 3,4-dihydro-2-[3,4-
bis[(trimethylsilyl)oxy]phenyl]-3,5,7-
tris[(trimethylsilyl)oxy]-, (trans)- 
trans-catechin 0.89 ± 0.22 
28 28.23 2H-1-benzopyran, 3,4-dihydro-2-[3,4,5-
tris[(trimethylsilyl)oxy]phenyl]-3,5,7-
tris[(trimethylsilyl)oxy]-, (cis)- 
cis-gallocatechin  21.6 ± 0.95 
29 23.53 2H-1-benzopyran, 3,4-dihydro-2-[3,4,5-
tris[(trimethylsilyl)oxy]phenyl]-3,5,7-
tris[(trimethylsilyl)oxy]-, (trans)- 
trans-gallocatechin 43.0 ± 1.83 
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3.5 Column Purification of the Ethyl Acetate Fraction of MD 
Nine sub-fractions were obtained from a solvent-polarity based column chromatography 
fractionation eluted with n-hexane/ethyl-acetate (gradient of polarity) based on the optimum 
TLC profile obtained from a mobile phase of n-hexane: ethyl acetate (1:1). The fractionation 
began with a 100% n-hexane and ended with 100% methanol. The obtained sub-fractions 
were evaluated for growth inhibition in the cell growth assays (Table 3.5). 
Table 3-5 The IC50 Values of the Sub-Fractions of MD-EA on A2780 cell line. Three 
independent experiments were carried out. The results are expressed as Mean±SEM, 
n=3 (for sub-fractions with activities <30 µg/mL). 
Sub-fractions of MD-EA A2780 Cell 
 Line IC50 Value (µg/ml) 
Solvent Fraction 
F1 >30                       N-hexane                                       
F2 >30 N-hexane/ethyl acetate 
F3 >30 “ 
F4 7.5±0.4 “ 
F5 6.3±0.7 “ 
F6 13.7±0.9 “ 
F7 >30 Ethyl acetate 
F8 >30 Ethyl acetate/Methanol 
F9 >30 Methanol 
 
Two of the sub-fractions; F4 and F5 showed notable activities, and were subjected to further 
purification, while no activity was measured in the other fractions. 
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Isolation of Compound MPHYF4 
Sub-fraction F4, was treated with hot methanol and recrystallized at a temperature of 0-4oC, 
to yield white needle crystals henceforth referred to as MPHYF4. The LC-MS analysis 
identified an ion with m/z of 457.36 [M + H]+, therefore the mass of this compound was 
456.36 with a match quality score of 99.78%. 
 
Figure 3.5 The LC-MS mass spectrum of MPHYF4, isolated from MD-EA 
The 1H NMR spectrum of MPHYF4 was obtained at 300 MHz with a Bruker 1D (DPX-300) 
NMR spectrometer in CDCl3[δ 3.50(s, 12H), 1.96(s, 3H), 1.72(s, 3H), 1.43(s, 3H), 1.26(s, 
3H), 0.95(m, 3H), 0.80(d, 3H, 4.8Hz)] and the data was consistent with the reported data in 
literature for betulinic acid (Rodrigues et al., 2008). The compound was tentatively identified 
as betulinic acid.  
 
 
 
 
Figure 3.6 The 
1
H NMR assignment of Betulinic acid 
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The 13C NMR spectrum of MPHYF4 was obtained at 400 MHz with a Bruker 1D (DPX-400) 
NMR spectrometer in CDCl3 [δ 150.43, 109.68, 97.39, 79.02, 55.40, 50.57, 49.33, 46.91, 
42.48, 38.88, 38.41, 37.24, 29.73, 28.00, 19.39, 18.32, 16.15, 16.05, 15.35, 14.72. This 
obtained NMR data was comparable with the data in literature, (Satiraphana et al., 2012). 
The compound was determined as betulinic acid. 
GC-MS analysis of the TMSi derivatized sample of MPHYF4 was carried out. The compound 
could not be detected when the GC oven temperature was set at 60oC to 300oC for 30min 
run time. However, when the oven temperature was raised to 250oC as the initial 
temperature and allowed to increase to 300oC at a run time of 65min, the compound was 
detected as a single peak with Retention time of 34.49min. The derivatized m/z was 585.5. 
Further confirmation of the compound was carried out by the GC-MS analysis of the 
derivatized standard betulinic acid, which also had the same Retention time. Again both 
compounds were mixed together in equal proportion and re-analysed on the GC-MS to 
observe the co-elution of the compounds at the same retention time as shown in Figure 3.7 
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Figure 3.7 The GC-MS analysis of the TMSi derivatized MPHYF4 and standard betulinic acid. 
GC-MS chromatograms of MPHYF4 (A), betulinic standard (B), the co-elution of both 
compounds (C), and the MS of the co-eluted compound (D). 
The chromatograms of MPHYF4 and the standard betulinic acid procured were exact 
matches with the chromatogram of the compounds when co-eluted. The retention time on the 
GC-MS was the same for the compounds singly and when co-eluted. Additionally, the 
spectrum shown in Figure 3.7(D),was identical for both MPHYF4 and the standard betulinic 
acid. Thus, MPHYF4 was unequivocally determined as betulinic acid (BA), from the LC-MS, 
1H NMR,13C NMR and GC-MS analysis. This compound was not initially detected in the GC-
MS analysis of the derivatized MD-EA fraction due to the low start-off temperature and short 
run time of the analysis. 
Isolation of Compound F(10)4 - Securinine 
The most potent sub-fraction, F5 was subjected to HPLC purification; with a mobile phase 
composition of 100% water acidified with 0.1% Trifluoroacetic acid (TFA) as solvent A and 
80% acetonitrile acidified with 0.1% TFA as solvent B. The gradient began with 100% of A for 
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5 min and increased to 80% B during 20 min of the run time, and then maintained at 100% B 
for 5 min of the analysis; making the total run time 30min. A yellow amorphous powder was 
obtained from the HPLC purification and the isolated compound was henceforth referred to 
as F(10)4, which upon GC-MS analysis was tentatively identified as securinine with m/z of 
217 and a retention time of19.34min. The GC-MS chromatogram and spectrum are 
presented in Figure 3.8. 
 
 
 
 
 
 
 
Additional confirmation was carried out by the  1H NMR spectrometry of F(10)4 on a 300 
MHz with a Bruker 1D (DPX-300) NMR spectrometer in CDCl3 [δ 6.62(m, 1H), 6.45 (m, 1H), 
5.57(s, 1H),  3.83(q, 1H), 2.97(m, 1H), 2.51(m, 2H), 2.17(s, 1H), 1.86(m, 1H), 1.77(dd, 1H), 
1.59(m, 2H), 1.28(s, 2H),  0.83(m. 1H)], which was consistent with the reported data of 
securinine in literature (Diallo et al., 2015). 
 
 
 
 
Thus, F(10)4 was determined as securinine. 
Figure 3.8 The GC-MS chromatogram of compound F(10)4 in (A) and the MS spectrum 
of the compound F(10)4 (B). 
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Identification and Confirmation of the Compounds (-)-Catechin and (-)-
Gallocatechin 
The TMSI-derivatized sample of sub-fraction 7 was analysed on the GC-MS, four 
compounds were identified; (-)-Catechin (cis-Catechin) and the structural isomer (+)-catechin 
(trans-catechin), which in the derivatized form gave a mass of 650.30 at a retention time of 
27.59min and 27.79 min respectively. The other two compounds were (-)-gallocatechin (cis-
Gallocatechin) and (+)-gallocatechin (trans-Gallocatechin) with a derivatized mass of 738.31 
at a Retention time of 28.22min and 28.42min respectively. However, the cis and trans- 
compounds (26 (28) could be 27 (29), vice versa) and perhaps exchangeable. The spectra of 
these compounds are contained in Figure 3.10. 
 
Figure 3.10 Full EI mass spectrum of TMSi derivative of cis-catechin (TMS-cis-catechin, 26) (A), 
TMSi derivative of trans-catechin (27) (B), TMSi derivative of cis-gallocatechin (TMS-cis-
gallacatechin, 28) (C), and TMSi derivative of trans-gallocatechin (29) (D). 
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Additional confirmation of (-)-Catechin and cis-Gallocatechin was made by a comparison of 
the Chromatograms and spectra of the GC-MS analysis of the procured derivatized 
standards of these compounds. A schematic representation of the possible electron impact 
fragmentation pathways for the TMSi derivative of cis-catechin (26) and the TMSi derivative 
of cis-gallocatechin (28) is described in Figure 3.11. 
 
Figure 3.11 Possible electron impact fragmentation pathways for the TMSi derivative of cis-
catechin (26) and the TMSi derivative of cis-gallocatechin (28) 
Identification of Gallic Acid 
Gallic acid was one of the compounds putatively identified by the GC-MS analysis of the MD-
EA fraction and shown in Figure 3.4 above. The identity of the compound was confirmned by 
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comparison of the GC-MS obtained spectrum with that of a standard gallic acid purchased 
from Sigma Aldrich. The spectra of both compounds were indistinguishable as shown in 
Figure 3.12 below. Thus, the identity of gallic acid was confirmed as a compound present in 
MD. 
 
 
 
 
 
 
 
 
 
 
3.6 Investigations of the anti-cancer activity of isolated compounds 
from MD-EA 
The five identified bioactive compounds were investigated for their cell growth inhibition on 
the ovarian cancer cell lines and on HOE (Table 3.6 and Figure 3.13). 
A B 
Figure 3.12 The GC-MS spectrum of the gallic acid contained in the TMSi derivatized 
sample of MD-EA (A) and the spectrum of the TMSi derivatized  gallic acid standard (B) 
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Table 3-6 The growth inhibition evaluation obtained by measuring the IC50 (µM) of the bioactive 
compounds of MD-EA on ovarian cancer cell lines in cell growth assays. The cells were treated 
for 72h with the indicated compound, followed by an estimation of the number of surviving cells by 
SRB staining. The results are expressed as mean ±SEM, n=3 experiments. 
Cell Line Securinine Gallic 
Acid 
(-)-
Catechin 
(-)-
Gallocatechin 
Betulinic 
Acid 
MPHYF4 
A2780 2.7±0.7 6.2±0.3 14.2±3.1 14.0±1.1 ND ND 
OVCAR 8 5.2±0.1 16.2±0.5 17.6±2.5 18.9±2.0 ND ND 
A2780CIS 5.4±0.3 6.5±0.4 56.6±4.6 13.7±2.1 ND ND 
OVCAR 4 8.7±0.1 26.9±4.1 ND ND 16.0±1.9 19.1±1.1 
HOE 10.7±1.2 73.5±3.8 ND ND 25.9±2.1 ND 
 
 
Figure 3.13 The Mean concentration-response curves of A bioactive compounds of MD-EA; 
Gallic acid on OVCAR 8 cell line. The cells were treated for 72h with the indicated compound, 
followed by an estimation of the number of surviving cells by SRB staining. The results were 
expressed as mean IC50 ± SEM, n=3 experiments. 
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The results of the growth inhibition evaluation of the identified bioactive compounds in MD-
EA showed that the five compounds possessed antiproliferative activities on the ovarian 
cancer cell lines, which when ranked in increasing order was shown to be securinine > gallic 
acid > betulinic acid> (-)-gallocatechin> (-)-catechin. Hypothesis a was tested by these 
results. Securinine had more potent activities in comparison with the other bioactive 
compounds on all the cell lines tested. This finding was in agreement with the previous report 
on the anti-cancer properties of this compound against colon cancer SW480 cell (Yong-hui et 
al., 2011). Further studies on securinine were carried out to validate these findings. 
3.7 Results of Further Evaluation and Drug Combination 
Experiments on Betulinic Acid   (BA) 
The trypan blue assay, TBA was carried out to determine whether the effect in the cell 
growth assays reflected inhibition of proliferation or cell death induced by by bioactive 
compounds of MD. The OVCAR 4 cell line was selected for this assay as this cell line is 
among the top five most resistant human ovarian cancer cell lines which typifies very serious 
ovarian cancer and thus is a suitable model for the investigation of in vitro anti-ovarian 
cancer activities (Domcke et al., 2013). 
BA was investigated at three concentrations singly and in combination with carboplatin. The 
observation from Figure 3.14 is that the antiproliferative activities of BA in the SRB are 
replicated in the trypan blue assay. Again, this activity is in a concentration-dependent 
manner, with the maximum concentration of 40µM exhibiting the most cytotoxicity. The effect 
of the combined use of BA and carboplatin on the cells were also investigated. The agents 
combined demonstrated significant synergism (p<0.05 for 40, 20 and 10µM BA) because all 
three concentrations elicited effects which exceeded that expected for the combination 
assuming additivity and calculated by the Bliss independence criterion. Furthermore, these 
results suggest potential synergism between BA and carboplatin. 
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Figure 3.14 The effect of betulinic acid (BA) at the indicated concentrations and in combination 
with carboplatin (CBPT), (40 µM) at 48h on cell viability. The cells were stained with trypan blue 
and the percentage of dead cells was obtained by microscopy. The horizontal blue bars 
indicate the expected effect obtained from the bliss independent effect calculation comparing 
the effect of the combination and the single agents. * denotes that the result is significantly 
different (P<0.05, paired t-test) from the effect expected from the Bliss independence criterion. 
The results were expressed as mean ±SD, n=3. 
 
Further studies to investigate the synergistic potentials in the growth inhibition activities of the 
drug combination between BA and carboplatin on OVCAR 4 cells were carried out (Figure 
3.15). 
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Figure 3.15 Mean concentration-response curves of untreated cell carboplatin-treated cells 
(maximum concentration of 100 µM) and the drug combination of betulinic acid at a fixed 
concentration of 6 µM and Carboplatin (Maximum concentration of 100 µM) on the OVCAR 4 
cell line determined after 72h of treatment. Results were expressed as mean of three 
experiments, Mean± SEM. 
 
The results contained in Figure 3.15, showed that the activity of carboplatin is increased 
when in combination with betulinic acid. This results revelaed a synergistic effect in the drug 
combination of carboplatin and betulinic acid, with a CI = 0.87±0.1, which was not significant 
from synergism) at p<0.05. This observation may be due to the 6µM fixed concentration of 
betulinic acid used. It was expected that at this concentration the compound would cause 5% 
growth inhibition of the cancer cells, judging from the activity of the compound from single 
agent studies.  An alternative would be to repeat these studies with different betulinic acid 
concentrations to see if significant synergy is observed.  
These results obtained from this present study suggest that betulinic acid could be used in 
chemoprevention and as a combinational agent for standard cancer drugs in the treatment of 
ovarian cancer. 
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3.8 The Results of Securinine TBA and Drug Combination Studies 
The growth inhibitory activities of securinine in cell growth assay was further assessed using 
the TBA to determine if these observed activities where due to the anti-proliferation or cell 
death induced by securinine (Figure 3.14). 
 
 
 
 
 
 
 
Figure 3.16 The Effect of securinine (SECU) at the indicated concentrations and in combination 
with carboplatin (CBPT) (40 µM) at 48h on cell viability. The vehicle-treated cells served as the 
control. The cells were stained with trypan blue and the percentage of dead cells was obtained 
by microscopy. The horizontal blue bars indicate the expected effect obtained from the bliss 
independent effect calculation comparing the effect of the combination and the single agents. * 
denotes that the result is significantly different (P<0.05, paired t-test) from the effect expected 
from the Bliss independence criterion. The results were expressed as mean ±SD, n=3. 
 
The results are in consonance with the observed inhibitory activities of securinine in the SRB 
assay and in a concentration-dependent manner, with the maximum concentration of 40µM 
exhibiting the most activity. The effect of the combined use of securinine and carboplatin on 
the cells were also investigated. The agents combined demonstrated significant synergism 
(p<0.05 for 40, 20 and 10µM securinine) as all three concentrations elicited effects which 
exceeded that expected for the combination assuming additivity and calculated by the Bliss 
independence criterion.  
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Further studies on the effect of drug combination between securinine and carboplatin on 
OVCAR 4 cells were carried out to investigate the synergistic potentials of securinine in 
increasing the growth inhibition activities of carboplatin (Figure 3.17).  
 
Figure 3.17 Mean concentration-response curves of vehicle-treated cells, carboplatin-treated 
cells (Maximum concentration of 100 µM) and the drug combination of securinine at a fixed 
concentration of 6 µM and Carboplatin (Maximum concentration of 100 µM), on the OVCAR 4 
cell line determined after 72h of treatment. The surviving cell number was estimated by 
staining with SRB. The results were expressed as mean of three experiments, Mean± SEM. 
 
The results showed that the activity of carboplatin was amplified by a combination of 6µM of 
securinine. The obtained CI for the drug combination of securinine, was 0.9±0.2 which 
indicates synergy but these results were not statistically significant from synergism at p<0.05. 
It is possible that at higher concentrations of securinine, significant synergy between 
securinine and carboplatin would be achieved. 
3.9 Apoptosis studies of Securinine 
In order to investigate, the possible route of cell death induced by securinine, experiments 
were conducted to evaluate the activity of securinine on caspase 3/7. In this experiment, the 
effect of drug combination between securinine and carboplatin/paclitaxel respectively were 
further examined (Figure 3.18). 
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Figure 3.18 The Effect of securinine (10 µM) combined with paclitaxel (10 nM) or carboplatin (10 
µM), on Caspase 3/7 activity at 48h for carboplatin (A) combination and 36h for paclitaxel (B) 
combination. The caspase activity was measured and normalized with corresponding SRB-
stained cells to estimate the surviving cell number. The horizontal blue bars indicate the 
expected effect obtained from the bliss independent effect calculation comparing the effect of 
the combination and the single agents. * denotes that the result is significantly different 
(P<0.05, paired t-test) from the effect expected from the Bliss independence criterion. While ## 
denotes significant difference (P<0.001) from the control, one-way ANOVA. The results were 
expressed as mean ±SD, n=3. 
 
The results demonstrated that securinine induced significant caspase activity at a 
concentration of 10µM with both carboplatin and paclitaxel. The combination of securinine 
and carboplatin (10µM) or paclitaxel (10nM), yielded an increase in caspases 3/7 activity 
which was greater than the bliss expected effect. A further comparison of the caspase 
activities of securinine and the vehicle-treated cells (control), showed that at 48h, securinine 
induced significant caspase activity p<0.001 significance. Although, at 36h, the induced 
caspase activity of securinine was not statistically different from the control, however this is 
an indication that securinine induces significant apoptosis in cells after 36h of treatment at a 
concentration of 10µM.  
Further investigation of the observed potential synergism between securinine and carboplatin 
was carried out by means of Annexin V/Propidium Iodide labelling, followed by flow 
cytometry analysis (Table 3.7, Figures3.19 and 3.20). 
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Table 3-7 The Effect of Securinine and carboplatin Combinations was assessed (for the 
apoptotic cells) after 48h of treatment by Annexin V/PI Staining of the cells followed by flow 
cytometry analysis.  *denotes that the result is significantly different (P<0.05, paired t-test) from the 
effect expected from the Bliss independence criterion. The results are expressed as mean ±SD, n=3. 
TREATMENT PERCENTAGE OF APOPTOTIC CELLS MEAN±SD 
CONTROL 3.2±0.4 
CARBOPLATIN(20µM) 14.4±1.1 
SECURININE(5µM) 4.0±0.1 
CARBOPLATIN+SECURININE 19.7±0.8* 
 
 
Figure 3.19 The effect of Securinine (5 µM) in combination with carboplatin (20 µM) and the 
agents singly on OVCAR 4 cells treated for 48h was assessed by Annexin V/PI staining, 
followed by flow cytometry analysis. The vehicle-treated cells were used as the control. The 
results were expressed as a representative of three experiments. 
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Figure 3.20 The effect of securinine (5 µM) combined with carboplatin (20 µM), and the agents 
singly on Annexin V/PI staining on OVCAR 4 cells analysed by flow cytometry at 48h. A 
representation of the quantification of the combined early and late phase apoptotic cells is 
shown. The horizontal blue bars indicate the expected effect obtained from the bliss 
independent effect calculation comparing the effect of the combination and the single agents. 
*denotes that the result is significantly different (P<0.05, paired t-test) from the effect expected 
from the Bliss independence criterion. The results were expressed as mean ±SD, n=3. 
 
The results of the Annexin V/PI studies (Table 3.7 and the Figures 3.19 and 3.20), showed 
that securinine in combination with carboplatin led to increased apoptosis. The results further 
demonstrated a statistically significant synergism between securinine and carboplatin in the 
Annexin V /PI assay, by which hypotheses b and c were tested. This result further confirms 
the observed synergism in the TBA, drug combination experiments in the cell growth assays 
and in the caspase 3/7 assay. Again, these results had huge significance at p<0.05, in 
comparison with the calculated bliss expected effect. 
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3.10 Discussions 
The investigations of the anti-ovarian cancer activities of MD have been undertaken in this 
research work. The results showed that the organic extract of the plant had more potent 
inhibition than the aqueous extract. Further purification of the extract led to the isolation of 
betulinic acid and securinine. While the identities of gallic acid, cis-catechin and cis-
gallocathecin where authenticated by the obtained standard compounds. Evaluation of the 
growth inhibition of these bioactive compounds was carried out and the activity of the 
compounds on the ovarian cancer cells showed that the compounds had a range of activity 
from 2.7-56.6µM, with securinine being the most potent compound. The results showed that 
gallic acid had notable antiproliferative activities on all the ovarian cancer cell lines with a 
SI>3.  Similarly, the inhibitory effect of the leaf extract of Toona sinensis, of which the major 
bioactive compound is gallic acid has been, demonstrated in a panel of human oral 
squamous carcinoma cell lines. The study indicated that gallic acid may be responsible for 
the observed anti-cancer activities of Toona sinensis (Chia et al., 2010). The inhibitory 
activities of gallic acid has been observed in cervical, gastric and prostate cancer (Komal et 
al., 2008; Bing et al., 2013; Hsieh-Hsun et al., 2013). An in-depth in vitro and in vivo study 
demonstrated significantly the apoptosis-inducing activities of gallic acid with indications that 
gallic acid could be exploited as a chemopreventive agent (Sharad et al., 2013). The results 
of this present study suggest that gallic acid, a phenolic acid which is found in many plants 
and is used as an anti-oxidant food supplement possess antiproliferative activities against 
cancer cells with very minimal cytotoxicity towards normal cells and thus would potentially be 
useful in the treatment and prevention of ovarian cancer. Further investigations of gallic acid 
are presented in chapter 4.  
Betulinic acid, a naturally occurring pentacyclic triterpenoid which was first isolated from the 
stem bark of Melaleuca cajuput in 1995, is a well-known anti-cancer agent, with significant 
cytotoxicity recorded on several human cancer cell lines which include, brain tumours, 
breast, colon, melanoma, prostate, head and neck, colorectal, lungs, ovarian, cervical 
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cancers and leukaemia (Alakurtti et al., 2006; Fulda 2008; De Melo et al., 2009; Bache et al., 
2011). The results obtained from this study also demonstrate that betulinic acid is a potent 
inhibitor of ovarian cancer in vitro and is a promising candidate for cancer therapeutics. The 
agent was previously evaluated in a Phase I/II clinical trial of twenty-eight participants for the 
treatment of high risk dysplastic nevi; a condition indicative of skin cancer. The trial was 
assigned an identification number: NCT00346502, (Udeani 2010). Further updates of the 
outcome of this trial are not currently available.  
Drug combinations between betulinic acid, BA and carboplatin were carried out in this study. 
The results suggest potential synergy between the agents. However this result was not 
significant from unity, which may be due to the concentration of BA used in the study. Similar 
drug combination studies involving BA and 5-Fluorouracil on OVCAR 432 ovarian cancer 
cells, reported synergism between the agents in western blot and flow cytometry experiments 
(Ying-Jian et al., 2015). These researchers also observed the involvement of caspase in the 
MOA of this combination with a significant increase in apoptotic cells. Again, this finding was 
further correlated by another study of BA and other cancer drugs by Fulda et al., in 2005, 
with observations of caspase activation and increased apoptosis (Fulda et al., 2005). The 
role of BA as an apoptosis inducer has been investigated on melanoma and neuro-
ectodermal tumour cells. The investigators also observed an improvement in the treatment of 
tumours by radiotherapy in hypoxic conditions with the administration of BA (Vadivelu et al., 
2012). 
The green catechins, a group of poly-phenolic compounds have long being recognised for 
their vast health benefits mainly due to their anti-oxidants and free radical scavenging 
properties, with studies indicating that the most abundant compound (-)-epigallocatechin 
gallate (EGCG) is the most bioactive. In this study two catechins; (-)-catechin or cis-catechin 
and (-)-gallocatechin or cis-gallocatechin were identified and investigated. The results 
presented in Table 3.7 showed that the (-)-gallocatechin was more bioactive than (-)-
catechin. This result is further strengthened by the findings of other researchers who 
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reported that (-)-gallocatechin gallate was the next more active catechin after EGCG in the 
inhibition of the growth/attachment of Porphyromonas gingivalis on the epithelial cells of the 
buccal cavity. The same investigators equally observed that (+)-catechin and (+)-
gallocatechin had lesser activities (Sakanaka et al., 1996). Studies on the synergism 
between catechins and anti-cancer drugs have been undertaken. The results from a study of 
42 in vitro and 13 xenograft mouse models drug combination experiments showed synergy 
between catechins and the standard treatment drugs (Hirota et al., 2015). 
The most potent bioactive compound obtained from this study of MD is securinine. Recently, 
the anti-cancer properties of L-securinine (a designation assigned to securinine when 
compared with its optical isomer D-securinine), against colon cancer SW480 cell has been 
reported (Yong-hui et al., 2011). Securinine has also been shown to exhibit antiproliferative 
activities against acute myeloid leukaemia, AML both in in vitro and in vivo studies (Gupta et 
al., 2011).  
Securinine’s MOA was identified as a GABA-antagonist by the compound’s ability to reverse 
GABA inhibition of cat spinal neurons. The compound stimulates the central nervous system 
and was used clinically for the treatment of neurological disorders in Russian pharmacopoeia 
in 1968, but was later deleted from subsequent editions (Raj et al., 2008).  The anti-
plasmodial activities against plasmodium falciparum has been reported, also the compound 
exhibited significant activities against T. gondii and has demonstrated anti-bacterial activities. 
Securinine’s potential as a promising agent in the treatment of acute myeloid leukaemia 
(AML) has been evaluated (Gupta et al., 2011). Studies have shown that securinine is a 
pharmacologically important compound, owing to the numerous bioactivities, such as anti-
malarial (Weenen et al., 1990) anti-bacterial (Mensah et al., 1990) and anti-Toxoplasma 
(Holmes et al., 2011) activities. The compound has previously being reported in M. discoidea 
obtained from Nigeria, and according to Bevan, the stembark of MD obtained from Nigeria, 
contains 0.2% securinine and minute quantities of allosecurinine and phyllanthine (Oliver-
Bever 1986).The findings from this present research showed potential synergism between 
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securinine and carboplatin/paclitaxel in the caspase 3/7 experiments, which was similarly 
demonstrated in the drug combination of securinine and carboplatin evaluated in the trypan 
blue assay and in the Annexin V/PI labelling assay. 
Similarly, observations of the inhibition activities of securinine on MCF-7 breast cancer cells 
in a time and dose dependent pattern have been documented. The results of the referenced 
study further observed that a concentration range of 0-40µM of securinine for 48h incubation 
resulted in a significant increase in the quantified apoptosis and an acute decline in the G1 
phase of the cell cycle (Li et al., 2014). Also, a related study on the effect of securinine on 
Acute Myeloid Leukaemia (AML), showed that securinine synergised with ATRA and 
decitabine, standard AML drugs (Gupta et al., 2011).  
Some researchers have reported that securinine exhibited selective cytotoxicity towards 
cancer cells by apoptosis through the p73-independent pathway (Rana et al., 2010), which 
was also demonstrated in the caspase 3/7 and Annexin V experiments carried out in this 
study.  
These findings strengthen the observations of the anti-cancer activities of securinine. 
Furthermore, an evaluation of the confirmed GABA receptor antagonist MOA of several 
securinine-type alkaloids on mice induced with tonic seizures, showed a very high IC50 of 
about 50µM, with a 7-fold decrease in the activity of securinine in comparison to bicuculline. 
A weak GABA antagonism was exhibited by securinine, according to the researchers 
(Beutler et al., 1985).  It is most likely that the GABA antagonism exhibited by securinine may 
be as a secondary MOA, while the compound’s main MOA is yet to be elucidated.  The view 
that securinine is majorly a GABA receptor antagonist, has resulted in the mis-application of 
the drug as a CNS stimulant, and led to the drug’s failure to deliver significant therapeutic 
benefits. This may be the reason while the use of securinine as a drug in the 1968, 10th 
Edition of the Russian Pharmacopeia, was discontinued, as the drug must have failed in its 
application as a CNS stimulant in the treatment of neurological diseases. 
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Subsequentlysecurinine nitrate was used as a stimulant and an anti-spasmodic in USSR. 
Again, the use of the drug was discontinued in the 1990s’, possibly due to lack of therapeutic 
benefits (Chirkin et al., 2015). This is also the view shared by a team of American 
researchers who evaluated the potentials of securinine in the treatment of Amytropic Lateral 
Sclerosis, ALS in nine patients and found the drug of no effect. A quote from these 
researchers is shown below: 
“To the Editor-In December 1971, E. G. Dimond made reference to research in China on the 
use of securinine in the treatment of poliomyelitis (218:1552, 1971). Spurred by this 
reference, we obtained a small amount of the drug and treated one case of amyotropic 
lateral sclerosis (ALS) with securinine (Pa Med 76:36, 1973). Subsequently, with the 
permission of the Food and Drug Administration (IND 8929), the drug was administered to 
eight additional patients, affording us sufficient experience to report our impressions. We do 
not believe that securinine has any significant effect on the progression of ALS. Not one of 
our patients experienced a remission, nor did any of our patients show a substantial slowing 
of the rate of progression. In this respect, our experience probably is in agreement with what 
must have been the negative experience of the Russian investigators who discovered the 
drug and who make no reference” (Copperman et al., 1974). 
The conclusions from this present study are that securinine possess anti-cancer activities, 
with apoptosis as the route of cell killing. The compound has demonstrated very significant 
synergism with carboplatin, a standard drug in the treatment of ovarian cancer and also with 
paclitaxel another first-line ovarian cancer drug. The potency of securinine is similar to that of 
carboplatin. Securinine does show preferential selective cytotoxicity for cancer cells, with 
less toxicity observed on normal cells in vitro. This compound is the lead bioactive compound 
in Margaritaria discoidea. 
 It may be suggested that the confirmed anti-cancer activities of MD could be as a result of 
these identified bioactive compounds. The anti-inflammatory activity of MD has been 
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documented and the acute toxicity of the plant was also investigated in an in vivo study. The 
researchers observed a lack of acute toxicity in the oral administration of 3200mg/kg of the 
aqueous extract in rats (Adedapo et al., 2009). This finding is of immense significance as the 
plant is usually taken as a decoction in ethno medicine. Again, the investigated bioactive 
compounds, all displayed selective inhibition activities towards cancer cells in comparison to 
normal cells. 
3.11 Conclusion 
In conclusion, an investigation of the anti-cancer activities of Margaritaria discoidea, MD, on 
ovarian cancer cell lines has been carried out. Previous studies have investigated the anti-
inflammatory and the analgesic effect of the aqueous extract of the stem back of M. 
discoideain rats. The results of this referenced study, observed significant activities 
comparable with the effect of indomethacin, the standard drug employed in the study 
(Adedapo et al., 2009). 
This present study showed that the organic extract had the notable anti-cancer activity. 
Furthermore the bioassay-guided fractionation of this extract showed that the ethyl acetate 
fraction had the most potency. The identified/isolated bioactive compounds of this fraction 
were securinine, gallic acid, betulinic acid, (-)-catechin and (-)-gallocatechin presented in the 
order of decreasing potency. The observed cytotoxic activities of these compounds were 
further compared with the observations of other researchers, which validated these finding. 
The lead compound in MD is securinine and the results of these studies have demonstrated 
that securinine is a promising agent for ovarian cancer treatment. The agent merits further 
investigation into the anti-cancer MOA of this pharmacologically important compound, which 
would guide the synthesis of more-potent securinine analogues. 
Furthermore, this study justifies and intensifies the necessity to revisit the libraries of drugs 
that are deemed to have failed in a particular activity evaluated. It is hoped that such drugs 
for instance, securinine would be found of immense therapeutic use for other activities. 
99 
 
Finally, this is the first report of the anti-cancer activities of Margaritaria discoidea, a plant in 
the Phyllanthaceae family, which could be used both as a chemopreventive decoction and in 
the treatment of cancer. 
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Chapter Four  
Anti-Ovarian Cancer Activities of Acalypha Wilkesiana  Müll. Arg. 
4.1 Introduction 
Acalypha wilkesiana Müll. Arg. (AW) popularly called copperleaf, Jacob’s coat and Fire 
dragon is a perennial plant belonging to the Euphorbiaceae family.  This plant specie has 
several cultivars, such as Godseffiana, Macrophylla, Marginata, Obovata cristata and 
Hoffmannii. The genus Acalypha has 450-570 species, widely distributed in tropical climates. 
Acalypha species have been utilised in ethno medicine by indigenous communities. 
Literature of the pharmacological studies of this genus showed that investigations have been 
carried out in about forty species, with a focus on the anti-microbial and anti-malarial 
activities of the species (Seebaluck et al. 2015). Phytochemical investigations have also 
been carried out in some species, with the identification of bioactive compounds. There are 
apparently very few anti-cancer studies carried out on many of the species. Literature search 
revealed that there are five taxonomically identified species of Acalypha native to Nigeria; A. 
alnifoliaKlein ex Willd. (A. capitata Willd.), A. fimbriataSchumach.&Thonn., A. torta Pax & K. 
Hoffm., A. racemosa Wall. Ex Baill.andA. wilkesiana Mull. Arg. (AW). Documented evidence 
has shown that AW has been employed in the indigenous treatment of breast tumours in the 
western parts of Nigeria (Quds et al., 2012). The ethyl acetate extract was shown to induce 
apoptosis by causing DNA breaks in human glioma and lung carcinoma cells (Lim et al., 
2011).There are scanty data on the anti-cancer activities of AW, and demonstrated studies 
that have identified the active principles responsible for the observed anti-cancer activities of 
AW. Hence this research work on the investigation of the anti-ovarian cancer activities of AW 
was undertaken.  
The research in this chapter aims to investigate the anti-cancer activities of AW on ovarian 
cancer cell lines. Through bioassay-guided fraction, the active compounds would be isolated 
and characterised. Further growth inhibition evaluation on cell-growth assay would be carried 
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out to validate the antiproliferative activities of the bioactive compounds. Selectivity index of 
the bioactive compounds with optimum activities would be undertaken. Preliminary SAR 
studies of the derivatives of the obtained bioactive compound would be carried out in order to 
guide future synthesis of more potent analogues and determine the anti-cancer activities of 
derivative compounds with potential therapeutic application in chemotherapy.   
4.2 Results and Discussion 
4.2.1 Extraction of Plant Materials 
The pulverised leaves (inclusive of flowers and seeds) of AW (Marginata) were extracted 
using a combination of dichloromethane and methanol to obtain the organic extract, followed 
by extraction with deionised water to yield the aqueous extract, according to the procedures 
(Figure 2.1) used by National Cancer Institute (NCI, USA). The amounts of the extracts and 
their yields obtained are shown in Table 4.1 
Table 4-1 Percentage Yield of the AW Extracts obtained from the extraction with 
dichloromethane/methanol (organic extract) and extraction with deionized water (aqueous 
extract). 
SAMPLE AMOUNT 
(g)    
ORGANIC EXTRACT 
(g)   
AQUEOUS EXTRACT 
(g)   
% YIELD OF TOTAL 
EXTRACT OF PLANT 
1000         12.5                                                        2.0                                         1.5 
 
From the data in Table 4.1, it was observed, that the leaves yielded relatively low amounts of 
solid extract. But in comparison with the yields from the stembark of MD and RP repectively, 
this yield of 1.5% was much.  Also, the organic extract is more than the aqueous extract. This 
may be due to the method of extraction, which was sequential; organic extraction, followed 
by aqueous extraction. 
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4.2.2 Screening of anti-ovarian cancer activity of the plant extracts 
The organic and aqueous extracts of AW were screened for their inhibition of cell growth on 
OVCAR4, OVCAR8 and A2780 ovarian cancer cell lines using a cell growth assay in which 
cell number was estimated by staining with SRB. The results of the IC50 values of the 
preliminary anti-cancer investigation of the plant extracts are presented in Table 4.2. 
Table 4-2  Results of Preliminary Screening of the Extracts of AW on ovarian cancer cell lines 
in cell growth assays. The cells were treated for 72h with the indicated extract, followed by an 
estimation of the number of surviving cells by SRB staining. The results are expressed as mean 
±SEM, n=3 experiments 
Extract                        IC50  in µg/mL 
A2780 OVCAR 8 OVCAR 4 
Organic Extract                   35.4±1.5                42.6±1.9                    46.7±1.8 
Aqueous Extract                54.7±2.2                 150.7±3.5                     73.9±1.3 
 
The results presented in Table 4.2 showed that AW extracts caused growth inhibition on the 
three ovarian cancer cell lines tested. The organic extract was more potent than the aqueous 
extract on all the tested cell lines. An important observation was that the IC50 of the organic 
extract was <50µg/mL on all three ovarian cancer cell lines. This IC50 is below the threshold 
which is considered to be significant from the perspective of the American national Cancer 
institute criteria, which from a screening of about 20,000 plant extracts, identified 452 
cytotoxic extracts with IC50<50µg/mL(Thomas 2010). Thus, the organic extract of AW with 
IC50s <50µg/mL warranted further purification and investigation for anti-cancer activity. 
Ethnopharmacological data showed that AW has been employed as an essential ingredient 
in a complex herbal preparation used in the indigenous treatment of breast tumour in the 
western part of Nigeria (Ikewuchi et al., 2010; 2013). The antiproliferative activity of AW has 
been reported (Madlener et al., 2009).  
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4.2.3 Bioassay-guided fractionation of AW 
Further solvent fractionation of 5.0 g of the crude organic extract of AW was carried out, by 
the sequential solvent partitioning of the organic extract in n-hexane, ethyl acetate, n-butanol 
and water, as described in the scheme presented in Figure 2.1 in the Materials and Methods 
chapter. The following yields were obtained (mass of solid compound recovered is shown in 
parentheses): n-hexane (2.5g), ethyl acetate (1.0g), n-butanol (0.7g) and aqueous (0.5g) 
fractions respectively. These fractions were investigated for growth inhibition on the OVCAR4 
cell line (Table 4.3). 
Table 4-3 The results of the evaluation of the growth inhibition of the fractions of AW on 
OVCAR 4 cell line in cell growth assays. The cells were treated for 72h with the indicated fraction, 
followed by an estimation of the number of surviving cells by SRB staining. The results are expressed 
as mean ±SEM, n=3 experiments. 
FRACTION                            ABBREV.                     IC50  (µg/ml) 
N-HEXANE                            N-HEX                           95.2±5.6 
ETHYL ACETATE                 EA                                  28.9±1.9 
N-BUTANOL                         N-BUT                            111.0±12.2 
AQUEOUS                            AQ                                   84.9±7.6 
 
The observations from the results were that the ethyl acetate fraction had the most significant 
antiproliferative activities on the OVCAR 4 cell line. The aqueous, the n-hexane and the n-
butanol fractions had moderate activities. Similar findings have been observed from previous 
studies, on the anti-microbial activities of the methanol extract and the obtained fractions of 
AW. The researchers reported that the ethyl acetate fraction had potent inhibitory activities 
on the bacteria and fungi tested than the other fractions (Haruna et al., 2013). Another study 
observed that the ethyl acetate extract of AW showed significant inhibitory activities on A549 
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human lung carcinoma and U87MG human brain glioblastoma with minimal inhibitory effects 
on the MRC5 normal human lung fibroblast (Lim et al., 2011). 
4.2.4 Chemical characterization of AW 
The TMSi derivatives of the organic extract, the aqueous extract and ethyl acetate fraction 
were prepared and analysed by GC-MS. The TMSi derivatives of the extracts and fraction of 
AW were obtained by the treatment of BSTFA and pyridine and subjected to further analysis 
on the GC-MS to determine the potential bioactive compounds that could be responsible for 
the observed activities. The GC-MS chromatograms of the TMSi derivatives gave a number 
of compounds, with the most compounds detected in the organic extract. A significant finding 
was the presence of gallic acid in the derivatized organic and aqueous extracts and in the 
ethyl acetate fraction. This observation suggests that the activity of the aqueous extract in 
this study is largely due to the presence of gallic acid. 
The GC chromatogram of the ethyl acetate fraction of AW displayed a large number of 
compounds. Twelve compounds with a >80% quality match with the NIST library were 
detected. These compounds are shown in Table 4.4.  
Three of the twelve identified compounds had a match quality of 99%. These were gallic 
acid, protocatechuic acid (PCA), and shikimic acid. Shikimic acid and PCA are compounds 
produced in the biosynthesis of gallic acid. Previous studies have documented the presence 
of gallic acid, together with geraniin and corilagin (Figure 4.1) as the bioactive compounds 
present in AW (Adesina et al., 2000). The anti-cancer activities of these other two 
compounds have been reported in literature, with investigations of corilagin carried out on 
SKOv3ip Hey and HO-8910PM ovarian cancer cell lines. The documented IC50 value on 
these cell lines for corilagin was <30µM (Jia et al., 2013). In a related study, geraniin has 
demonstrated anti-cancer activities on breast cancer MCF-7 cells with the observation of a 
range of IC50s from 9.9-42.3 µM in a time-dependent manner (Zhai et al., 2016). 
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Table 4-4 TMSi derivatives detected in the ethyl acetate fraction of AW by GC-MS. 
PEAK  RETENTION 
TIME (MIN) 
TMSi DERIVATIVE  PARENT MOLECULES 
IN PLANT 
MATCH 
QUALITY 
1 3.43 Butanedioic acid, [(trimethylsilyl)oxy]-, bis(trimethylsilyl) ester Butanedioic acid 96 
2 5.99 1-Cyclohexene-1-carboxylic acid, 3,4,5-
tris[(trimethylsilyl)oxy]-, trimethylsilyl ester, [3R-
(3.alpha.,4.alpha.,5.beta.)]- 
Shikimic acid 99 
3 6.11 D-(-)-Fructofuranose, pentakis(trimethylsilyl) ether (isomer 1) D-(-)-Fructofuranose 
  
89 
4 6.16 Benzoic acid, 3,4-bis[(trimethylsilyl)oxy]-, trimethylsilyl ester
  
Protocatechuic acid 99 
5 6.29 D-(-)-Fructopyranose, pentakis(trimethylsilyl) ether (isomer 
1)  
D-(-)-Fructopyranose 
  
93 
6 6.71 D-Pinitol, pentakis(trimethylsilyl) ether    D-Pinitol   90 
7 6.95 .beta.-D-Glucopyranose, 1,2,3,4,6-pentakis-O- .beta.-D-Glucopyranose 95 
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(trimethylsilyl)-   
8 7.46 Benzoic acid, 3,4,5-tris(trimethylsiloxy)-, trimethylsilyl 
ester  
Gallic acid 99 
9 7.62 Inositol, 1,2,3,4,5,6-hexakis-O-(trimethylsilyl)-, D-chiro-  Inositol 97 
10 7.72 Glucopyranose, pentakis-O-trimethylsilyl-  Glucopyranose 93 
11 12.86  Hexadecanoic acid, 2,3-bis[(trimethylsilyl)oxy]propyl ester 
  
Hexadecanoic acid 91 
12 13.69 alpha-D-Glucopyranoside, 1,3,4,6-tetrakis-O-(trimethylsilyl)-
.beta.-D-fructofuranosyl 2,3,4,6-tetrakis-O-(trimethylsilyl)- 
alpha-D-
Glucopyranoside 
   
   
94 
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Figure 4.1 The chemical structures of two previously identified bioactive compounds in AW (Adesina et al., 2000). 
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The anti-cancer activities of PCA have been reported on human leukaemia cells (Babich et 
al., 2002). Gallic acid has demonstrated significant antiproliferative activities on the A549 
human lung adenocarcinoma in vitro in a dose-dependent manner at an experimental time of 
24h. Further investigations showed that the compound induced the activation of caspase 3; a 
strong indication of apoptosis (Dharmendra et al., 2011). 
 
4.2.5 Bioassay-Guided Fractionation of Ethyl Acetate fraction of AW 
Further bioassay-guided fractionation of the ethyl acetate (EA) fraction of AW was carried 
out. A trial of three different solvent combinations was first undertaken on TLC to ascertain 
the most suitable solvent system for the silica gel column fractionation of the EA fraction. 
Upon TLC of the CHCl3: Methanol (10:1), 2 spots were visualised on the TLC plate. While for 
EA: n-hexane (2:1) solvent systems, 4 spots were detected. Then for EA: n-hexane (1:1) 
solvent system, 7 spots were observed. Eighteen sub-fractions were obtained from a solvent-
polarity based fractionation which utilised various combinations of n-hexane/ethyl acetate. 
The fractionation began with a 100% n-hexane and ended with 100% methanol. TLC of the 
collected sub-fractions showed that some sub-fractions had identical TLC characteristics, 
and thus these sub-fractions were bulked together resulting in eight sub-fractions. The 
obtained sub-fractions were evaluated for cell growth inhibition on OVCAR 4 cell line (Table 
4.5). 
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Table 4-5 The Results of the evaluation of the growth inhibition activity of the Sub-Fractions of 
the ethyl acetate fraction of AW on OVCAR 4 cell line in cell growth assays. The cells were 
treated for 72h with the indicated fraction, followed by an estimation of the number of surviving cells by 
SRB staining. The results are expressed as mean ± SEM, n=3 experiments. 
Sub-fractions of EA OVCAR4 cell line (µg/ml) 
F1 >200 
F2 34.5 ±1.8 
F3 15.7±0.1 
F4 50.7±3.9 
F5 47.2±6.8 
F6 17.8±1.8 
F7 >200 
F8 >200 
 
The results of the cell growth inhibition evaluation of the obtained sub-fractions showed that 
sub-fractions 3 (F3) and 6 (F6) were potent with significant inhibitory activities on the 
OVCAR4 cell line. TMSi derivatization of F3 was carried out to detect the possible bioactive 
compounds in that sub-fraction. The detection of eleven compounds with a match quality of 
>80% was made. Some of these compounds were also present in the parent ethyl acetate 
fraction. The GC chromatogram of the EA fraction 3 is shown in Figure 4.2. 
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Figure 4.2 The GC-MS chromatogram of the TMSi derivatized ethyl acetate fraction F3, showing 
several peaks, with the gallic acid peak highlighted. 
The MS of gallic acid in the fraction and the corresponding spectrum of standard gallic acid in 
the NIST library are presented in Figure 4.3.The detected compounds are listed in Table 4.6. 
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Figure 4.3 The mass spectrum of the derivatized gallic acid contained in ethyl acetate fraction 
F3 (above) and the spectrum of gallic acid obtained from the NIST Library of the GC-MS 
(below). 
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Table 4-6 TMSi derivatives of Compounds detected in F3 sub-fraction of ethyl acetate fraction of AW by GC-MS. 
PEA
K 
RETENTION 
TIME (MIN) 
TMSi DERIVATIVE PARENT MOLECULES IN 
PLANT 
MATCH 
QUALITY 
AREA 
OF 
PEAK 
(%) 
(N=3) 
1 10.67  Glycerol, tris(trimethylsilyl) ether GLYCEROL 90 3.2±0.5 
2 17.63 1-Cyclohexene-1-carboxylic acid, 3,4,5-
tris[(trimethylsilyl)oxy]-, trimethylsilyl ester, [3R-
(3.alpha.,4.alpha.,5.beta.)]-    
SHIKIMIC ACID 99 14.5±1.5 
3 17.76  D-Psicofuranose, pentakis(trimethylsilyl) ether 
(isomer 1)  
D-PSICOFURANOSE 91 3.4±0.8 
4 17.87  D-(-)-Fructopyranose, pentakis(trimethylsilyl) ether 
(isomer 1)  
D-(-)-FRUCTOPYRANOSE 95 5.1±0.6 
5 18.39 D-Pinitol pentakis(trimethylsilyl) ether 
   
D-PINITOL 90 12.5±1.1 
6 18.65  .beta.-D-Glucopyranose, 1,2,3,4,6-pentakis-O- BETA-D- 94 4.6±0.4 
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(trimethylsilyl)-   GLUCOPYRANOSE 
7 19.24  Benzoic acid, 3,4,5-tris(trimethylsiloxy)-, 
trimethylsilyl ester  
GALLIC ACID 99 28.7±1.2 
8 19.36  Inositol, 1,2,3,4,5,6-hexakis-O-(trimethylsilyl)-, D-
chiro- 
INOSITOL 87 2.7±0.2 
9 19.53 Glucopyranose, pentakis-O-trimethylsilyl- GLUCOPYRANOSE 95 4.2±0.4 
10 20.71  Myo-Inositol, 1,2,3,4,5,6-hexakis-O-(trimethylsilyl)-
   
MYO-INOSITOL 95 0.8±0.1 
11 25.66  alpha-D-Glucopyranoside, 1,3,4,6-tetrakis-O-
(trimethylsilyl)-.beta.-D-fructofuranosyl 2,3,4,6-
tetrakis-O-(trimethylsilyl)-   
ALPHA-D-
GLUCOPYRANOSIDE 
91 1.4±0.3 
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The prime compounds gallic acid and shikimic acid were among the detected compounds in 
the F3 sub-fraction of ethyl acetate fraction of AW. Again these compounds were detected 
with a match quality of 99%.  
A calculation of the peak area was made and used as a measurement of the amount of the 
compounds present in the fraction. This quantification showed that gallic acid was 28.7% and 
shikimic acid was 14.5%. These two compounds were the most abundant compounds 
contained in the F3 sub-fraction of the ethyl acetate fraction of AW. This finding strongly 
suggests that the significant anti-cancer activity of AW is attributable to the vast amount of 
gallic acid contained in the plant. This finding could be exploited in the commercial sourcing 
of natural gallic acid for both food and pharmaceutical industries. TMSi derivatization of 
Fraction 6 was carried out and analysed on the GC-MS, but no significant compound was 
detected. Fraction 6 was subjected to hplc purification, but effective separation of the 
compounds contained in the fraction could not be achieved as there were too many peaks 
with very close retention times. Given the insufficient amount of the fraction, further 
investigation of this fraction was discontinued.  In order to identify the potential bioactive 
compounds in F3, further purification of F3 was carried out by semi-prep HPLC on the C-18 
column with a mobile phase composition of 100% water acidified with 0.1% Trifluoroacetic 
acid (TFA) as solvent A and 80% acetonitrile acidified with 0.1% TFA as solvent B. The 
gradient began with 100% of A for 5 min and increased to 100% B for 25 min of the run time. 
and maintained for 5 min of the analysis; making the total run time 35 min. 
Ten hplc-fractions were isolated upon separation and these hplc fractions were further 
investigated for inhibitory activities on OVCAR 4 cell line (Table 4.7). 
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Table 4-7 The Results of the evaluation of the growth inhibition of the HPLC fractions of F3 on 
the OVCAR 4 cell line in cell growth assays. The cells were treated for 72h with the indicated 
fraction, followed by an estimation of the number of surviving cells by SRB staining. The results are 
expressed as mean ±SEM, n=3 experiments. 
HPLC FRACTIONS OF F3 Retention time (min) IC50 (µg/ml) 
1 2.2-2.4 83.3±6.2 
2 2.4-2.5 38.0±2.5 
3 2.5-2.7 14.9±0.4 
4 2.7-2.8 31.9±4.9 
5 2.8-3.4 10.9±0.7 
6 7.4-9.2 54.4±4.2 
7 10.9-11.3 49.6±1.9 
8 11.4-12.3 29.8±4.6 
9 12.4-13.0 11.9±0.9 
10 18.8-19.4 48.1±7.8 
 
The results of the screening of the HPLC fractions of F3 presented in Table 4.7 showed that 
the fraction 5 at 2.8-3.4 min was the most potent fraction.  HPLC fraction 5 was a white 
amorphous powder. Documented phytochemical studies of the red-Acalypha, a cultivar of 
AW (closely-related to the Marginata cultivar used in this study), recorded the presence of 
gallic acid and geraniin from n-butanol fraction, obtained from an aqueous ethanol extract. 
The fractionation procedure, used by these researchers by-passed the use of ethyl acetate. 
The researchers further reported the effect of seasonal variation on the constituents of the 
plant. According to the study, AW collected in the month of July (Peak Rainy Season in 
Nigeria), contained corilagin. While AW collected in the month of November (Dry Season in 
Nigeria) contained gallic acid (Adesina et al., 2000). This finding may explain while the 
presence of corilagin was not detected in this current study of AW. The collection period of 
the plant materials utilised for this research was during the Dry season in Nigeria (December-
March). The presence of geraniin, with an m/zof 952.64 could not be detected by the GC-
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MS, as upon TMSi derivatization, the detectable m/z, would have been above the detection 
limit of the GC-MS. LC-MS is needed for identification of such compounds.  
The HPLC fraction 5 was derivatized and analysed on the GC-MS using a modified program, 
with an increase start-off oven temperature. This was necessary in order to detect 
compounds which could not be detected at lower temperatures.  The GC-MS, chromatogram 
(Figure 4.5) below showed a massive peak with a retention time of 7.43-7.48min and > 95% 
purity, corresponding to gallic acid. The presence of an unknown peak accounted for <3% of 
the isolated compound, while a minute amount of shikimic acid (<0.6%) was present in the 
isolated gallic acid obtained from the GC-MS analysis. The proton NMR analysis carried out 
in methanol-d4 showed a single peak [δ (ppm) =7.04 (s, 2H)].
13C NMR (CD3OD),[δ (ppm) = 
170.51, 146.59, 139.85, 121.86, 110.20]. The NMR spectra were comparable with the 
reported spectra in literature for gallic acid, (Kamatham et al., 2015).Thus, hplc fraction 5 
was unequivocally determined as gallic acid. 
 
 
 
 
 
Figure 4.4
1
H NMR Assignment of HPLC fraction 5 (Gallic acid) 
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Figure 4.5 GC-MS chromatograms of hplc fraction 5 (retention time 2.8-3.4) after TMSi 
derivation. 
The mean IC50 curves of Acalypha EA-fraction, the sub-fraction F3 and the HPLC fraction 5 
(retention time 2.8-3.4 min) are shown in Figure 4.6.The results showed that there is a 
progressive increase in the potency of the fractions from the Acalypha EA-fraction to HPLC 
fraction 5, with the purification of the sample. Further investigation into the selectivity index of 
HPLC fraction 5 was carried out by investigation of the growth inhibition of the compound on 
HOE (Table 4.8 and Figure 4.6). 
Table 4-8 The Mean IC50 Values of HPLC Fraction 5 on OVCAR 4 and HOE Cell Lines, and the 
Calculated Selectivity Index (SI). The results are expressed as Mean IC50 ± SEM, n=3. 
FRACTION IC50 OF OVCAR 4 (µg/ml) IC50 OF HOE (µg/ml) SI 
HPLC FRACTION 5  
(gallic acid) 
10.9±0.7 39.3±1.6 3.6 
 
2 .0 0 4 .0 0 6 .0 0 8 .0 0 1 0 .0 0 1 2 .0 0 1 4 .0 0 1 6 .0 0 1 8 .0 0
2 0 0 0 0 0 0
4 0 0 0 0 0 0
6 0 0 0 0 0 0
8 0 0 0 0 0 0
   1 e + 0 7
 1 .2 e + 0 7
 1 .4 e + 0 7
 1 .6 e + 0 7
 1 .8 e + 0 7
   2 e + 0 7
 2 .2 e + 0 7
 2 .4 e + 0 7
 2 .6 e + 0 7
 2 .8 e + 0 7
   3 e + 0 7
 3 .2 e + 0 7
 3 .4 e + 0 7
T im e -->
A b u n d a n c e
T IC :  A C A L Y P H A _ A Q _ E X T _ E A _ F R A C T _ 2 _ 8 T O 3 _ 4 _ 2 .D \ d a ta .m s
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Figure 4.6 The mean concentration-response curve of the ethyl-acetate fraction of AW, the sub-
fraction of EA, F3 and the hplc fraction 5 on OVCAR 4 cell line. The cells were treated for 72h 
with the indicated compound, followed by an estimation of the number of surviving cells by 
SRB staining. The results were expressed as Mean IC50± SEM, n=3. 
 
Figure 4.7 The mean concentration-response curve of hplc fraction 5 (gallic acid) on the human 
ovarian epithelial cell line (HOE). The cells were treated for 72h with the indicated compound, 
followed by an estimation of the number of surviving cells by SRB staining. The results were 
expressed as Mean IC50 ± SEM, n=3. 
The selectivity index of gallic acid (hplc fraction 5), was obtained as 3.6, which showed a 
very significant preferential selectivity in the killing of cancer cells, with minimal inhibition on 
normal cells. Similar observations have been reported by Lim and his co-researchers, from a 
study of the evaluation of the cytotoxicity of the ethyl acetate extract of AW on A549 lung 
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cancer cell line and the corresponding normal lung cell line, MRC5. The researchers 
observed potent antiproliferation on the cancer cells, without any significant inhibition on the 
normal cells (Lim et al., 2011). 
4.2.6 Investigations of the Synergistic Potentials of Gallic Acid (GA) and 
Clinically Used Ovarian Cancer Drug 
Further investigation to determine whether the effect in the cell growth assays reflected 
inhibition of proliferation or cell death was undertaken by TBA. Also, the synergistic potentials 
of gallic acid with carboplatin was investigated in this assay. The cells were plated in 12 well 
plates at a seeding density of 1 x105 cells/well. The cells were exposed to 40µM, 20µM and 
10µM concentrations of gallic acid. 40µM Carboplatin was the reference standard, while the 
vehicle-treated cells were used as the control. A combination of 40µM Carboplatin and the 
three gallic acid concentrations was also carried out to investigate the combined effects of 
both compounds and an assessment of the viability of the cells was carried out after 48h 
incubation, by haemocymeter counting of the live and dead cells, pre-stained with trypan 
blue(Figure 4.8). 
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Figure 4.8 The effect of gallic acid at the indicated concentrations and in combination with 
carboplatin (40 µM) at 48h on cell viability. The vehicle-treated cells served as the control. The 
cells were stained with trypan blue and the percentage of dead cells was obtained by 
microscopy. The horizontal blue bars indicate the expected effect obtained from the bliss 
independent effect calculation comparing the effect of the combination and the single agents. * 
denotes that the result is significantly different (P<0.05, paired t-test) from the effect expected 
from the Bliss independence criterion. While ## detones significant difference from the control 
(P<0.001, one-way ANOVA). 
 
The results of the trypan blue assay, TBA carried out for gallic acid, GA at concentrations; 
10-40µM, and their respective combinations with carboplatin (40µM), (Figure 4.8) showed 
that the activity of GA was in a concentration-dependent manner, with the lowest 
concentration of 10µM exerting the least antiproliferative effect. The 40µM concentration of 
GA had increased activity than the standard drug, carboplatin (20µM).Similar results have 
been reported from an evaluation of the cytotoxicity of GA combined with flutamide on AR+ 
LNCaP human prostate cancer cells with the observation that the activity of 50µg/ml of gallic 
acid was significantly greater than the activity of the standard drug flutamide at a 
concentration of 25µM (Larry et al., 2011).In comparison to the control, the 40µM and 20µM 
concentrations had statistically significant p<0.001 significance, while the 10µM didn’t attain 
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a p<0.05 significance which may be indicative of the effective concentration of gallic acid 
being above 10µM. 
Further examination of the results of the combination of the different concentrations of gallic 
acid and carboplatin (40µM) showed that40µM and 20µM GA combinations with carboplatin 
had better activity than the single use of the agents alone. However, the results were not 
significant from that which would be expected for additivity with the bliss expected effect. It 
was observed from the results that the 10µM gallic acid combination with carboplatin did not 
attain the bliss expected effect criterion at p<0.05. The results demonstrate the possibility of 
antagonism between carboplatin and GA at the 10µM concentration. 
Studies on the effect of drug combination between gallic acid and carboplatin on OVCAR 4 
cells were carried out to investigate the synergistic potentials of gallic acid in increasing the 
growth inhibition activities of carboplatin by the fixed dose method (Figure 4.9). 
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Figure 4.9 Mean concentration-response curves of vehicle-treated cells carboplatin-treated 
cells (Maximum concentration of 100 µM) and the drug combination of gallic acid at a fixed 
concentration of 10 µM and Carboplatin (Maximum concentration of 100 µM), on the OVCAR 4 
cell line determined after 72h of treatment. The surviving cell number was estimated by 
staining with SRB. The results were expressed as mean of three experiments, Mean± SEM. 
 
The results shown in Figure 4.9 revealed an antagonistic effect in the drug combination of 
10µM of gallic acid and carboplatin. This result was statistically significant from antagonism 
at p<0.05. This observation may be due to the 10µM fixed concentration of gallic acid used 
which was expected that at this concentration the compound would cause 5% growth 
inhibition of the cancer cells, judging the activity of the compound from single agent studies. 
Importantly, this finding supports the observed antagonism shown in the TBA results of 
carboplatin and gallic acid at the 10µM concentration. 
4.3 Discussions of Acalypha wilkesiana and Gallic Acid 
The anti-ovarian cancer activities of A. wilkesiana, AW were investigated in this research, by 
the screening of the extracts of the plant. The results (Table 4.2) showed that the organic 
extract had more potent inhibition activities than the aqueous extract. Other studies have 
documented anti-hypertensive and hypoglycaemic activities of the aqueous extract of AW 
(Ikewuchi et al., 2013), with no mention of an organic extract. Similarly, the ethanol extracts 
of AW has been shown to possess significant anti-microbial activities both from in vitro 
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Haruna et al., 2013) and in vivo (Oyelami et al., 2003; Chukwuemeka et al., 2013) studies. 
These documented researches, suggest that the active principles in AW are of moderate 
polarity, hence when the extraction is carried out by water or ethanol and methanol, the 
extracts have been found to be active. This finding thus justify the indigenous use of the 
water extract of AW in the treatment of neonatal jaundice, diabetes, skin infections and 
stomach problems (Soladoye et al., 2008; Iniaghe et al., 2013). However, when the plant is 
extracted sequentially by a polar organic solvent, followed by aqueous extraction, then the 
organic extract possesses a better activity than the aqueous extract, as seen in the results 
contained in Table 4.2 above. 
Fractionation of the organic extract by solvent partitioning of the extract sequentially in n-
hexane, ethyl acetate, n-butanol and methanol to obtain four fractions was carried out. The 
evaluation of these fractions on the ovarian cancer cell lines demonstrated that the ethyl 
acetate fraction had notable activities. GC-MS analysis of the Tmsi derivatized sample of the 
ethyl acetate fraction showed that gallic acid constituted 28.7% of the fraction in comparison 
to the other identified compounds. Further bioassay-guided purification carried out by both 
column chromatography and hplc, led to the isolation of gallic acid.  
Gallic acid (Figure 4.10) is a phenolic acid, which belongs to the tannin class of compounds. 
The compound is widely distributed in many plants such as Belamcanda chinensis (Liu et al., 
2012), Boswellia dalzielii (Alemika et al., 2007), Camillia sinensis (Zhu et al., 2013), 
Phyllanthus emblica (Calixto et al., 1998), and Toona sinensis (Yi-Chen et al., 2010). The 
compound is contained in some fruits such as berries, grapes, mango, pomegranate and 
gallnuts. 
Phenolic compounds have long being recognised for their beneficial roles in the prevention of 
diseases due to their oxidation-reduction properties. Importantly, gallic acid, one of the 
phenolic compounds had received much scientific interest owing to the presence of three 
hydroxyl groups and a carboxylic acid in the chemical structure. Additionally, the compound 
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possesses a small molecular mass of 170, and has the propensity to prevent oxidative 
damages triggered by reactive oxygen species, ROS. Therefore, gallic acid has immense 
benefits in cardio protection (Priscilla et al., 2009), hepato protection (Jagan et al., 2008), 
nephron protection (Vijaya et al., 2011) and neuroprotection (Lu et al., 2006). The anti-
oxidant and free-radical scavenging activities of gallic acid, has being documented, with the 
compound shown to be the major compound responsible for the anti-oxidant, anti-radical and 
in some cases anti-cancer compound of many plants (Agarwal et al., 2006; Yi-Chen et al., 
2010; Palafox-Carlos et al., 2012). The compound has potent anti-inflammatory, (Kroes et 
al., 1992; Tsang et al., 2016), anti-microbial (Borges et al., 2013), anti-ulcer, (Siddaraju et al., 
2007), and anti-viral activities, (Jadel et al., 2008).  
Recently, investigations into the anti-cancer activities of Gallic acid have being documented 
for several cancers in vitro. Gallic acid has been found to exert cytotoxic activities on breast 
(García-Rivera et al., 2011; Wang et al., 2014), cervical, (Zhao et al., 2013), colon (Yoshioka 
et al., 2000; Salucci et al., 2002; Jebakkan et al., 2010; Aruna et al., 2016), glioma (Lu et al., 
2010),  stomach (Yoshioka et al., 2000), leukaemia (Chandramohan et al., 2012), lung (You 
et al., 2011), pancreatic (Cedó et al., 2014), and prostate (Agarwal et al., 2006; Veluri et al., 
2006) cancers. 
The investigation of the growth inhibition activity of gallic acid in cell growth assays 
demonstrated that the agent had selective potent antiproliferative activities on ovarian cancer 
cells with minimal inhibition observed on normal cells. Further studies were carried out to 
determine whether the effect in the cell growth assays reflected inhibition of proliferation or 
cell death. The findings from this study showed that the compound may be cytotoxic on 
cancer cells. Additionally it was observed that the effective concentration for the activity of 
gallic acid on OVCAR 4 cells was >10µM. This is not unusual as a significant drawback of 
polyphenols is their observed poor bioavailability, which from a review of 97 kinetic studies of 
18 major polyphenols showed that plasma concentrations of the polyphenols were between 
0-4µmol/L from 50mg consumption of the equivalent aglycone. The researchers observed 
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that Gallic acid and isoflavones were the most absorbed of the polyphenols, followed by the 
catechins (Manach et al., 2005). 
Importantly, these results suggest that gallic acid is cytotoxic to the OVCAR 4 cancer cells; a 
cell line that is ranked among the most resistant cell lines of the human ovarian cancer, and 
which typifies serious ovarian cancer. By implication, these results have provided some 
evidence that gallic acid would be cytotoxic on most ovarian cancer cell lines. This view is 
further supported by the cytotoxic studies of gallic acid on two ovarian cancer cell lines; 
OVCAR 3, A2780/CP70 (a cisplatin-resistant cell line) and a normal ovarian cell line, ISOE-
364. The researchers reported that gallic acid significantly inhibited cell viability on the 
ovarian cancer cell lines, without a commensurate inhibition on the ISOE-364 cells. It was 
also noted that 40µM concentration of gallic acid had better inhibitory effects on the ovarian 
cancer cell lines than 20µM cisplatin (Zhiping et al., 2016).  
 Diverse studies into the mechanism of action of gallic acid have been undertaken by 
different researchers. The major consensus is that gallic acid perturbed the G2/M phase 
resulting in cell cycle arrest (Salucci et al., 2002; Ou et al., 2010). The agent has been shown 
to be an apoptosis inducer (Agarwal et al., 2006; Veluri et al., 2006). Gallic acid has been 
implicated in the generation of ROS, which are cytotoxic to cancer cells and resistant to 
normal cells. The agent has been shown to trigger an elevation of intracellular calcium level 
(Isuzugawa et al., 2001).  
Further evaluation of the synergistic potentials of gallic acid in enhancing the growth 
inhibition activities of carboplatin was undertaken by drug combination experiments in this 
study. The findings suggest antagonism between gallic acid and carboplatin which was also 
observed in the trypan blue assay. Other researchers have also observed significant 
antagonism in the combined use of the gallic acid and three other cancer drugs; 5-
fluorouracil, mitomycin C and gemcitabine (Peter et al., 2007). It maybe suggested that 
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higher concentrations of gallic acid (>40µM) may be required in order to achieve synergism 
between gallic acid and carboplatin. 
 A significant finding from this study is that gallic acid selectively inhibits cancer cells with 
very minimal inhibitory effect towards normal cells, which shows that gallic acid potentially 
could be employed as a chemopreventive agent and also in the treatment of ovarian cancer. 
Further investigations on gallic acid were not deemed worthwile as the compound has been 
shown to induce apoptosis from several other studies.  
Given the renewed interest in the pharmacological investigations of phenolic compounds as 
potential sources of chemotheraupeutic agents, this research evaluated the cell growth 
inhibition activities of some common gallic acid derivatives in order to obtain some structure 
activity relationship (SAR) information that would guide the synthesis of more potent gallic 
acid derivatives for anti-ovarian cancer activities. 
 
4.4 Investigations of Gallic Acid Derivatives 
Derivatives of gallic acid are currently in use as food additives, which may offer added 
advantages such as anti-oxidants which could hamper the peroxidation of lipids and enhance 
the prevention of a number of diseases such as cardio vascular diseases and hypertension. 
One study has shown that some gallic acid derivatives; methyl gallate, propyl gallate and 
lauryl gallate possess free-radical scavenging properties and were better inhibitors of the 
peroxidation of phospholipids in ox brain than parent gallic acid (Aruoma et al., 1993). 
This research work further investigated the growth inhibition of some common gallic acid 
derivatives on ovarian cancer cell lines, in order to obtain some preliminary SAR information 
that would guide the synthesis of more potent gallic acid analogues (Table 4.9 and Figure 
4.10). 
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Table 4-9 The growth inhibition evaluation of Gallic Acid Derivatives in cell growth assays. The cells were treated for 72h with the indicated compound, 
followed by an estimation of the number of surviving cells by SRB staining. The results are expressed as mean IC50 ±SEM, n=3 (IC50 values are in µM). 
 
CELL LINE GALLIC ACID (GA) 
Dose range 
 (0.8-40µM) 
LAURYLGALLATE 
(L-GAL) 
Dose range  
(0.02-5µM) 
ETHYLGALLATE  
(E-GAL) 
Dose range 
 (0.6-160µM) 
3,4,5-
TRIMETHOXYBENZ
OIC ACID  
(345-MBA)  
Dose range  
(1.25-320µM) 
PROTOCATECHUIC 
ACID (PCA) 
Dose range 
 (0.2-50µM) 
CARBOPLATIN 
Dose range  
(0.2-40µM) 
A2780 6.2±0.3 0.8±0.0 61.8±11.6 30.3±0.3 0.6±0.2 ND 
OVCAR 8 16.2±0.5 0.8±0.1 58.1±3.1 81.2±0.7 3.3±0.5 10.8±1.3 
CIS-A2780 6.5±0.4 0.3±0.05 60.0±0.05 34.2±1.6 3.7±0.9 ND 
OVCAR 4 26.9±4.1 2.5±0.1 63.2±1.2 ND ND 11.3±0.7 
HOE >100 2.3±0.05 ND ND ND ND 
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Figure 4.10 The mean concentration-response curves of two gallic acid derivatives ethyl gallate 
(E-GAL) on CIS-A2780 cell line  (A) and 3,4,5-TRIMETHOXYBENZOIC ACID (345-MBA) on CIS-
A2780 cell line (B). The cells were treated for 72h with the indicated compound, followed by an 
estimation of the number of surviving cells by SRB staining. The results were expressed as 
Mean IC50 ±SEM (n=3). 
 
The structures of the evaluated gallic acid derivatives shown in Figure 4.11 below. 
 
 
 
 
 
 
 
 
 
Figure 4.11 Chemical structures of gallic acid derivatives investigated for growth inhibition on 
ovarian cancer cell lines. 
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4.5 Discussion of Gallic acid Derivatives 
The results in Table 4.9 and in Figure 4.10 above showed that all the gallic acid derivatives 
demonstrated inhibitory activities on the ovarian cancer cell lines. A ranking of the order of 
activity in increasing antiproliferative activities is given as: 
L-GAL> PCA> GA>345-MBA >E-GAL 
Significant inhibition activities were demonstrated by L-GAL and PCA, which was≥ 10-fold 
increase in potency for L-GAL on all the cell lines, while for PCA, a 10 fold increase was 
showed on A2780, and a 4-fold increase on OVCAR 8. Similar findings have been reported 
from a study of phenolic acids, caffeic and gallic acid derivatives on three human cancer cell 
lines; HeLa cervical cancer cell line, MDA-MB-231 breast cancer adenocarcinoma and 
MOLT-3 lymphoblastic leukaemia. Among the compounds investigated were gallic  acid, 
PCA and some catechols. The study concluded that all the phenolic compounds were 
antiproliferative on all three cancer cell lines (Gomes et al., 2003). 
A closer look at the structures of the compounds showed that PCA has two hydroxyl groups 
on the ring, while parent GA has three hydroxyl groups on the benzene ring. The loss of one 
hydroxyl group, may have contributed to the significant increase in activity of PCA. Several 
researchers have reported the effect of the number of hydroxyl groups of gallic acid esters on 
anti-cancer activity. Their observation was that anti-cancer activity is enhanced by an 
increase in the number of hydroxyl groups on the aromatic ring (Gomes et al., 2003; Fiuza et 
al., 2004; Locatelli et al., 2008). In particular, one group that investigated a series of tri-
hydroxyl and di-hydroxyl gallic esters noted that the tri-hydroxyl esters exhibited better 
inhibitory activities on the human cervical cancer cell line HeLa (Fiuza et al., 2004). However, 
the result of this present study did not observe an enhancement of anti-cancer activity due to 
an increase in the number of hydroxyl groups’ on the aromatic ring in the ovarian cancer cell 
lines A2780, CIS-A2780 and OVCAR 8 evaluated. Another observation is the diminished 
activity of 345-MBA. This finding has been demonstrated in two studies. One research group 
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observed that at a concentration of 100µM, the compound had no inhibition on L-1210 
leukaemia cells (Locatelli et al., 2008).The results from this present study further suggested 
that a short-chain alkyl substituent on the ring may result in decreased activity, while a long-
chain alkyl substituent would significantly increase the activity of the compound as observed 
from the extremely low IC50 values of L-GAL in comparison with E-GAL. This observation has 
being documented by the above-referenced researchers and in particular the effect of alkyl-
chain length was observed in both di-hydroxyl and tri-hydroxyl gallic acid esters on all the 
human cancer cell lines investigated. This increase in activity exhibited by long alkyl-chain 
substituent may be attributed to the required interaction of a drug in the hydrophilic 
(cytoplasm) and the lipophilic (membrane) environments that enable the process of drug 
uptake in the body. The ability of a drug to interact optimally with these two environments is a 
bonus to activity. The long-chain alkyl substituent signified increased lipophilicity of the 
molecule, which may be of therapeutic benefit (Lu et al., 2006). The anti-cancer activity of L-
GAL has been reported in a study involving three diverse human breast cancer cells: MCF7, 
MDA-MB-231 and MCF7 ADR which were significantly inhibited by L-GAL. Importantly, the 
MCF7 ADR cell line is a multi-resistant cancer cell line. The report further observed low 
cytotoxicity on normal cells and an increase in apoptosis on all the cancer cell lines 
(Calcabrini et al., 2006). The results from this study showed that L-GAL has demonstrated 
significant growth inhibition on cancer cells in vitro, with a significantly much lower IC50 value 
compared to carboplatin, a first-line drug used in the treatment of ovarian cancer and has 
displayed preferential selectivity for cancer cells in comparison to normal cells on three 
ovarian cancer cell lines. Additionally, the agent has been shown to prevent the peroxidation 
of mitochondrial lipid (Kubo et al., 2002), which has immense therapeutic potentials in cancer 
therapy and other diseases (Kubo et al., 2003; Rogério et al., 2015). Furthermore L-GAL is 
officially a food additive (E312) and anti-oxidant since 1976and is currently used as a food 
additive for the prevention of bacterial and fungi growth in oils and fatty food products. 
Studies on the safety profile of the agent documented in the European Food Safety Authority, 
EFSA Journal reported that the agent hampered tumour growth in a long-term study with no 
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sign of genotoxicity, a further assessment of L-GAL carried out by the EFSA Panel  in 2015, 
recommended the continued use of L-GAL as a food additive, (EFSA, 2015; 2014). Further 
studies on L-GAL are merited as this agent could be a potential candidate for ovarian cancer 
prevention and treatment. 
4.6 Conclusion 
In conclusion, the investigation of the anti-cancer activities of Acalypha wilkesiana on ovarian 
cancer cell lines has been carried out. The study showed that the main active compound 
isolated from the plant is gallic acid, which can be extracted by polar organic solvents. 
Cytotoxic investigations of the plant showed that the AW possesses anti-cancer activities in 
vitro, which may provide evidence for the indigenous use of the plant for the treatment of 
cancer. 
Further findings from this present research are the potential existence of significant 
antagonism between gallic acid (10µM) and carboplatin, as observed in the trypan blue 
assay and drug combination experiments.  
The investigations of four derivatives of gallic acid were further conducted, and the results 
demonstrated  that all four derivatives; ethyl gallate, lauryl gallate, 3, 4, 5 -trimethoxybenzoic 
acid and protocatechuic acid were inhibitory on the cell lines. Significant inhibition was 
observed in lauryl gallate, a food additive. This agent was more potent than carboplatin; a 
standard first-line drug employed in the clinical treatment of ovarian carcinoma, and thus is a 
promising hit compound for future development.  
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Chapter Five  
Anti-Ovarian Cancer Compounds from Rutidea parviflora DC. 
5.1 Introduction 
Rutidea parviflora DC (RP) belongs to the Rubiaceae family, in the Angiosperm category of 
plants. A review of the Rubiaceae family published in 2015 showed that there were no 
reported phytochemical studies on the genus Rutidea (Martins et al., 2015).This genus has 
21 species and there are no documented investigations on the bioactivities of the species. R. 
parviflora is thus a; relatively un-exploredspecie for biological activities and this has 
prompted this research work, as the first reported investigations of the anti-ovarian cancer 
activities of RP.  
The research in this chapter aims to investigate the anti-cancer activities of RP on ovarian 
cancer cell lines.  Through bioassay-guided fraction, the active compounds were isolated and 
characterised. Growth inhibition evaluation using cell-growth assays were carried out to 
investigate the antiproliferative activities of the bioactive compounds. An estimation of the 
selectivity index of the bioactive compounds was undertaken. Through the apoptosis studies, 
the possible route, by which the most potent bioactive compound kills the cancer cells, was 
investigated. Drug combination studies were carried out to identify potential synergy between 
the most potent bioactive compound and clinically used ovarian cancer drugs both in cell 
growth assays and in apoptosis studies.  
5.2 Results and Discussions 
5.2.1 Extraction of plant materials 
The pulverised stembarks of RP were extracted using a combination of dichloromethane and 
methanol to obtain the organic extract, followed by extraction with deionised water to yield 
the aqueous extract, according to the procedures (Figure 2.1) used by National Cancer 
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Institute (NCI, USA). The amounts of the extracts and their yields obtained are shown in 
Table 5.1. 
Table 5-1 Percentage Yield of the RP Extracts obtained from the extraction with 
dichloromethane/methanol (organic extract) and extraction with deionized water (aqueous 
extract). 
SAMPLE 
AMOUNT (G) 
ORGANIC 
EXTRACT (G) 
AQUEOUS 
EXTRACT (G) 
% YIELD OF TOTAL 
EXTRACT  
1000 7.2 1.5 0.9% 
 
From the data in Table 5.1, it was observed, that the stembark yielded relatively low amounts 
of solid extract. Also, organic extract is more than the aqueous extract. This may be due to 
the method of extraction, which was sequential; organic extraction, followed by aqueous 
extraction. 
5.2.2Screening of Anti-ovarian cancer of the plant extracts 
The organic and aqueous extracts of RP were tested for their inhibition of the growth of 
OVCAR8, OVCAR4, A2780, and CIS-A2780 ovarian cancer cell lines using a cell growth 
assay in which cell number was estimated by staining with SRB (Table 5.2). 
Table 5-2 Results of Preliminary Screening of the Extracts of RP on ovarian cancer cell lines in 
cell growth assays. The cells were treated for 72h with the indicated extract, followed by an 
estimation of the number of surviving cells by SRB staining. The results are expressed as 
mean ±SEM, n=3 experiments (IC50 is in µg/ml). 
EXTRACT A2780  OVCAR8  CIS-A2780  OVCAR 4  
ORGANIC EXTRACT 3.2±0.3 8.7±0.5 ND 6.6±1.6 
AQUEOUS EXTRACT 2.2±0.5 5.9±0.03 3.7±0.03 ND 
 
The aqueous and organic extracts of RP, had very significant inhibition activities, as 
observed from the plant extracts’ IC50 values of CIS-A2780, A2870, OVCAR4 and 
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OVCAR8ovarian cancer cell lines, respectively presented in Table 5.2. These IC50s were 
below the threshold which is considered to be significant from the perspective of the 
American national Cancer institute criteria, which from a screening of about 20,000 plant 
extracts, identified 452 cytotoxic extracts with IC50<50µg/mL(Thomas 2010). Thus, both the 
organic and aqueous extracts of RP with IC50s <50µg/mL on the investigated cell lines were 
deemed worthy of further purification and investigation for anti-cancer activity.  
These findings are consistent with the reported observations of a study on Tarennagrevei, a 
plant native to the Madagascar dry forest in the Rubiaceae family, belonging to the genus 
Tarenna, which exerted a moderate cytotoxicity on the A2780 ovarian cancer cell line 
(Kingston et al., 2012). Presently, research on the anti-cancer activities of the Rutidea genus 
is lacking.  
5.2.3 Bioassay-guided fractionation of RP 
Given that both the aqueous and organic extracts were active, further solvent fractionation of 
5.0 g of the crude organic extract of RP, using four solvents was perfomed (mass of solid 
compound recovered is shown in parentheses); n-hexane (2.0g), ethyl acetate (1.3g), n-
butanol (0.9g) and aqueous (0.5g) fractions. The fractionation of the aqueous extract could 
not be undertaken as more intricate and advanced techniques such as extractions with 
buffers, ion exchange chromatography, gel filtration and desalting would be required inorder 
to achieve a separation of the constituents (Shimizu et al., 2006). This situation was further 
compounded by the low yield of the extract. 
The obtained organic fractions were further evaluated in cell growth assays (Table 5.3). 
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Table 5-3 The Results of the growth inhibition evaluation of the fractions of the organic extract 
of RP on ovarian cancer cell lines in cell growth assays. The cells were treated for 72h with the 
indicated fraction, followed by an estimation of the number of surviving cells by SRB staining. The 
results are expressed as mean ±SEM, n=3 experiments (IC50 is in µg/ml). 
Fraction OVCAR4  OVCAR8  A2780  
n-Hexane 23.3±1.0 18.3±0.3 7.3±0.8 
Ethyl Acetate 5.4±0.3 5.8±0.4 2.5±0.2 
n-Butanol 2.6±0.1 2.6±0.3 1.7±0.2 
Aqueous 22.9±1.3 22.1±1.1 12.8±1.3 
 
The results of the investigation of the antiproliferative activities of the fractions of the organic 
extract of RP showed that the ethyl acetate and the n-butanol fractions were the most 
bioactive fractions. Further fractionation of these fractions was undertaken. 
5.2.4 Chemical characterization of bioactive organic extract of RP 
In order to find out the anti-cancer components in RP organic extract, the TMSi derivatives 
was prepared and analysed by GC-MS. 
The TMSi derivative of RP was obtained by the treatment of BSTFA and pyridine and 
subjected to further analysis on the GC-MS to determine the potential bioactive compounds 
that could be responsible for the activity of the extract. The identified compounds with a 
match quality >80%, are presented in Table 5.4, and Figure 5.1 is the obtained GC-MS 
chromatogram for the compounds listed in Table 5.4 below.
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Table 5-4 The Compounds Identified by the GC-MS Analysis of the Organic extract of RP. 
RP-dcmm-tmsi      Quality 
match 
Retention 
time 
 
         
Glycerol, tris(trimethylsilyl) ether    91 10.97  
3-Pyridinecarboxylic acid, trimethylsilyl ester   94 11.19 
Butanedioic acid, bis(trimethylsilyl) ester   98 11.48 
Propanoic acid, 2,3-bis[(trimethylsilyl)oxy]-, trimethylsilyl ester 91 11.82 
meso-Erythritol, tetrakis(trimethylsilyl) ether   91 14.24 
Benzoic acid, 4-ethoxy-, ethyl ester    95 14.50 
L-Threonic acid, tris(trimethylsilyl) ether, trimethylsilyl ester  95 14.83 
Benzenepropanoic acid, .alpha.-[(trimethylsilyl)oxy]-, trimethylsilyl ester 87 15.29 
D-Ribose, 2,3,4,5-tetrakis-O-(trimethylsilyl)-   89 15.76 
D-Ribose, 2,3,4,5-tetrakis-O-(trimethylsilyl)-   91 16.14 
Xylitol, 1,2,3,4,5-pentakis-O-(trimethylsilyl)-   93 17.06 
Ribitol, 1,2,3,4,5-pentakis-O-(trimethylsilyl)-   91 17.12 
Benzoic acid, 3,4-bis[(trimethylsilyl)oxy]-, trimethylsilyl ester   99 18.07 
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.beta.-D-(-)-Tagatopyranose, pentakis(trimethylsilyl) ether  81 18.23 
D-(-)-Fructopyranose, pentakis(trimethylsilyl) ether (isomer 1) 93 18.21 
alpha.-D-Galactopyranose, 1,2,3,4,6-pentakis-O-(trimethylsilyl)- 91 19.14 
Benzoic acid, 3,4,5-tris(trimethylsiloxy)-, trimethylsilyl ester   99 19.58 
Glucopyranose, 1,2,3,4,6-pentakis-O-(trimethylsilyl)-, D-  94 19.89 
Myo-Inositol, 1,2,3,4,5,6-hexakis-O-(trimethylsilyl)-  89 20.17 
D-Gluconic acid, 2,3,4,5,6-pentakis-O-(trimethylsilyl)-, trimethylsilyl ester 93 20.23 
Myo-Inositol, 1,2,3,4,5,6-hexakis-O-(trimethylsilyl)-  99 21.10 
beta.-Gentiobiose, octakis(trimethylsilyl) ether   80 21.38 
D-(+)-Cellobiose, octakis(trimethylsilyl) ether (isomer 2)  87 21.51  
Glyceryl-glycoside TMSether     87 22.05  
Stigmasterol trimethylsilyl ether    99 26.15 
Urs-12-en-24-oic acid, 3-oxo-, methyl ester, (+)-    99 27.33 
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Figure 5.1 The GC-MS chromatogram of the organic extract of RP for the 10-30min range of 
compounds. 
 
The GC-MS analysis of the organic extract of RP detected fifty-eight compounds, twenty six 
of which, had a match quality >80% and were identified by comparison of their mass spectra 
with those in the NIST library as shown in Table 5.4 and in Figure 5.1. Importantly two 
bioactive compounds were identified from the GC-MS analysis. Gallic acid, a bioactive 
compound with demonstrated cytotoxicity on many cancer cell lines (already discussed in 
Chapter 4), and Urs-12-ene-24-oic acid, 3-oxo-methyl ester; a ursolic acid derivative.  Ursolic 
acid from previous studies has been shown to exert cytotoxic activities on a number of 
cancer cell lines, which includes A2780 and SK-OV3 ovarian cancer cell lines (Song et al., 
2012), HT29 colon cancer cell line and PC-3 prostate cancer cell line (Bai et al., 2012).  
Recently the anti-cancer activities of some ursolic acid derivatives have been reported (Shao 
et al., 2011; Chen et al., 2015). 
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5.2.5 Fractionation of the Ethyl Acetate Fraction of RP (RP-EA) 
Ten sub-fractions of RP-EA were obtained from a silica gel column chromatography which 
utilised different combinations of n-hexane/ethyl acetate. The elution began with a 100% n-
hexane, followed by several combinations of n-hexane and ethyl acetate, then with 100% 
ethyl acetate. The column was finally eluted with 100% methanol.  
The obtained sub-fractions were further evaluated in cell growth assays (Table 5.5).  
Table 5-5 The Results of the growth inhibition evaluation of the sub-fractions of RP-EA on 
OVCAR 4 cell line in cell growth assays. The cells were treated for 72h with the indicated fractions, 
followed by an estimation of the number of surviving cells by SRB staining. The results are expressed 
as mean ±SEM, n=3 experiments. 
Sub-fractions of RP-EA OVCAR 4 (µg/ml) Solvent Fraction 
F1 >200 N-hexane 
F2 4.2±0.2 N-hexane/Ethyl acetate 
F3 65.9±10.1 “ 
F4 >200 “ 
F5 36.2±1.4 “ 
F6 90.6±9.6 “ 
F7 17.4±2.3 “ 
F8 11.6±1.0 “ 
F9 37.3±6.5 “ 
F10 >200 Ethyl acetate 
F11 3.6±0.8  Methanol 
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Two of the sub-fractions (F2 and F11) showed potent activities. Fraction 2, which was 
obtained from the elution of the chromatographic column by a solvent system of n-hexane 
and ethyl acetate, 1:1, appeared white in colour. This fraction was treated with hot methanol 
and recrystallized at a temperature of 0-4oC to yield white crystals (12.8%). The identity of 
this compound was investigated by GC-MS. A single peak with a mass of 468 was identified 
as Urs-12-ene-24-oic acid, 3-oxo-methyl ester, by the NIST-Library with a retention time of 
27.33 min. The compound was tentatively determined as Urs-12-ene-24-oic acid, 3-oxo-
methyl ester, and was henceforth referred to as EA2, with the structure shown in Figure 
5.2.This compound has been identified from the GC-MS analysis of the ethanolic extract of 
the whole plant; Canscora perfoliata used in the treatment of poisonous bites (Thanga et al., 
2012). 
 
 
 
 
 
Figure 5.2 The structure of URS-12-ENE, 24-OIC ACID, 3-OXO-METHYL ESTER (EA2) 
Fraction 11 was obtained from 100% methanol elution of the chromatographic column, which 
suggests a high polarity of the compounds present. This fraction was not subjected to further 
purification, as the isolation of the potential bioactive compounds in the fraction may require 
more elaborate techniques as with the aqueous extract mentioned above. 
1H NMR spectra of EA2 was obtained at 300 MHz with a Bruker 1D (DPX-300) NMR 
spectrometer in CDCl3 δ: 3.57(s, 3H), 2.4(m, 3H), 1.83(s, 3H), 1.62(s, 3H), 0.95(s, 3H)}. The 
13C NMR was obtained at a 400 MHz Bruker NMR in CDCl3 δ: 31.96, 31.46, 30.24, 29.72, 
29.49, 29.38, 29.00, 27.63, 24.90, 22.73, 21.32, 16.52, 14.15. Attempts to obtain the 
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literature reported 1H and 13 C NMR for this compound proved abortive, as the data could not 
be obtained from NIST, PUBMED, Chemspider and Chembl databases and from literature 
search. The identity of the compound was assigned tentatively as Urs-12-ene-24-oic acid, 3-
oxo-methyl ester. However, given the GC-MS match quality of 99% and the proton NMR data 
which had some similarities with the proton NMR of ursolic acid (Seebacher et al., 2003), 
there is some evidence to suggest that EA2 would most likely be Urs-12-ene-24-oic acid, 3-
oxo-methyl ester. 
5.2.6 Investigation of the cell growth inhibition of EA2, the isolated Bioactive 
Compound of RP-EA 
The identified bioactive compound, EA2 was further investigated in cell growth assays (Table 
5.6). 
Table 5-6 Results of growth inhibition evaluation of EA2 on ovarian cancer cell lines and HOE 
in cell growth assays. The cells were treated for 72h with EA2, followed by an estimation of the 
number of surviving cells by SRB staining. The results are expressed as mean ±SEM, n=3 
experiments. 
 
 
 
 
The results of the inhibition experiments showed that EA2 exhibited moderate inhibition of 
the growth of ovarian cancer cell cultures. The compound also showed apparently no effect 
on normal cells, which is an indication of advantageous safety profile. 
Further investigation of the compound’s antiproliferative activities was carried by the trypan 
blue assay (TBA), to determine whether the effect in the cell growth assays reflected 
inhibition of proliferation or cell death (Figure 5.3). 
Cell Line A2780  OVCAR8 OVCAR 4  HOE 
      
IC50 in µM 31.6±3.3 48.9±2.0 85.4±2.4  >200 
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Figure 5.3 The Effect of EA2 at the indicated concentrations and carboplatin (CBPT), (40 µM) at 
48h on cell viability. The cells were stained with trypan blue and the percentage of dead cells 
was obtained by microscopy.  # denotes significant difference from the control, (P<0.001, one-
way ANOVA). The results were expressed as mean ±SD, n=3. 
 
The results obtained from the TBA study showed that EA2 exerted antiproliferative activities 
on cancer cells in a concentration-dependent manner. The 40µM concentration had 
significant activity, (P<0.001) in comparison to the control. The activity of the compound is 
moderate and these results suggest that the activity of the extracts and the ethyl acetate 
fractions in the cell growth assay was at least in part due to cell death. This implies that EA2 
maybe cytotoxic to ovarian cancer cells. However the compound was less active than 
carboplatin, the reference drug. Previous studies have reported the anti-bacterial and anti-
microbial activities of plants’ fractions that contain Urs-12-ene-24-oic acid, 3-oxo-methyl ester 
(Natarajan et al., 2012; Adebayo et al., 2014).  
The observation made from the investigation of the growth inhibition of EA2 is that this 
compound is partly responsible for the activity of RP-EA, but there might be other bioactive 
compounds present in the fraction, which may have contributed to the activity of RP-
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EA2possibly through synergism with EA2.  However, due to insufficient quantity of this 
fraction, other compounds could not be isolated. 
5.2.7 Apoptosis studies of EA2 
In order to investigate, the possible route of cell death caused by EA2, the effect of the 
compound was measured in caspase 3/7 experiments (Figure 5.4). 
 
Figure 5.4 The Effect on caspase 3/7 activity measured after 48h on OVCAR 4 cell line by the 
vehicle-treated cells (control), carboplatin (CBPT), EA2 at 40 µM, 20 µM and 10 µM 
concentrations. The results were expressed as mean ±SD, n=3, which were obtained as 
fractions of the treated cells when compared with the reference standard; the carboplatin-
treated cells after normalization with corresponding SRB-stained cells to estimate the 
surviving cell number. 
 
The results of the caspase 3/7 study observed that EA2 exhibited slight increase in caspase 
3/7 activity in comparison to the control and carboplatin. There is the possibility that at 
increased concentrations of the compound, the caspase 3/7 activity would be more evident. 
However it is noteable that 40µM EA2 was sufficient to cause antiproliferation and cell death 
(measured by trypan blue staining) without substantially increasing caspase 3/7 activity. 
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Further studies on EA2 were not deemed worthwhile given the moderate activity of the 
compound.  
Previous researchers have documented the anti-asthma, anti-arthritic, anti-inflammatory, 
anti-microbial and diuretic activities of Urs-12-ene-24-oic acid, 3-oxo-methyl ester 
(Ramalingam et al., 2015). It may be suggested that EA2 could be benefical in 
chemoprevention given the other activities of the compound. 
5.2.8 Results of the fractionation of the n-butanol fraction of RP (RP-BUT) 
Nine sub-fractions were obtained from the column fractionation of RP-BUT by means of a 
solvent-polarity based fractionation which utilised various combinations of ethylacetate/ 
methanol which entailed a ratio-based decrease in the volume of ethyl acetate, with a 
progressive increase in the volume of methanol. The fractionation began with a 100% ethyl-
acetate and ended with 100% methanol. The obtained sub-fractions were further evaluated 
in the cell growth assays (Table 5.7) below. 
The results in Table 5.7 showed that five of the RP-NBUT fractions were active against the 
OVCAR 4 cell line. This cell line is ranked among the top five most resistant human ovarian 
cancer cell lines which typifies very serious ovarian cancer and thus is a suitable model for 
the investigation of in vitro anti-ovarian cancer activities (Domcke et al., 2013). A closer look 
at these results showed that sub-fraction 3 and 7 were the sub-fractions with optimum 
inhibitory activities on the cancer cells. Further purification of these two sub-fractions was 
undertaken. 
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Table 5-7 The Results of the growth inhibition evaluation of the sub-fractions of RP-BUT on 
ovarian cancer cell line in cell growth assays. The cells were treated for 72h with the indicated 
fraction, followed by an estimation of the number of surviving cells by SRB staining. The results are 
expressed as mean ±SEM, n=3 experiments. 
SUB-FRACTION OF RP-
NBUT 
IC50 (µg/ml) Solvent Fraction 
RP-NBUT-1 >200 Ethyl acetate 
RP-NBUT-2 >200 Ethyl acetate/Methanol 
RP-NBUT-3 1.9±0.3 “ 
RP-NBUT-4 4.8±1.6 “ 
RP-NBUT-5 >200 “ 
RP-NBUT-6 >200 “ 
RP-NBUT-7 2.8±0.1 “ 
RP-NBUT-8 8.0±0.0 “ 
RP-NBUT-9 18.9±0.4 Methanol 
 
5.2.8.1 Purification of RP-NBUT-7 
This sub-fraction was subjected to HPLC separation on a semi-preparative column with a 
mobile phase composition of 100% water acidified with 0.1% Trifluoroacetic acid (TFA) as 
solvent A and 80% acetonitrile acidified with 0.1% TFA as solvent B. The gradient began with 
100% of A for 5 min and increased to 80% B for 25 min of the run time. Then the gradient 
was increased to 100% B and maintained for 6 min of the analysis; making the total run time 
36 min. Fifteen hplc-fractions were collected. The yield of eight of these fractions were <2%, 
and thus could not be evaluated in the cell growth assays. The remaining seven fractions 
were evaluated in the cell growth assays (Table 5.8). 
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Table 5-8 The growth inhibition evaluation of the HPLC-fractions of RP-BUT-7 on OVCAR 4 cell 
line in cell growth assays and the masses found by LC-MS for the most potent fractions. The 
cells were treated for 72h with the indicated fraction, followed by an estimation of the number of 
surviving cells by SRB staining. The results are expressed as mean ±SEM, n=3 experiments. 
SUB-FRACTION OF 
RP-NBUT-7 
(RETENTION TIME) 
Code for the 
sample 
IC50 OF OVCAR 4 CELL 
LINE (µgG/mML) 
Mass found by 
LC-MS 
2.2-2.6 - >100  
2.6-3.1 - >100  
19.0-19.6 - 3.5±0.3  
19.7-21.3 nbut-7-1 2.0±0.4 544.3469, 
C26H48N4O8 
27.4-28.2 nbut-7-2 0.7±0.2 330.2194, 
C21H30O3 
28.5-31.5 nbut-7-3 1.5±0.6 297.3394 
32.2-33.2 - >100  
 
Three bioactive hplc-fractions were identified out of fifteen hplc-fractions. These fractions 
were henceforth referred to as nbut-7-1 at retention time (Rt) of 19.7-21.3, nbut-7-2 with Rt 
27.4-28.2, and nbut-7-3 with Rt 28.5-31.5 min on the hplc (Table 5.8). 
The LC-MS was carried out and the following findings were made.  
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For nbut-7-1 
The mass of a major compound peak in this chromatogram was given as 544.3469 with a 
match quality score of 99.34%. The Retention time was 8.705min. The predicted chemical 
structure of this compound was given as C26H48N4O8. Several other peaks were identified. 
These included 352.2459 and 358.2138. This fraction was impure and further hplc 
purification was not feasible due to insufficient quantity of the sample. 
For nbut-7-2 
The LC-MS detected a small peak with a mass of 330.2194 (predicted chemical formula as 
C21H30O3) with a match quality score of 99.7%. The Retention time of the peak was 
11.729min. The fraction contained many other peaks and thus was impure. The identity of 
this compound could not be established, as further purification could not be undertaken due 
to insufficient quantity of the fraction. 
For nbut-7-3 
The LC-MS detected a tiny peak with mass 297.3394 and a score of 99.67% at a retention 
time of 15.412min.Also other peaks were detected. The peak signals from these 
chromatograms were very weak. Further purification efforts were not feasible due to 
insufficient quantities. 
5.2.8.2 Purification of RP-NBUT-3 
This sub-fraction was subjected to HPLC separation on a semi-preparative column; with a 
mobile phase composition of 100% water acidified with 0.1% Trifluoroacetic acid (TFA) as 
solvent A and 80% acetonitrile acidified with 0.1% TFA as solvent B. The gradient began with 
100% of A for 5 min and increased to 80% B for 25 min of the run time. Then the gradient 
was increased to 100% B and maintained for 6 min of the analysis; making the total run time 
36 min. Eighteen hplc fractions were collected, but due to insufficient quantities of eleven of 
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the fractions with yields <2%, only seven of these fractions were subjected to further 
evaluation in the cell growth assays (Table 5.9) 
Table 5-9 The Results of the growth inhibition evaluation of the HPLC-fractions of RP-BUT-3 on 
OVCAR 4 cell line in cell growth assays. The cells were treated for 72h with the indicated fraction, 
followed by an estimation of the number of surviving cells by SRB staining. The results are expressed 
as mean ±SEM, n=3 experiments. 
SUB-FRACTION OF RP-NBUT-3 
(CODED BY THEIR HPLC RETENTION 
TIME) 
IC50 OF OVCAR 4 CELL LINE 
(µgG/mML) 
2.2-2.5 >100 
2.5-3.4 >100 
11.3-11.9 1.2±0.3 
15.4-17.0 0.7±0.3 
21.6-22.6 0.9±0.4 
26.8-27.4 0.02±0.3 
32.1-32.6 31.4±2.7 
 
Three bioactive hplc-fractions were identified out of eighteen hplc-fractions. These fractions 
were nbut-3-1 at Retention time of 15.4-17, which had a characteristic yellow colour, nbut-3-2 
with Retention time of 21.6-22.6, and nbut-3-3 with Retention time of 26.8-27.4 min on the 
hplc. The hplc subfractions obtained from RP-NBUT-3 were analysed by LC-MS (Table 5. 
10). 
149 
 
Table 5-10 The Identified Peaks from the LC-MS analysis of the bioactive hplc subfractions of 
RP-NBUT-3. 
HPLC 
SUBFRACTIONS 
IDENTIFIED PEAKS LC-MS RETENTION 
TIME 
NBUT-3-1 352.1548 7.7835 
NBUT-3-2 338.3421 
311.106 
11.6742 
13.965 
NBUT-3-3 374.2466 
312.1135 
9.2590 
10.0962 
 
Further hplc purification of nbut-3-1 was carried out to improve the purity of the compound as 
the yield was sufficient (23.8%) by a slight modification of the hplc purification method. The 
hplc retention time of the purified compound was found to be 15.2 min. The proton NMR 
analysis was carried out and the compound tentatively determined as Palmatine. 
Palmatine:  
1H NMR (500 MHz, CD3OD), δ 9.76 (1H,s), 8.80 (1H, s), 8.12 (1H, d,  J = 9.0 Hz), 8.01 (1H, 
d,  J = 9.1 Hz),  7.67 (1H, s), 7.05 (1H, s), 6.88 (1H, s), 5.29 (2H, t,  J = 6.5Hz), 4.21 (3H, s), 
4.11 (3H, s), 3.99 (3H, s), 3.94 (3H, s), 3.28 (2H, t, J =6.4 Hz). HSQC: 144.9, 118.3, 126.3, 
122.6, 108.1, 110.1, 118.8, 60.9 (OCH3), 55.5 (OCH3), 54.9 (OCH3), 54.5 (CH2), 54.6 
(OCH3), 26.2 (CH2).
 1H NMR (300 MHz, CDCl3), δ 8.42 (1H, s), 7.88 (2H, dd), 7.56 (1H, s), 
7.04 (1H, s), 6.88 (1H, s), 5.29 (2H, t), 4.33 (3H, s), 4.11 (3H, s), 4.09 (3H, s), 4.02 (3H, s), 
3.36 (2H, t).13C NMR (500 MHz, CD3OD), δ 152.45, 150.52, 149.54, 145.00, 144.37, 138.45, 
133.90, 128.68, 126.69, 123.03, 119.9, 116.52, 110.82, 78.15, 77.88, 77.63, 73.92, 56.25, 
50.54. 
 
150 
 
 
 
 
 
 
 
Figure 5.5
1
H NMR (left) and 
13
C NMR (right) Assignment of Palmatine 
The LC-MS analysis of nbut-3-1 (Figure 5.6) was carried out. The identity of the nbut3-1 
hplc-fraction was unequivocally identified to be palmatine by comparing with the standard 
compound. The comparison showed that the mass of the standard palmatine was 352.1549, 
while the isolated palmatine had a mass of 352.1548 which was consistent with the 
compound being palmatine. Further hplc analysis of the standard palmatine gave a Retention 
time of 15.2min consistent with the isolated compound. 
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Figure 5.6 LC-MS Chromatogram (above) and MS of nbut-3-1 (below). 
Palmatine which is intense yellow in colour is a quaternary protoberberine alkaloid that is 
present in Rhizoma coptidis, an important medicinal plant commonly used in the Traditional 
Chinese Medicine, TCM, (Ding et al., 2012). The compound has been previously isolated 
from several medicinal plants such as Rhizoma coptidis, (Zhao et al., 2010), Fibraurea 
tinctoria, (Su et al., 2007), Jateorhiza macrantha (PROTA 2008), Chasmanthera dependens 
(Iwu 2014) and Enantia chlorantha (Vennerstrom et al., 1988). 
Studies on Rhizoma coptidis and Fibraurea tinctoria have documented the presence of 
berberine, coptisine, epiberberine, jatrorrhizine and palmatine in these plants (Ding et al., 
2012;Suet al., 2007).Other phytochemical studies on Jateorhiza macrantha and 
Chasmanthera dependens, showed that palmatine, has been obtained with columbamine 
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and Jatrorrhizine; two other protoberberine alkaloids. Additionally, three diterpenes; palmarin, 
columbin and chasmanthin were found (PROTA2008; Iwu 2014).Columbin and chasmanthin 
are bitter non-nitrogenous compounds. Chasmanthin and Palmarin have the same mass of 
374. The 358.2138 peak identified in the RP-N-BUT-7-1 subfraction may be that of columbin, 
given the mass of columbin is 358. It is very likely that the peak with mass 374 in nbut-3-3 
may be either chasmanthin or palmarin. 
The minor peak found in nbut3-2 with a mass of 338.3421could be either jatrorrhizine with 
mass 338.38 or columbamine whose mass is 338.3771. The occurrence of both compounds 
and palmatine has been observed in Jateorhiza macrantha and Chasmanthera dependens 
(Prota 2008;Iwu 2014).  
 
Figure 5.7 Structure of palmatine, a bioactive compound isolated from RP and the possible 
structures of some compounds of the Identified Peaks in the LC-MS Analysis of RP. 
5.2.9 Investigation of the Cytotoxicity of Palmatine 
Growth inhibition studies were carried in cell growth assays for palmatine on the ovarian 
cancer cell lines and on HOE (Figure 5.8and Table 5.11). 
The results in Table 5.11 and Figure 5.7 examined the growth inhibition of the standard 
palmatine and the isolated palmatine by the SRB assay. The IC50s of both compounds were 
indistinguishable, a further confirmation that the two compounds possess antiproliferative 
activities in vitro, and that the purification processes had not compromised the activity of the 
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isolated palmatine. This result is in agreement with the reported cytotoxicity of palmatine on 
MCF-7 breast cancer cell line evaluated by the MTT assay (Wu et al., 2016b).  
 
Figure 5.8 The mean IC50 concentration-response curves of the isolated Palmatine (352) and 
palmatine standard investigated on A2780 ovarian cancer cell. The cells were treated for 72H 
and the cell number obtained by SRB-staining of the surviving cells. The results were 
expressed as mean ±SEM, for n=3 experiments. 
 
Table 5-11The evaluation of the growth inhibition of standard palmatine and the isolated 
palmatine (352) on ovarian cancer cell lines in cell growth assays. The cells were treated for 
72h with the indicated compound, followed by an estimation of the number of surviving cells 
by SRB staining. The results are expressed as mean ±SEM, n=3 experiments. 
 
CELL LINE Commercial PALMATINE 
(IC50 in µM) 
ISOLATED PALMATINE  
(IC50 in µM) 
A2780 
CIS-A2780 
5.6±1.0 
5.2±1.3 
6.6±0.5 
5.5±0.9 
OVCAR4 7.6±1.4 7.4±0.3 
OVCAR8 6.8±0.4 7.9±0.5 
HOE 25.1±5.0 ND 
SI (against A2780) 4.5 - 
Another important observation is that the compounds demonstrated selective growth 
inhibition towards cancer cells, with less effect on normal cells. 
154 
 
Further evaluation of the cytotoxicity and synergistic effects of palmatine were carried out 
and discussed below. 
5.2.10 The Drug Combination Studies of Palmatine 
The antiproliferative activities of palmatine was further investigated by trypan blue assay, to 
determine whether the effect in the cell growth assays was as a result of inhibition of 
proliferation or cell death. The synergistic potentials of palmatine in combination with 
carboplatin, was also investigated (Figure 5.9). 
 
 
 
 
 
 
 
 
Figure 5.9 The Effect of palmatine at the indicated concentrations and in combination with 
carboplatin (CBPT) (40 µM) at 48h on OVCAR 4 cell viability. The cells were stained with trypan 
blue and the percentage of dead cells was obtained by microscopy. The horizontal blue bars 
indicate the expected effect obtained from the bliss independent effect calculation comparing 
the effect of the combination and the single agents. * denotes that the result is significantly 
different (P<0.05, paired t-test) from the effect expected from the Bliss independence criterion. 
The results were expressed as mean ±SD, n=3. 
 
The results of the TBA showed that palmatine maybe cytotoxic to cancer cells in a 
concentration-dependent manner, with the maximum concentration of 40µM exhibiting the 
most cytotoxicity. The effect of the combined use of palmatine and carboplatin on the cells 
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were also investigated. The agents combined demonstrated significant synergism (p<0.05) 
because all three concentrations used in the study elicited effects which exceeded that 
expected for the combinations assuming additivity and calculated by the Bliss  independence 
criterion, by which hypothesis a was tested. These results showed potential synergism 
between palmatine and carboplatin. Also these results are a confirmation of the observed 
inhibition of cancer cells by palmatine in the SRB assay. 
Drug combination studies between palmatine and carboplatin on OVCAR 4 cells were carried 
out to investigate the synergistic potentials of securinine and carboplatin by the fixed dose 
method on the cell growth assay using the SRB protocol (Figure 5.10). 
 
Figure 5.10 Mean concentration-response curves of vehicle-treated cells, carboplatin-treated 
cells (Maximum concentration of 100 µM), and the drug combination of palmatine at a fixed 
concentration of 6 µM and Carboplatin (Maximum concentration of 100 µM) on the OVCAR 4 
cell line determined after 72h of treatment. Results were expressed as mean of three 
experiments, mean±SEM. 
An examination of the results presented in Figure 5.10revealed an additive effect in the drug 
combination of Carboplatin and Palmatine which was not statistically significant from 
additivity. This observation may be due to the 6µM fixed dose of palmatine used. It was 
expected that at this dose the compound would cause 5% growth inhibition of the cancer 
cells, judging the activity of the compound from single agent studies. An alternative would be 
to repeat these studies with different palmatine concentrations to see if synergy is observed. 
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This observed activity of the agent, as a result of the concentration used is further shown 
from a study of palmatine on the induction of tumour suppressor miRNA miR-200c in MCF7 
breast cancer cells. These researchers noted that palmatine could induce the MiRNA miR-
200c at a dose of 10µM, and exerted antiproliferative activities on the breast cancer cells 
(Keitaro et al., 2015).  
5.2.11 Apoptosis studies of Palmatine 
Caspase 3/7 activity 
In order to investigate the possible route of cell death, experiments were conducted to 
evaluate the activity of palmatine on caspase 3/7. In these experiments, the effect of drug 
combination between palmatine and carboplatin was further examined. Additionally, the 
effect of palmatine and paclitaxel was also investigated (Figure 5.11). 
 
 
 
 
 
 
Figure 5.11 The effect of palmatine (10 µM) combined with carboplatin (10 µM), or Paclitaxel (10 
nM) on Caspase 3/7 activity at 48h for carboplatin (A) combination and 36h for paclitaxel (B) 
combination on OVCAR 4 cell line. The caspase activity was measured and normalized with 
corresponding SRB-stained cells to estimate the surviving cell number. The horizontal blue 
bars indicate the expected effect obtained from the bliss independent effect calculation 
comparing the effect of the combination and the single agents. * denotes that the result is 
significantly different (P<0.05, paired t-test) from the effect expected from the Bliss 
independence criterion. While ** and ## denotes significant difference (P<0.05; P<0.001) 
respectively from the control, one-way ANOVA. The results were expressed as mean ±SD, n=3. 
from the Bliss independence criterion. While ** and ## denotes significant difference (P<0.05; 
P<0.001) respectively from the control, one-way ANOVA. The results were expressed as mean 
±SD, n=3. 
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The results contained in Figure 5.11, demonstrated that palmatine significantly increased 
caspase 3/7 activity at greater at p<0.05 in comparison to the vehicle-treated cells (control) at 
a concentration of 10µM for an experimental period of 36-48h. The combinations with 
paclitaxel also showed statistically significant caspase 3/7 activity, greater at p<0.001than 
that which would be expected for additivity with the bliss expected effect. However, it was 
observed that the combination of palmatine and carboplatin did not attain the bliss expected 
effect and the result was not statistically significant. These findings suggest potential synergy 
between palmatine and paclitaxel. While the results from the combination of palmatine with 
carboplatin may be indicative of mild additivity which was also demonstrated in the drug 
combination studies. It may be that the observed synergy in the trypan blue assay was due 
to the use of an increased concentration of carboplatin 40µM in the combination with 10µM 
palmatine. 
Flow Cytometric analysis 
Further investigation of the observed apoptosis of palmatine, and potential synergism 
between palmatine and carboplatin was carried out by means of Annexin V/Propidium iodide 
labelling, followed by flow cytometry analysis (Table 5.12, Figure 5.12and 5.13). 
Table 5-12 The Effect of Palmatine and carboplatin Combinations was assessed (for the 
apoptotic cells) after 48h of treatment by Annexin V/PI Staining of the OVCAR 4 cells followed 
by flow cytometry analysis. Results are expressed as mean±SD, n=3 experiments. 
TREATMENT PERCENTAGE OF APOPTOTIC CELLS MEAN±SD 
CONTROL 6.2±0.7 
CARBOPLATIN(20µM) 17.0±1.8 
PALMATINE(10µM) 10.0±1.0 
PALMATINE + CARBOPLATIN 22.8±1.1 
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Figure 5.12 The effect of palmatine (10 µM) combination with carboplatin (20 µM) and the 
agents singly on OVCAR 4 cells treated for 48h was assessed by Annexin V/PI staining, 
followed by flow cytometry analysis. The vehicle-treated cells were used as the control. The 
results were expressed as a representative of three experiments. 
 
Figure 5.13 The Effect of palmatine (10 µM) combined with carboplatin (20 µM) and the agents 
singly on Annexin V/PI staining on OVCAR 4 cells analysed by flow cytometry at 48h. It was 
assumed that at a concentration of 20 µM, carboplatin caused a maximum effect. However, this 
was not the case. A representation of the quantification of the combined early and late phase 
apoptotic cells is shown. The horizontal blue bars indicate the expected effect obtained from 
the bliss independent effect calculation comparing the effect of the combination and the single 
agents. ** denotes that the result is significantly different (P<0.05, paired t-test) from the 
control. The results were expressed as mean ± SD, n=3. 
The results of the Annexin V/PI studies shown in Table 5.12 and Figure 5.13 showed that 
palmatine induced significant increase in apoptosis compared to the control. Again these 
results did not demonstrate synergism between palmatine and carboplatin at the 10µMwhich 
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further confirmns the mild additivity observed in the caspase 3/7drug combination 
experiments and in the SRB cell growth assay. An important observation is that palmatine’s 
route of cell death may be by apoptosis. This view is again amplified, by the flow cytometry 
analysis of palmatine-treated MCF-7 cells, which showed significant apoptosis and an 
increase in intracellular ROS level, as reported by Wu and co-workers (Wu et al., 2016b). 
Further investigations of the combination of Palmatine (20µM) and carboplatin (40µM) was 
undertaken to determine the possible existence of synergism between the agents  was 
carried out by means of Annexin V/Propidium iodide labelling, followed by flow cytometry 
analysis (Figure 5.14). 
 
Figure 5.14 The Effect of palmatine (20 µM) combined with carboplatin (40 µM) and the agents 
singly on Annexin V/PI staining on OVCAR 4 cells analysed by flow cytometry at 48h. A 
representation of the quantification of the combined early and late phase apoptotic cells is 
shown. The horizontal blue bars indicate the expected effect obtained from the bliss 
independent effect calculation comparing the effect of the combination and the single agents. * 
denotes that the result is significantly different (P<0.05, paired t-test) from the effect expected 
from the Bliss independence criterion. While ** denotes that the result is significantly different 
(P<0.05, paired t-test) from the control. The results were expressed as mean ± SD, n=3. 
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The results presented in Figure 5.14demonstrated synergism between palmatine and 
carboplatinat an increased concentration of both agents. The induced apoptosis of palmatine 
was significant from the control. By means of these results hypotheses b and c where 
tested. Furthermore, these results have shown that significant synergism between palmatine 
and carboplatin may be observed at concentrations ≥10µM for palmatine and for 
concentrations of carboplatin ≥40µM. The lack of synergism in the drug combination of the 
caspase 3/7 and in the SRB cell growth assay was due to the concentrations of the agents 
employed in the assay.Further investigations of the apoptosis induced by palmatine were 
monitored microscopically for 48-72h. 
Morphological change 
The morphological changes of cells treated with palmatine were monitored microscopically at 
48-72h (Figure5.15). 
 
Figure 5.15 The effects of palmatine (20 µM) on cell morphology of OVCAR 4 cells monitored by 
light microscope (100 µm) for 48-72h after treatment. The Morphological changes observed in 
the vehicle-treated OVCAR 4 cells which was used as the control (A), OVCAR 4 cells treated 
with 20 µM palmatine at 48h (B), cells treated with 20 µM palmatine at 72h (C), cells treated with 
40 µM carboplatin at 48h (D), cells treated with a combination of carboplatin and palmatine at 
48h (E) and at 72h (F) respectively. The results were expressed as a representative of three 
experiments. 
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The characteristic features of apoptosis such as blebbing and shrinkage of cells were clearly 
observable in the pictures of the cell morphology (Figure 5.15). The finding from the caspase 
and the Annexin V/PI staining was consistent with the observed morphological changes and 
indicative of apoptosis. 
 
Western Blotting 
To confirm these results, measurement of PARP [Poly (ADP-Ribose) Polymerase] (which is 
a DNA repair nuclear enzyme) cleavage (Figure 5.16) below was assessed by immuno-
staining.  
 
 
Figure 5.16 PARP Cleavage by the indicated concentrations of Palmatine and carboplatin (40 
µM), singly and in combination on OVCAR 4 cell line at 48h post treatment, determined by 
immunoblotting. The vehicle-treated cells served as the control. The results were expressed as 
a representative of three experiments. 
 
PARP cleavage is a well-established method of apoptosis investigation, as PARP is a 
substrate for caspase 3, which is cleaved in the course of apoptosis into two fragments 
(D’Amours et al., 1998). PARP is a DNA repair nuclear enzyme which detects DNA 
fragmentation (Trucco et al., 1998). The cleavage of PARP-1, often referred to as PARP is a 
confirmation of apoptosis. It is also considered that caspase 7 is involved in the in vivo 
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cleavage of PARP (Germain et al., 1999).Significant PAPR-1 cleavage was observed after 
treatment of palmatine or a combination of palmatine with carboplatin. 
These results were consistent with the induced apoptosis activities of palmatine in the 
caspase 3/7 assay, the Annexin V/Propidium Iodide staining analysed by flow cytometry and 
the microscopic examinations of treated cells at 48h and 72h respectively. 
The findings from this present research showed significant synergism between palmatine 
and carboplatin which was demonstrated in the TBA cell growth drug combination. But in the 
caspase 3/7 and SRB cell growth drug combination studies this synergy was not observed 
which may be attributed to the concentration of the agents employed in these assays.  
 
5.3 Discussions of Rutidea parviflora and Palmatine 
The research in this chapter is the results of the investigations of the anti-cancer activities of 
R. parviflora (RP) on ovarian cancer cells. The preliminary screening of the plant for growth 
inhibition showed that the crude extracts of the plant had significant antiproliferative activities. 
Fractionation of the organic fraction showed that the potent compounds in the extract were in 
the ethyl acetate and n-butanol fractions. Further purification resulted in the isolation of two 
bioactive compounds: Urs-12-en-24-oic acid, 3-oxo-, methyl ester, which was determined by 
NMR and GC-MS analysis, and Palmatine which was confirmned by NMR and LC-MS. The 
third bioactive compound; Gallic acid was determined by GC-MS. Evaluation of the inhibitory 
activities of these compounds demonstrated that palmatine was the most potent bioactive 
compound. The anti-cancer activities of palmatine have been reported from several studies. 
An evaluation of the cytotoxicity of palmatine on three human cancer cell lines; CEM (acute 
lymphoblastic leukaemia), CEM/VCR(vincristine-resistant CEM) and SMMC7721, and two rat 
cancer cell lines; Lewis (lung carcinoma) and K III a melanoma showed that the compound 
was cytotoxic at micromolar concentration in all the cell lines investigated. Further in vivo 
study of the compound on a murine sarcoma, S180 xenograft model recorded a tumour 
inhibition rate of 34.09% at a dose of 2.5mg/kg (Lei et al., 2012). Similar findings were made 
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in a study of osteoporosis using mouse preosteoclastic cell line (RAW 264.7) (Shintaro et al., 
2016). The compound has been found active against prostate cancer in vitro (Hambright et 
al., 2015). Palmatine has also been shown to demonstrate significant photo-cytotoxicity in 
colon cancer HT-29 cells (Wu et al., 2016a) and MCF-7 breast cancer cells, (Wu et al., 
2016b). The anti-malarial activities of berberine, palmatine and jatrorrhizine which are also 
berberine-type alkaloids have been reported in vitro. The compounds exhibited similar 
activities comparable to that of quinine (Vennerstrom et al., 1988). 
Further investigations of the cytotoxic activities of palmatine by trypan blue assay were 
undertaken in the cell growth assay. The results demonstrated that palmatine was cytotoxic 
to ovarian cancer cells. These results confirmed the antiproliferative activities of the 
compound observed in the SRB cell growth assay. Apoptosis studies were carried out to 
investigate the possible route of cell death induced by palmatine. The results showed that 
palmatine induced significant apoptosis both in the caspase 3/7 assay and in the Annexin 
V/Propidium iodide labelling, which was analysed by flow cytometry. 
There have been conflicting reports about the apoptosis-inducing action of palmatine. One 
Group had earlier reported a lack of apoptosis in a DNA interaction study of HL-60 leukaemia 
cells, in which 25µg/mL of the agent was used. The experimental time was 24h (Kuo et al., 
1995). Recently, the apoptosis inducingactivity of palmatine on RAW 264.7, a mouse pre-
osteoclastic cell line was observed at concentrations of 10µM, 40µM and 100µM for a 
treatment period of 24h (Shintaro et al., 2016).  
The results of this present studies is in line with the findings of the later researchers. This 
current research has investigated the apoptotic activities of palmatine at a concentration of 
10-20µM at an experimental duration of 36-48h. The observations from these studies were 
that palmatine is an apoptosis inducer and potentially synergises with the standard ovarian 
cancer drug-carboplatin. 
Previous studies have showed that berberine and coptisine, which are classed together with 
palmatine as protoberberine cationic alkaloids, due to the presence of a quaternary nitrogen 
atom, bearing a positive charge are capable of inhibiting mitochondrial respiration and induce 
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cancer cell death by causing alterations in the mitochondrial bioenergetics(Barreto et al., 
2003). 
Palmatine has been shown to accumulate mitochondrial potential, Δψm, which has been 
exploited in the targeting of anti-oxidants into the mitochondria (Félix et al., 
2015).Mitochondria have being implicated in cellular death, especially by apoptosis, through 
the intrinsic pathway(Galluzzi et al., 2010). This research work shows that palmatine is an 
apoptosis inducer and merits further studies on the agent’s mechanism of action in cancer 
cells and in vivo. 
 
5.4 Conclusion 
An investigation of the anti-cancer activities of RP on ovarian cancer cells has been 
undertaken. This research is the first pharmacological and phytochemical study of this plant. 
Ethno medicinal use of this plant in folklore is limited, and no research has reportedly been 
carried out to validate these traditional medicinal uses. RP, a member of the Rubiaceae 
family from the genus Rutidea which has 21 species require further investigation for possible 
bioactivities. 
This research work has shown that RP has significant cytotoxic activities on cancer cells. 
Activity was demonstrated in both the aqueous and organic extracts of the plant, with the 
focus of this research work on the organic extract. Three bioactive compounds: Palmatine, 
Urs-12-ene-24-oic-3-oxo-methyl ester and Gallic acid were identified and 
isolated/authenticated. The most bioactive compound isolated in this study was palmatine, 
which showed significant activity both in the cell growth assays and in the apoptosis assays.  
 
In conclusion, this present study has shown that palmatine possess anti-cancer activities, 
with apoptosis as the route of cell killing. The compound has demonstrated very significant 
synergism with carboplatin, a first-line clinically used drug in the treatment of ovarian cancer 
in the TBA experiment. However, a lack of synergy with carboplatin was observed in the SRB 
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cell growth drug combination experiment, caspase 3/7 and Annexin V/PI assays as a result 
of the low concentrations used. Further apoptosis studies undertaken observed significant 
increase in apoptosis induced by palmatine singly and in combination with paclitaxel in the 
caspase 3/7 assay. At an increased concentration of palmatine and carboplatin, an 
investigation for potential synergy between the agents by Annexin V/Propidium iodide 
labelling, followed by flow cytometry analysis was carried out. The obtained results 
demonstrated increased apoptosis of the combined agents, which was significant from the 
bliss expected effect at P<0.05; an indication of the existence of a possible synergism 
between the agents. Again, there is some evidence from the caspase experiments that this 
compound may synergise with paclitaxel, another first-line ovarian cancer drug. Palmatine 
does show some preferential selective cytotoxicity for cancer cells, with minimal inhibition on 
normal cells. This study has shown that palmatine is a potential agent for the treatment of 
ovarian cancer and the agent merits further investigations.  
 
Finally, this is the first report of the anti-ovarian cancer activities of Rutideaparviflora, a 
medicinal plant, identified from folk medicine. 
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Chapter Six  
Anti-Ovarian Cancer Investigations of Synthetic Thymoquinone 
Analogues. 
6.1 Introduction 
Thymoquinone (TQ), the most bioactive compound in nigella sativa (NS) is a benzoquinone 
that has received intense scientific attention evidenced by the numerous pharmacological 
researches on the compound, since its isolation and characterization in 1963 by El-
Dakhakhny. Documented activities of TQ abound with the compound shown to be a potent 
inhibitor of several cancer cell lines such as prostate, ovarian, colon, breast, and pancreatic 
cancers, including leukaemia and osteosarcoma (El-Mahdy et al., 2005; Rooney et al., 2005; 
Richards et al., 2006; Roepke et al., 2007; Kaseb et al., 2007; Alhosin et al., 2010; Jafri et 
al., 2010; Koka et al., 2010; Effenberger-Neidnicht et al., 2011; El-najjair et al., 2011; Woo et 
al., 2011). TQ is reported to possess Chemo preventive activity against pancreatic cancer. 
Other bioactivities of TQ include anti-inflammatory and anti-oxidant activities. Also, 
investigations into the anti-microbial, anti-asthmatic, immunostimulant, anti-hyperglycemic, 
anti-histaminic and anti-parasitic have been carried out (Al-Ali et al., 2008). 
While most researches have focused on the investigation of TQ’s anti-cancer activities, less 
emphasis have been placed on the development of novel TQ-analogues, with more potent 
anti-cancer activities. The need for more potent TQ analogues is further heightened by the 
moderate anti-cancer activities of TQ, despite the compound’s apparent safety as suggested 
by the large LD50 values obtained from both oral and intraperitoneal administration of the 
compound in mice and rats reported in literature. These values obtained from intraperitoneal 
injection and oral administration of the compound respectively were 10-15 times and 100-150 
times more than the doses required for the induction of anti-cancer, anti-oxidant and anti-
inflammatory activities (Al-Ali et al., 2008). 
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The research in this chapter aims to synthesise more potent analogues of TQ, investigate the 
growth inhibition of TQ analogues on A2780, OVCAR 8, CIS-A2780, and HOE cell lines. In 
order to generate a SAR for TQ, ten commercially available analogues were procured and 
evaluated together with eleven synthesised analogues on OVCAR 8, A2780, and CIS-A2780 
ovarian cancer-cell lines. Further investigation into the selectivity index of these analogues 
was carried out on the human ovarian epithelial (HOE) cells to determine the preferential 
selectivity in the inhibitory activities of the analogues for cancer cells in comparison with 
normal cells. Solubility studies were carried out to determine the solubility of TQ, the most 
promising synthesised analogue and the most potent procured analogue. The most 
promising synthesised analogue was further investigated for cytotoxicity by the trypan blue 
assay. Apoptosis investigations were further carried out by measurement of caspase 3/7 
activity and flow cytometry to determine the possible route of cell death induced by the most 
potent synthesised analogue. Drug combination experiments of the most potent synthesised 
analogue and clinically used first line ovarian cancer drugs were also undertaken. 
6.2 Experimental methods 
6.2.1 Design of TQ analogues 
Previous synthesis of TQ analogues with anti-cancer activities, have been carried out by 
some researchers. One group conjugated TQ with terpenes such as fatty acids found in the 
nigella sativa oil and betulinic acid. Their observation was that activity was dependent on the 
length of the spacer group between the quinone and the terpene. Analogues with a four-
carbon spacer exhibited better cytotoxicity on the four cancer cell lines tested. The range of 
IC50s obtained in this study was, 7-79.9µM for the cervical carcinoma cell line, KB-V1/Vbl 
(Effenberger et al., 2010). Banerjee and his co-workers synthesised 27 TQ analogs in a SAR 
study of TQ for Pancreatic Cancer. This study investigated a series of 2, 5-bis (alkyl/aryl-
amino) 1,4-benzoquinones amines. The researchers observed from the study that bulkier 
substituents had IC50s >10µM, while the IC50s of compounds with smaller substituents were 
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<10µM on pancreatic cancer in vitro (Banerjee et al., 2010). This same researchers recently 
synthesised anti-cancer TQ analogues investigated on pancreatic cancer, published in 2013 
(Yusufi et al., 2013). The referenced paper reported the moderate activities of 3-
aminothymoquinone which was the building block for some of the analogues which were not 
disclosed. Also, the researchers observed from the comparison of the cytotoxic effect of one 
hydroxylated TQ analogue and one fluorinated TQ analogue that the hydroxylated TQ 
analogue had better activities than the fluorinated derivative. 
 In designing the TQ analogues to be synthesised, three objectives were considered: 
Synthesis of six amino-TQs aimed at investigating the role of the position of amino 
substituent group on the aromatic ring on anti-cancer activity; 
An investigation of the effect of bulky substituent groups on the anti-cancer activity; 
Synthesis of five hydroxylated TQs aimed at a comparison of the activities of the 
corresponding benzoquinones and these synthesised hydroxylated TQs. 
These considerations formed the basis of the synthesis of the eleven TQ analogues. 
The ten procured analogues were selected based on four aims: 
The investigation of the effect of halogen atoms on the aromatic ring on anti-cancer activity 
The effect of chain length of alkyl substituents on the aromatic ring on anti-cancer activity 
Comparison of the activity of an isopropyl group and a tertiary butyl group on the aromatic 
ring. 
A further comparison of the activity of a 2,5-substituent group and a 2,6-substituent group on 
the aromatic ring. 
This study employed these seven aims to derive a SAR for the anti-ovarian cancer activities 
of TQ.  
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6.2.2 Materials and Methods of Synthesis 
6.2.2.1 Materials 
Procured TQ Analogues; 2-Isopropyl-5-methyl-1,4-benzoquinone (TQ), 2-Methyl-1,4-
benzoquinone, 2,5-Dibromo-6-Isopropyl-3-Methyl-1,4-Benzoquinone, 2-Tert-butyl-3,6-
dichloro-5-methyl-1,4-benzoquinone, 2,5-Di-tert-butyl-1,4-benzoquinone, 2-Tert-butyl-1,4-
benzoquinone, 2,6-Di-tert-butyl-1,4-benzoquinone, 2,6-Dimethylbenzoquinone, 2,5-Bis-(1,1-
Dimethyl-propyl)-1,4-benzoquinone, 2-Tert-butyl-5-methyl-1,4-benzoquinone and 2,5-Di-tert-
octyl-1,4-benzoquinone were purchased from Sigma Aldrich. 
Reagents and solvents; 4-fluoroaniline, sodium azide, sodium hydrosulphite and deuterated 
chloroform were procured from Sigma Aldrich.  Dimethyl amine, diethyl amine, glacial acetic 
acid, n-hexane, ethyl acetate, ethanol, methanol, trichloroacetic acid, hydrochloric acid, and 
sodium hydrogen carbonate were purchased from Fischer Scientific. 
Gas chromatography Mass Spectroscopy 
The GC-MS system consisted of an Agilent 7890 A gas chromatography systems, coupled to 
an Agilent MS model 5975C MSD with triple axis detector (Agilent Technologies, US). The 
instrument’s column is a HP5-MS column. 
The gas chromatography began with an oven temperature of 60°C for 2min, which increased 
to 300°C at the rate of 10°C/min, which was held at 300°C for 9 min to yield a total run of 
30min under a constant helium pressure (10psi). The mass spectrometry utilized an electron 
impact (EI) source at 70eV with an ion source temperature of 230°C. 
1H NMR Spectroscopy 
1H NMR spectra were obtained at 300 or 400 MHz with a Bruker 1D NMR spectrometer.  13C 
and DEPT NMR spectra were obtained at 75 MHz or 100MHz with a 300 or 400 Bruker NMR 
spectrometer respectively. 
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6.2.2.2 Methods of Synthesis of the TQ Analogues 
6-Isopropyl-2-methylamino-3-methyl-1,4-benzoquinone (3). 164mg of TQ was added to 
0.5ml of dimethyl amine in a round-bottom flask. 1ml of water was added into the mixture. 
The mixture was stirred for 2h at RT, followed by evaporation of the water on a rotary 
evaporator. The dried product was subjected to TLC in a 2:1 n-hexane: ethyl acetate solvent 
system, upon which four spots were obtained. Column chromatography yielded four 
fractions. One of which gave one-spot with an rfof 0.5, fractions 2 (compound 3, 11.8mg, 
yield of 7.2%) a bright red amorphous powder was obtained. GC-MS, Retention time 
(Rt)=16.116 min. MS [electron ionization (EI)] m/z (relative intensity, %): 193.1 (100) [M]•+, 
178.1 (35) [M-CH3]
•+, 165.1 (50) [M –CH2CH3]
•+, 136.1, 122.1, 108.1, 94.1, 69.1, 53.0, 
41.1.1H NMR (300MHz, CD3OD), δ 6.36 (s, 1H), 3.19 (s, 3H), 3.09 (m, 1H), 2.08 (s, 3H), 1.13 
(d, 6H, J =7.0 Hz).13C NMR (300 MHz, , CD3OD), δ 133.22, 117.69, 113.03, 32.73, 27.34, 
26.85, 26.48, 22.67, 21.34, 15.38, 9.97. 
Fraction 5 contained compound 3a (6-isopropyl-2-dimethylamino-3-methyl-1,4-
benzoquinone)and several impurities, (compound 3a, 27.6mg, yield of 15.3%), GC-MS, 
Retention time (Rt)=14.713 min.  MS [electron ionization (EI)] m/z (relative intensity, %): 
207.1 (100) [M]•+, 192.1 (90) [M-CH3]
•+, 177.1 (40) [M –CH3CH3]
•+, 164.1, 149.1, 136.1, 122.1, 
108.1, 94.1, 69.1, 53.0, 41.1.1H NMR (300MHz, CDCl3), δ 6.30 (s, 1H), 3.00 (s, 6H), 3.00 (m, 
1H), 1.95 (s, 3H), 1.10 (d, 6H, J =7.0 Hz). 13C NMR (CDCl3), δ 188.43, 185.91, 152.42, 
151.54, 130.41, 122.80, 108.2, 43.42, 26.62, 21.4,14.43. Column chromatography 
purification was carried out, but the compound could not be obtained without the impurities. 
Further attempts to purify the compound on the HPLC, resulted in the presence of more 
impurities in the fraction. This compound was considered impure (<90% purity) and was 
excluded in the cytotoxicity assays. 
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2-Ethylamino-6-isopropyl-3-methyl-1,4-benzoquinone (4). 164mg of TQ was added to 
1ml of Diethylamine in a round-bottom flask equipped with a stirrer, 1ml of water was 
introduced into the reaction mixture to act as catalyst, The reaction was heated for 2h at a 
temperature of <30oC with stirring. The resultant solution was dried on a rotary evaporator at 
a temperature <40oC. The obtained dry product was subjected to TLC in a 2:1 n-hexane: 
ethyl acetate solvent system, upon which three spots were obtained. The dry product was 
purified on a column using various combinations of the n-hexane and ethyl acetate solvent 
system. 19 Fractions were obtained and subjected to TLC, of which fraction 4(compound 4, 
73.5mg, 32.0%), a bright red amorphous powder gave a single spot with an rfof 0.5.GC-MS, 
Rt=14.521 min. MS [electron ionization (EI)] m/z (relative intensity, %):207.1 (70) [M]•+, 192.1 
(100) [M − CH3]
•+, 178.1 (20) [M –CH2CH3]
•+,164.1,150.0,136.1. 1H NMR (300MHz, CDCl3) δ: 
6.34 (s, 1H), 3.47 (q, 2H, J = 7.0 Hz), 2.89 (m, 1H), 2.01 (s, 3H), 1.19 (t, 3H, J = 7.2Hz), 1.03 
(d, 6H,J =6.8 Hz). 13C NMR (CDCl3), δ 186.94, 184.72, 149.67, 144.40, 133.23, 108.11, 
40.02, 26.53, 21.34, 16.22, 10.11. 
Fraction 6 contained 4a, (2-Diethylamino-6-isopropyl-3-methyl-1,4-benzoquinone, another 
compound 4b,2-Diethylamino-6-isopropyl-3-methyl-1,4-hydroquinone and three other 
unknown impurities (compound 4aand 4b, 32.6mg, yield of 14.2%), GC-MS, Retention time 
was (Rt)=17.223 min and 17.511min respectively for 4a and 4b.  MS [electron ionization (EI)] 
m/z (relative intensity, %) for 4a: 235.2 (30) [M]•+, 220.2 (100) [M-CH3]
•+, 206.1 (10) [M –
CH2CH3]
•+, 192.1, 176.1,162.1, 150.0, 133.1, 121.1, 103.0, 91.1, 77.0, 67.0, 53.1, 41.1.MS 
[electron ionization (EI)] m/z (relative intensity, %) for 4b: 237.2 (70) [M]•+, 222.2 (90) [M – 
CH3]
•+, 208.2 (100) [M –CH2CH3]
•+, 194.1, 178.1, 164.1, 152.0, 135.1, 123.1, 105.0, 93.1, 
79.0, 67.0, 55.1, 43.1. 
Column chromatography and HPLC purifications were carried out, but these compounds 
could not be resolved and thus were considered impure and excluded from further 
cytotoxicity assays. 
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2-Dimethylamino-5-methyl-1,4-benzoquinone (6) and 6-Dimethylamino-5-methyl-1,4-
benzoquinone (7). 122mg of 2-methyl-p-benzoquinone was added to 0.5µl of dimethyl amine 
in a round-bottom flask.1ml of water was added to catalyse the reaction. The reaction was 
stirred for 2h at room temperature. The resultant solution was extracted with petroleum ether 
and the petroleum extract fraction dried on the rotary evaporator at a temperature of <40ᴑC. 
The obtained product was subjected to TLC in a solvent-system of 2:1 n-hexane to ethyl 
acetate. Five spots were observed from the TLC. Subsequently, the dried product was 
purified by column chromatography. Six fractions were collected of which fraction 5 gave one 
spot upon TLC investigation. Fraction 6 was further purified on column to obtain three sub-
fractions. TLC investigation showed that one of the sub-fractions (sub-fraction 3) gave one 
spot. Fraction five and sub-fraction 3 were further subjected to GC-MS and 1H NMR 
investigation which showed that the fractions were isomers of the same compound. Fraction 
5(compound 6, 49.5mg, yield of 30.00%) is a dull red amorphous powder. GC-MS, Rt 
=14.666 min.MS [electron ionization (EI)] m/z (relative intensity, %): 165.1 (100) [M]•+, 150.1 
(38) [M – CH3]
•+, 137.1 (30) [M – CHCH3]
•+, 122.1, 108.1, 94.1, 82.1, 69.1, 53.1, 42.1. 1H 
NMR (300MHz, CDCl3), δ 6.40 (s, 1H), 5.50 (s, 1H), 3.11 (s, 6H), 1.95 (s, 3H). 
13C NMR 
(CDCl3), δ 185.92, 185.64, 151.22, 142.74, 134.5, 104.53, 42.41, 15.82. 
Sub-fraction 3 (compound 7, 9.76mg, yield of 8.0%); a dull red amorphous powder. GC-MS, 
Rt= 14.479 min.MS [electron ionization (EI)] m/z (relative intensity, %): 165.1 (43) [M]•+, 
150.1 (65) [M – CH3]
•+, 137.1 (11)[M – CHCH3]
•+, 122.1, 108.1, 96.1, 82.1, 69.1, 53.1, 42.1. 
1H NMR (300MHz, CDCl3), δ 6.30 (s, 1H), 5.52 (s, 1H), 3.10 (s, 6H), 1.98 (s, 3H). 
13C NMR 
(CDCl3), δ 185.44, 185.43, 150.62, 147.41, 131.13, 104.24, 42.33, 15.82. 
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Figure 6.1
1
H NMR and 
13
C NMR Assignment for Compound 6 
2-(4’-Fluoroanilinyl)-5-methyl-p-benzoquinone or 2-(4’-Fluoroanilinyl)-6-methyl-p-
benzoquinone (8). 0.48ml of HCl and 0.48ml of iced deionised water were placed in a 
round-bottom flask equipped with a stirrer. 0.11ml of fluoroaniline was added drop wise. The 
mixture was stirred for 2h at 0-5oC and yielded a clear solution which was filtered. The filtrate 
was added drop wise to a mixture of 120mg of 2-methyl-p-benzoquinone, 200mg of sodium 
bicarbonate and 70ml of water in a flask. The reaction mixture was stirred at 8-12oC for 2h 
and then at room temperature for 2h. A brown solution was obtained. This was subsequently 
extracted with 200ml of ethyl acetate to yield the reaction product. Upon TLC, three spots 
were visualised. The reaction product was purified by column chromatography. Ten fractions 
were obtained using a solvent-system of different combinations of n-hexane and ethyl 
acetate. Fractions 5gave one spot in the TLC (compound 8, 6.2mg, yield of 2.7%); a 
brownish red amorphous powder. GC-MS, Rt=19.771min.MS [electron ionization (EI)] m/z 
(relative intensity, %): 231.1 (100) [M]•+, 202.1 (30) [M –CH2CH3]
•+, 184.1 (15),162.1 
(40),135.1,108.1,89.1,68.1,41.1.1H NMR (300MHz, CDCl3), δ: 7.17(s, 4H), 6.58(s, 1H), 
6.05(s, 1H), 2.11(s, 3H), 1.67(s, 1H).13C NMR (400 MHz, CDCl3), δ:166.55, 164.59, 152.83, 
147.19, 127.56, 117.73, 117.13, 102.27, 101.73, 100.88, 92.21, 68.34, 32.73. 
2-Methyl-1,4-hydroquinone (10) and 2-Isopropyl-5-methyl-1,4-hydroquinone (11). 
Reduction of 2-methyl-p-benzoquinone and TQ respectively by the addition of Sodium 
hydrosulphite dissolved in 2ml of water in a ratio of 1:2 (TQ/MBQ dissolved in 2 ml of 
Methanol: Na2S2O4). The reaction mixture was stirred continuously for 4h, during which the 
reaction was monitored by TLC for completion. This was followed by the evaporation of the 
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solvent. The obtained product was extracted severally by ethyl acetate. The combined ethyl 
acetate extracts was washed with water (3 × 10 mL) and then dried over sodium sulphate. 
After evaporation of ethyl acetate, the pure hydroxylated quinones were obtained as: 
(compound 10, red crystals(103.8 mg, yield of 70%), GC-MS, Rt = 12.165 min.MS [electron 
ionization (EI)] m/z (relative intensity, %): 124.1 (53) [M]•+, 107.1 (100) [M − CH3]
•+, 95.1 (40)  
[M – CH2CH3]
•+, 77.1, 67.1, 55.1, 41.1.1H NMR (300MHz, CDCl3), δ: 6.60, 6.50, 6.40, 2.55 (s, 
3H), 2.05 (s, 3H).13C NMR (δ, 149.19, 147.76, 117.83, 117.63, 115.78, 113.32, 15.95. 
Compound 11, white-yellow coloured crystals (139.7mg, 83.8%), GC-MS, Rt = 14.873min. 
MS [electron ionization (EI)] m/z (relative intensity, %): 166.1 (43) [M]•+, 151.1 (100) [M − 
CH3]
•+, 137 (4), 123.1 (11), 95.1 (10), 77.1 (10), 53.0 (3), 41.1.1H NMR (300MHz, CDCl3) 
δ:6.56 (s, 1H), 6.47 (s, 1H), 3.06 (m, 1H), 2.10 (s, 3H), 1.14 (d, 6H, J = 7.2 Hz). 13C NMR 
(400 MHz, CDCl3), δ 147.75, 146.30, 133.12, 121.62, 117.71, 113.06, 26.87, 22.66, 21.05, 
15.36 
2-Isopropyl-5-methyl-3-amino-1,4-benzoquinone (12). 50mg of TQ was reacted in 65 mg 
of sodium azide dissolved in 1ml of 10% TCA. The reaction was maintained at 60-70oC for 
4h. The reaction was further monitored on the GC-MS to obtain the desired product. On 
completion of the reaction, the reaction mixture was extracted with ethyl acetate to obtain the 
crude product which was subjected to TLC and subsequently to column chromatography 
using a solvent system of n-hexane: ethyl acetate in a ratio of 1:1. Five fractions were 
obtained, of which fraction 3 had one spot on the TLC which yielded Compound 
12(Compound 12, 9.6 mg, yield of 11.6%), an orange coloured amorphous powder. GC-MS, 
Rt=15.032 min. m/z: 179, 164, 151, 136, 124, 108, 91, 81, 67, 53, 41.1H NMR (300 MHz 
CDCl3) δ: 6.54(s, 1H), 2.98(s, 2H), 1.77(s, 3H), 1.53(m, 1H), 1.19(d, 6H).
13C NMR (300 MHz, 
CDCl3) δ, 150.08, 122.50, 21.80, 8.20. 
2,5-Dibromo-6-Isopropyl-3-Methyl-1,4-hydroquinone (20), 2,6-Dimethyl-1,4-
hydroquinone (21) and 2-Tert-Butyl-5-methyl-1,4-hydroquinone (22). Reduction of 2,5-
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Dibromo-6-Isopropyl-3-Methyl-1,4-benzoquinone, 2,6-Dimethyl-1,4-benzoquinone and 2-
Tert-Butyl-5-methyl-1,4-benzoquinone respectively by the addition of sodium hydrosulphite 
dissolved in 2ml of water in a ratio of 1:2 (parent compound dissolved in 2 ml of Methanol: 
Na2S2O4). The reaction mixture was stirred continuously for 4h, during which the reaction 
was monitored by TLC for completion. This was followed by the evaporation of the solvent. 
The obtained products were extracted severally by ethyl acetate. The combined ethyl acetate 
extracts was washed with water (3 × 10 mL) and then dried over sodium sulphate. After 
evaporation of ethyl acetate, the pure hydroxylated quinones were obtained as: 
Compound 20, reddish-yellow crystals(183.5 mg, yield of 85.0%). GC-MS, Rt=18.158 
min.MS [electron ionization (EI)] m/z (relative intensity, %): 324.1 (65) [M]•+, 308.9 (100) [M − 
CH3]
•+,  228.1 (33), 121.1, 79.1, 67.1, 51.1.1H NMR (300MHz, CDCl3) δ: 3.49(m, 1H), 2.37(s, 
3H), 1.29(d, 6H, J=7.2Hz).13C NMR (300 MHz, CDCl3) δ: 144.56, 144.15, 130.46, 122.26, 
114.92, 19.83, 16.99. 
Compound 21, white crystals (134.8 mg, yield of 86.0%), GC-MS, Rt=12.914 min.MS 
[electron ionization (EI)] m/z (relative intensity, %): 138.1 (55) [M]•+, 123.1 (100) [M − CH3]
•+, 
109.1 (64), 95.1, 77.1, 65.1, 53.0, 41.1.1H NMR (300MHz, CDCl3) δ: 6.47(s, 2H), 2.17(s, 
6H).13C NMR (300 MHz, CDCl3) δ: 187.90, 145.84, 133.32, 16.17. 
Compound 22,brownish crystals (128.3mg, yield of 75.6%), GC-MS, Rt=15.682 min.MS 
[electron ionization (EI)] m/z (relative intensity, %): 180.1 (40) [M]•+, 165.1 (100) [M − CH3]
•+,  
137.1 (80), 97.1, 65.1, 41.1.1H NMR (300MHz, CDCl3) δ: 6.73(s, 1H), 6.45(s, 1H), 2.15(s, 
3H), 1.37(d, 9H). 13C NMR (400 MHz, CDCl3)  δ: 147.76, 147.14, 135.46, 134.84, 131.56, 
121.72, 118.85, 114.14, 34.19, 29.68, 15.13. 
Determination of aqueous solubility of TQ (1), compounds 6 and 16 
The aqueous solubility of TQ (1), compounds 6 and 16 were investigated by the method 
described by Salmani and co-workers (Salmani et al., 2014). 10mg of each compound was 
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added to 1 ml of phosphate buffer (pH=7.4) in sealed amber glass bottles to prevent photo 
degradation and maintained on a shaker for 24h at a temperature of 37ᴑC. The solutions 
were filtered through a membrane filter of size 0.45µm, and subsequently diluted before 
analysis of the dissolved solutes by HPLC. Quantification was carried out by calibration 
curves derived from five concentrations of the compounds prepared from a stock solution of 
1mg of the respective compounds dissolved in 1mL of ethanol which was diluted with the 
phosphate buffer (pH=7.4) to yield 10, 20, 40, 60  and 80µg/mL concentrations. These 
experiments were replicated three times. 
6.3 Results and Discussion 
The synthesised TQ analogues are described in the schematic representation (Figure 6.1). It 
could be seen that the hydroxylated analogues (reduced hydroquinones) had very high 
product yields, this could be as a result of the simple reduction reaction utilised in the 
synthesis of these compounds. Another observation is that the one-pot synthesis approach 
utilised less toxic chemicals, the method is economical with less environmental impact. 
Additionally, from this method, two new compounds were synthesised. A library search 
showed that compounds 4 and 8 have not being previously synthesised. While compounds 3 
(Zincke 1881) and 6 (Kallmayer et al., 1986) had been synthesised previously but with no 
reported pharmacological activity. Previous syntheses of the hydroxylated compounds (10, 
11, 20, 21, and 22) were not taken into account as the possibility that these compounds may 
have been synthesised by others could not be ruled out. The aim of the synthesis of these 
hydroxylated analogues was to compare their antiproliferative activities with the 
corresponding quinones and in the determination of a SAR for the anti-ovarian cancer 
activities of TQ. The purity of the synthesised compounds were >93% as confirmed from the 
GC-MS quantification of the peaks.  
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Figure 6.2 The schemes for the synthesis of TQ analogues 3 and 4 (A), compounds 6 and 7 (B), 
compound 8 (C), compound 12 (D), and compounds, 10, 11, 20, 21 and 22 (E). 
 
Synthesis of 3, 4, 6 and 7 was carried out using a modified green protocol to obtain the 
aminobenzoquinones (Jhillu et. al., 2008). The benefits of carrying out amine addition to 
benzoquinones using the green protocol, is enormous. The protocol is cost- effective, has a 
high degree of environmental friendliness and additionally is a one-pot synthesis. Synthesis 
of 2-(4’-Fluoroanilinyl)-5-methyl-p-benzoquinone or 2-(4’-Fluoroanilinyl)-6-methyl-p-
benzoquinone (structure 8), was undertaken using a method described for the synthesis of 
poly (aryl ether ketones) from new bisphenol monomers (Guang et. al., (2010). This 
synthesis was carried out in order to obtain a secondary amine analogue of TQ that has a 
bulky substituent. This was necessary as all the other synthesised analogues, were 
secondary amine analogues, with a two-carbon side chain. Structure 12 was synthesised 
according to a modified method described by Moore and Shelden (Moore et al., 1968). 
Structures 10, 11, 20, 21 and 22 were synthesised by the reduction of the corresponding 
benzoquinone to hydroquinones. The GC-MS and 1H NMR characterizations were carried 
out for all the synthesised compounds. 
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Both the synthesised TQ analogues and the procured TQ analogues were investigated for 
growth inhibition on three ovarian cancer cell lines. The results of these investigations were 
used in obtaining a SAR for the anti-ovarian cancer activities of TQ. Further investigation of 
the Selectivity index, SI was carried out by comparing the IC50 of the analogues on the CIS-
A2780 cell line with the compounds IC50 on the human epithelial ovarian cell line (HOE). The 
Selectivity index, SI of these compounds were determined (Table 6.1 and in Figure 6.3).
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Table 6-1 The Results of the growth inhibition evaluation on ovarian cancer cell lines and calculated SI and log P values of the TQ Analogues. The 
cells were treated for 72h with the indicated compound, followed by an estimation of the number of surviving cells by SRB staining. The results are 
expressed as mean ±SEM, n=3 experiments 
No. Compound LOG P   A2780(µM) OVCAR8(µM) CIS-A2780(µM) HOE  
(µM) 
SI 
1  
 
 
 
 
1.04 7.9 ± 0.2 11.6 ± 0.3 7.8 ± 0.2 17.8±0.4 >2 
2  
 
 
 
 
1.66 4.9 ± 0.2 3.6 ± 0.3 5.3 ± 0.5 7.3±0.4 2.1 
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3  
 
0.01 14.0 ±0.4 12.9 ±0.6 7.3 ± 0.3 36.8±3.0 >7 
4  
 
0.35 12.6 ± 0.2 16.0±0.7 9.6 ± 0.6 30.3±2.0 >2 
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5  
 
 
 
1.59 4.5±.05 6.0±0.4 4.2±0.6 3.1±0.3 <2 
6  
 
-0.71 6.2 ± 0.2 5.6 ± 0.4 4.7 ± 0.5 7.9±0.9 <2 
7  
 
-0.71 16.7±2.0 35.6±6.6 20.5±.3.0 28.2±3.9 <2 
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8  
 
0.74 15.0 ± 0.5 32.0 ± 3.9 21.8 ± 0.3 20.2±2.1 <2 
9  
 
-0.06 12.1±0.4 13.4±2.5 11.8±0.5 6.0±0.3 <2 
10  
 
1.74 5.7±0.4 6.2±0.2 4.7±0.2 6.3±0.7 <2 
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11  
 
2.98 3.1±0.2 8.9±0.7 9.8±0.3 14.0±2.4 4.5 
12  
 
-0.51 19.9±0.6 35.1±0.4 19.3±1.5 138.9±5.0 >7 
13  
 
 
 
 
 
2.73  34.0±5.6 51.2±0.4 42.5±1.9 117.4±1.6 <5 
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14  
 
1.16 5.7±0.5 10.0±0.5 4.9±1.2 10.3±1.1 >2 
15  
 
2.73 24.6±0.6 37.4±1.5 31.1±4.1 51.5±0.5 >2 
16  
 
0.29 3.2±0.2 5.2±0.2 2.9±0.3 5.3±0.5 1.8 
185 
 
17  
 
3.56 36.1±0.1 54.2±1.6 48.8±5.4 In-active >100 
18  
 
 
 
 
1.51 7.5±1.2 13.5±1.5 7.9±2.0 55.8±6.2 7.5 
19  
 
 
 
 
6.06 44.2±0.3 56.5±0.6 51.8±3.1 In-active >100 
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20  
 
 
 
 
 
4.63 3.4±0.4 11.6±0.5 4.8±0.4 11.0±2.1 >2 
21  
 
2.23 3.6±0.4 8.3±0.7 3.6±0.6 7.8±1.6 >2 
22  
 
 
 
 
3.45 6.4±1.5 12.2±0.5 11.5±0.3 85.6±5.2  
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23 Cell Culture Media  >10,0000 >10,0000 >10,0000 -  
24 DMSO 0.1% (vehicle)  >10,0000 >10,0000 >10,0000 -  
25 Carboplatin (clinical drug)  ND 10.8±1.3 ND -  
26 Paclitaxel (clinical drug)  0.009± 
0.0009 
0.01 ± 0.004 ND -  
188 
 
 
Figure 6.3 The Graphical Representation of the growth inhibition evaluation of the 21 TQ 
analogues on A2780 (A), OVCAR 8 (B), CIS-A2780 (C) and HOE (D). The treated cells were 
incubated for 72h, followed by SRB staining and the surviving cell numbers estimated. The 
results are for three individual experiments with the Mean IC50s calculated. (Mean ±SEM). 
The Figure 6.3 contain the results of the TQ analogues evaluated on the three ovarian 
cancer cell-lines and the human ovarian epithelial cell line (HOE). The results showed the 
antiproliferative activities of the twenty-one TQ analogues and TQ. The compounds had 
more inhibitory effects on the A2780 cell line with the IC50 of eleven compounds being 
<10µM. A ranking of the activities of the twenty-one analogues is shown below: 
11>20>21>16>5>2>10>14>6>22>18>9>4>3>8>7>12>15>13>17>19 
Further observation, showed that three of the hydroxylated TQ analogues (compounds 11, 
20, 21) exhibited potent antiproliferative activities; these compounds were followed by 16, a 
procured analogue. The next potent compound was 5, a chlorinated procured analogue 
which exhibited more potent activity than compound 2, the brominated analogue. Compound 
10 another hydroxylated analogue was more potent than 14, a procured analogue which had 
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a single substituent at position two (tertiary butyl). This compound had slightly more potency 
than compound 6. Two other compounds which were more potent than parent TQ were 
compound 22, another hydroxylated analogue and compound 18, which is structurally 
different from 14, by an additional substituent (methyl group) at position five. Importantly, all 
the analogues induced inhibitory activities within an IC50 range of 3.1-56.5µM on the A2780 
cell line. 
The activities of the analogues on the OVCAR 8 cell line showed similar trend as in the 
A2780, but with eight analogues having IC50s of <10µM. It could be seen that the analogues 
had less inhibitory effects on this cell line, an indication that OVCAR 8 is a more resistant cell 
line. A ranking of the activities of the analogues is shown: 
2>16>6>5>10>21>11>14>15>20>22>3>9>18>4>8>12>17>18>21>13 
The ranking of the activities of the analogues on the OVCAR 8 cell line showed that 
compounds 2, 6 and16 were the most potent of the analogues. Further observations showed 
that only two of the hydroxylated analogues had IC50s<10µM.  Also among the synthesised 
analogues, compound 6 was the most potent. The results showed that eight analogues were 
more potent than TQ on the OVCAR 8 cell line. 
Again from the results in Table 6.1 and Figure 6.3, the analogues were all potent on the CIS-
A2780 cell line. The compounds exhibited similar activities as in the A2780 cell line. Ten 
analogues had IC50s <10µM. A ranking of the activity of the analogues is shown: 
16>21>5>6>10>20>14>2>3>18>11>15>22>9>4>12>7>8>13>17>19 
The ranking of the activities of the analogues showed that the most potent analogue was 16, 
followed by the compound’s corresponding hydroxylated analogue. Importantly it was 
observed again that the chlorinated analogue was more active than the brominated 
analogue. Also, the next more potent analogue was compound 6. Three of the hydroxylated 
analogues had IC50s<10µM and were more antiproliferative than their corresponding 
190 
 
benzoquinones. This result is a confirmation that hydroxylated TQ analogues were more 
potent than the corresponding benzoquinone analogues. As observed from the evaluation of 
the potency of the analogues on the OVCAR 8 cell line, it could be seen that 9 analogues 
were more potent than TQ on the CIS-A2780 cell line. 
The growth inhibition of the analogues was evaluated on the HOE cell line, with the 
observation that most of the analogues had less inhibition on the HOE cells than on the 
cancer cells. The calculated SI contained in Table 6.1 showed that the chlorinated analogue 
(5) had no selectivity. Further observations showed that more potent compounds had SI <2, 
while the less potent compounds had SI >2. The results also showed that the analogues with 
bulkier groups had very high SI which for compounds 17 and 19 were >100. 
An estimation of the Log P values of the TQ analogues was carried out by means of the 
ChemBioDraw software in order to investigate the correlation between the inhibition of the 
analogues and their lipophilicity. This data is shown in Table 6.1. The observation from the 
estimated Log P values of the TQ analogues showed that most of the analogues had Log P 
values <2. A comparison of the Log P values with the obtained IC50 values (Table 6.1) which 
is a measure of the antiproliferative activities of the compounds; showed that compounds 
which had smaller IC50s also had smaller Log P values, while compounds such as 13, 17 and 
19 with higher IC50s, equally had higher Log P values. An exception was observed in the 
hydroxylated compounds, which had higher Log P values and smaller IC50s when compared 
to the corresponding benzoquinones. However, the Log P values was<5 for the hydroxylated 
compounds. These results suggest that higher lipophilicity as a result of bulkier substituents 
on the aromatic ring may diminish inhibitory activities in benzoquinones. But for hydroxylated 
compounds, the presence of the OH group enhances activity; thus, higher lipophilicity does 
not result in diminished inhibitory activity. 
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Aqueous solubility studies of TQ, compounds 6 and 16  
Further solubility studies of TQ, compounds 6 and 16 were undertaken in order to determine 
the solubility of these compounds in a physiological buffer, which could be indicative of the 
bioavalability of the compounds and thus the potency of the compounds. In order to achieve 
this, phosphate buffer (pH=7.4) was used and the experiment was carried out at 37ᴑC. A 
comparison of the obtained solubility data was compared with the estimated Log P values 
obtained by the use of the ChemBioDraw software. A correlation between the activities of the 
compounds and their solubility was made. The results of these experiments are 
demonstrated below (Table 6.2) and compared with the Log P values. 
Table 6-2The solubility study of TQ, Compounds 6 and 16 obtained from the dissolution of the 
individual compounds in phosphate buffer (pH 7.4). The measurements were obtained at 37
 ᴑ
C, 
after 24h. The results are expressed as mean±SD, n=3 independent experiments. The Log P values 
were obtained by the use of ChemBioDraw. 
Compound Water Solubility (µg/mL) Log P Value 
TQ (1) 467.8±2.2 1.04 
6 8320.7±0.7 -0.71 
16 5043.0±6.5 0.29 
 
The results presented in Table 6.2, showed that the more potent analogues were more 
soluble than TQ. The obtained solubility of TQ is consistent with the previously documented 
solubility of TQ (Salmani et al., 2014). The results in Table 6.2 correlate with the estimated 
Log P values of the compounds which showed that TQ had the highest value, and was the 
most lipophilic of the compounds. Further evaluation of the results in Table 6.2, 
demonstrated that compound 6 which had the least Log P value, was about 16 times more 
soluble than TQ. While compound 16 was about 8 times more soluble than TQ. This finding 
is significant as poor aqueous solubility is a major deterrant to the clinical advancement of 
almost 50% of potent compounds classed as new chemical entities (NCEs). Low aqueous 
solubility could impair absorption, posing challenges in the bioavailability of drugs, with a 
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resultant effect in the diminished potency of the agents (Savjani et al., 2012). The low 
solubility of TQ may be responsible in part for the reduced potency of the compound in 
comparison with the more potent analogues as observed from this study.   
6.4 Derivation of the Anti-ovarian cancer SAR for the TQ Analogues 
The results of the growth inhibition of the TQ analogues on the three ovarian cancer cell lines 
were analysed to derive a structure activity relationship (SAR). It could be seen that the 
isopropyl group or an isopropyl-like group enhances the cytotoxic activity of a compound, as 
demonstrated by 2,5,6,14, and 18. Similar finding has been reported from a study that 
evaluated the pharmacological potentials of five structurally related para-benzoquinones to 
verify the pentylenotetrazol-induced seizures model in order to establish the structural 
characteristics that influence the anti-convulsant activity of TQ. It was further observed that 
the di-substituted benzoquinones having two alkyl groups were active. However, activity was 
enhanced when the alkyl group at position 2 was replaced with an isopropyl group (Sousa et 
al., 2011).  
Again, additional substituent on the side of the isopropyl group diminishes activity as seen in 
13, 17, 19 and 8 where a bulky aromatic substituent is present. This phenomenon has 
previously been reported from a structure activity study of TQ analogues (Banerjee et. al., 
2010) which showed that 2,5-dimethylamino-6-isopropyl-3-methyl-1,4-benzoquinone and 
other TQ analogues with phenyl substituent groups attached to the aromatic ring had no 
significant activity. An interesting observation, from the results, showed that the presence of 
two methyl groups at positions 2 and 6 on the ring, tends to favour activity, Also, when a 
comparison of compound 13 and 15 was made, there was a significant difference in the 
activities of these two compounds on all the cell lines. The key difference in the structures of 
these compounds, showed that compound 13, has two substituents at positions 2 and 5. 
While compound 15, has these same substituents at positions 2 and 6. Further observations 
were that the presence of electronegative groups, such as bromine and chlorine on the ring 
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could contribute significantly to the increase in activity. Again the presence of nitrogen-
containing group in a substituent attached to the ring would boost activity, when para to a 
methyl group as demonstrated in compound 6.  
The SAR studies further observed that reduction of the ketone group to a hydroxyl group 
impacts activity to a compound. This finding was clearly manifested in five compounds:10, 
11, 20, 21, and22 in comparison with their keto-counterparts:1, 2,9,16 and 18. This finding 
has been reported in a study of alkylated hydroquinones, in which two compounds: 
Violaceiod C and D were evaluated on five leukaemia cell lines. The study reported that the 
range of LD50 was 5.9-8.3µM. A third compound Violaceiod F was cytotoxic on HCT116 cell 
line at a concentration of 6.4µM (Yusuke et al, 2014). This enhanced cytotoxicity exhibited by 
hydroxylated compounds may not be unconnected with the generation of reactive oxygen 
species (ROS) which is known to inflict severe damages to the cells. The OH radical is a 
short-lived radical which is very reactive and thus affects a number of macromolecules (Hoyt 
et al., 2011). 
The activities of compound 12, which is 3-amino-thymoquinone, was in the IC50 range 
reported in a similar study of the structure activities of the potentials of several synthesised 
amino-thymoquinone on pancreatic cancer. The results of the cited study recorded IC50 
values of >10µM for eight compounds (Banerjee et al., 2010). 
The results of the evaluation of the analogues on HOE are contained in the Table 6.1 and in 
the Figure 6.3 above. The aim of this investigation was to determine the selectivity index of 
the analogues. 
The observation made is that the less active analogues had the most selectivity, while the 
more active analogues had the least selectivity with the SI values averaged around 2. Similar 
values were found in literature for some currently used drugs, such as digoxin (Calderon-
Montano et al., 2014) and paclitaxel (Marcos et al., 2015). 
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A comparison of the activities of the synthesised analogues observed that three of the 
hydroxylated analogues (11, 20 and 21), performed better than the benzoquinones on the 
A2780. However, on the OVCAR 8 cell line compound 6 was the most potent. Similarly, on 
the CIS-A2780 cell line, compound 21 was the most potent, with compound 6 being the 
second most potent compound. The hydroxylated analogues were not considered for further 
investigation. Compound 6 was chosen for further cytotoxic investigations based on the 
activity of the analogue on the three cell lines evaluated. An evaluation of the antiproliferative 
activities of TQ and compound 6 was carried out on the OVCAR 4 cell line which was chosen 
for further cytotoxic and apoptosis studies. 
Table 6-3The growth inhibition evaluation of TQ and 6 on OVCAR 4 cell line in cell growth 
assays. The cells were treated for 72h with the indicated compound, followed by an estimation 
of the number of surviving cells by SRB staining. The results are expressed as mean ±SEM, 
n=3 experiments 
Compound Mean IC50 on OVCAR 4 Cell Line 
TQ 23.1±2.3 
6 11.2±1.9 
 
The result of the comparison of the activities of TQ and compound 6 on the OVCAR 4 cell 
line is presented in Table 6.3. It could be seen that compound 6 displayed a two-fold 
increase in potency than parent TQ on the OVCAR 4 cell line. Similar results were observed 
from the IC50 values of the compounds on the A2780, CIS-A2780 and OVCAR 8 cell lines 
presented in Table 6.1 and Figure 6.3. The increased activities of compound 6 over TQ was 
statistically significant at p<0.05 for the four ovarian cancer cell lines. The mean 
concentration-response curves of TQ and compound 6 is presented in Figure 6.4. 
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Figure 6.4 The mean concentration-response curves of CIS-A2780 cells treated with either TQ 
or 6 for 72h. The surviving cell number was estimated by staining with SRB. The vehicle-
treated cells served as the control. The mean was calculated from three independent 
experiments, (Mean±SEM). 
 
The evaluation of the inhibition of 6 and TQ determined on the CIS-A2780 cell line showed 
that 6 is more potent than TQ as observed in Figure 6.3. It could be seen that 6 exhibited 
more activity than TQ in seven out of the nine concentrations in the dose-response curve; a 
confirmation that the compound possessed better inhibitory activities than TQ. Further 
investigation of possible literature-reported bioactivities of 6 was warranted. 
A library search of compounds, by use of Reaxys search engine was undertaken to find out 
reported bioactivities of 6 by other researchers. An in-depth search revealed that compound 
6was synthesised in 1986 by two researchers in Germany, while investigating quinone-amine 
reactions. The compound’s Reaxys number is 6192682. The method of synthesis employed 
was by the reaction of desipramine: an anti-depressant drug(which is a known inhibitor of the 
uptake of serotonin and norepinephrine) and 2,5-dimethyl-1,4-benzoquinone, with copper (II) 
acetate and atmospheric oxygen used as catalyst (Kallmayer et al.,1986). This synthesis was 
aimed at studying the physiochemical properties of the synthesised amino-quinones, without 
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further investigation for pharmacological activities. The literature search revealed that there 
has been no report of the bioactivities of compound 6 from previous researches. 
A schematic representation of the literature-reported method of synthesis of 6 is shown in 
Figure 6.5 below: 
 
 
 
 
Figure 6.5 Schematic representation of synthesis of compound 6 by reaction of desipramine 
with 2,5-dimethyl-14-benzoquinone. 
 
In contrast to the reported method of synthesis shown in the scheme above, the method of 
synthesis employed in this research, followed a guide: an existing literature of some 
synthesised TQ analogues evaluated for pancreatic cancer. This research work was further 
motivated by a drive to achieve TQ analogues with increased potency on human ovarian 
cancer cell lines. Furthermore, this research has obtained a simplified method for the 
synthesis of 6, which is very economical and has less impact on the environment. The 
possible electron impact fragmentation pathway of 6in the EI-MS is shown in Figure 6.6. 
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Figure 6.6 Possible electron impact fragmentation pathways for Compound 6. 
Further evaluation of the cytotoxicity of 6 was assessed by the TBA to determine whether 6 
induced cytotoxicity and antiproliferative activities on the cancer cells. Also the compound’s 
synergistic potentials with carboplatin and paclitaxel were investigated on drug combination 
studies in the TBA, caspase 3/7 and by flow cytometric analysis. 
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6.5 The Results of the Drug combination Studies of Compound 6 
The cytotoxicity of 6 on cell growth assay was further assessed using the TBA (Figure 6.7). 
 
Figure 6.7 The effect of 6 at the indicated concentrations and in combination with carboplatin 
(CBPT) (40 µM) at 48h on cell viability.  The cells were stained with trypan blue and the 
percentage of dead cells was obtained by microscopy. The horizontal blue bars indicate the 
expected effect obtained from the bliss independent effect calculation comparing the effect of 
the combination and the single agents. * denotes that the result is significantly different 
(P<0.05, paired t-test) from the effect expected from the Bliss independence criterion. The 
results were expressed as mean ±SD, n=3. 
The results of the TBA showed that 6is cytotoxic to cancer cells in a concentration-
dependent manner, with the maximum concentration of 40µM exhibiting the most 
cytotoxicity. The effect of the combined use of 6 and carboplatin on the cells were also 
investigated. The agents combined demonstrated significant synergism (p<0.05) because all 
three concentrations used in the study elicited effects which exceeded that expected for the 
combinations assuming additivity and calculated by the Bliss  independence criterion. From 
these findings hypotheses a and c were tested. Further cytotoxic investigations of the 
treated cells stained by TBA at 72h incubation(results not shown) observed that 40µM of6 
had very scanty cells, the 20µM and 40µM of6 drug combinations with carboplatin were 
almost void of cells; an indication that virtually all the cells were death. These results in 
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Figure 6.6 showed potential synergism between 6 and carboplatin. Again these results are a 
confirmation of the observed inhibition of cancer cells by 6 in the SRB assay. 
Further studies on the effect of drug combination between 6 and carboplatin on OVCAR 4 
cells were carried out to investigate the synergistic potentials of these agents in cell growth 
assays by the fixed dose method using the SRB protocol (Figure 6.8). 
 
Figure 6.8 Mean concentration-response curves of 6 and carboplatin (TOP), the vehicle-treated 
cells, carboplatin-treated cells (maximum concentration of 100 µM), and the drug combination 
of 6 at a fixed concentration of 6 µM with carboplatin. Mean concentration-response curves of 6 
and paclitaxel (DOWN), Vehicle-treated cells, Paclitaxel-treated cells (Maximum concentration 
of 50 nM), and the drug combination of 6 at a fixed concentration of 6 µM and paclitaxel 
(Maximum concentration of 50 nM) on the OVCAR 4 cell line determined after 72h of treatment, 
followed by an estimation of the number of surviving cells by SRB staining. Results were 
expressed as mean of three experiments ± SEM. 
 
An evaluation of the results of the drug combinations showed that there was significant 
synergy between6 and carboplatin at p<0.001,which was stastistically significant from 
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synergism. Also, the combination with paclitaxel demonstrated similar synergistic 
significance greater than p<0.05. Again these results were statistically significant from 
synergism.  
Similar findings have been observed in a drug combination of carboplatin and silibinin; a 
quinone. The researchers reported significant synergy in the combination of both agents on 
the MCF-7 breast cancer cell line in both cell growth assay and in the quantification of 
apoptosis (Tyagi et al., 2004). 
6.6 Apoptosis studies of compound 6 
In order to investigate the possible route of cell death caused by 6, the effects of 6 on 
caspase 3/7 activity were measured. In these experiments, the effect of drug combination 
between 6 and carboplatin was further examined. Additionally, the effect of 6 and paclitaxel 
was also investigated. Previous apoptotic studies of combinations of carboplatin and silibinin; 
another quinone compound, that has documented cytotoxicity on cancer cells, have indicated 
synergism in a range of concentration (25-100µM) of silibinin with 2-20µg/mL of carboplatin 
(Cheung et al., 2010; Tyagi et al., 2004). For this present study, 10µM of 6 was used in 
combination with 10µM of carboplatin and 10nM paclitaxel (Figure 6.9). 
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Figure 6.9 The Effect of 6 (10 µM) combined with carboplatin (10 µM) or Paclitaxel (10 nM), on 
Caspase 3/7 activity at 48h for carboplatin (A) combination and 36h for Paclitaxel (B) 
combination. The vehicle-treated cells served as the control. The caspase activity was 
measured and normalized with corresponding SRB-stained cells to estimate the surviving cell 
number. The horizontal blue bars indicate the expected effect obtained from the bliss 
independent effect calculation comparing the effect of the combination and the single agents. * 
and # denotes that the result is significantly different (P<0.05 and P<0.001 paired t-test) from 
the effect expected from the Bliss independence criterion. While ***, ## denotes significant 
difference (P<0.01 and P<0.001) from the control, one-way ANOVA. The results were expressed 
as mean ±SD, n=3. 
 
The results contained in Figure 6.9, observed that 6 significantly increased caspase 3/7 
activity at greater than p<0.001 in comparison to the vehicle-treated cells (control) at a 
concentration of 10µM for an experimental period of 36-48h. The combination with 
carboplatin and paclitaxel also showed statistically significant caspase 3/7 activity, greater at 
p<0.05 and p<0.001 respectively than that which would be expected for additivity with the 
bliss expected effect. These results tested hypotheses b and c. 
Further investigation of the observed apoptosis of 6, and potential synergism between 6and 
carboplatin was carried out by means of Annexin V/Propidium iodide labelling, followed by 
flow cytometry analysis (Table 6.4, Figure 6.10 and 6.11). 
 
 
C
O
N
TR
O
L
PA
C
LI
TA
XE
L 6
6+
PA
C
LI
TA
XE
L
0
10
20
30
40
50
60
70
#B
***
TREATMENT ADMINISTERED
C
A
S
P
A
S
E
 3
/7
A
C
T
IV
IT
Y
C
O
N
TR
O
L
C
A
R
B
O
PL
A
TI
N 6
6+
C
A
R
B
O
PL
A
TI
N
0
10
20
30
40
*
##
A
TREATMENT ADMINISTERED
C
A
S
P
A
S
E
 3
/7
A
C
T
IV
IT
Y
202 
 
 
Table 6-4 The Effect of 6 and carboplatin Combinations was assessed (for the apoptotic cells) 
after 48h of treatment by Annexin V/PI Staining of the cells followed by flow cytometry 
analysis. * denotes that the result is significantly different (P<0.05, paired t-test) from the effect 
expected from the Bliss independence criterion. The results are expressed as mean ±SD, n=3. 
TREATMENT RECEIVED BY THE CELLS PERCENTAGE OF APOPTOTIC CELLS 
MEAN±SD 
CONTROL  3.2±0.4 
CARBOPLATIN (20µM) 14.4±1.1 
6 (10µM) 5.8±0.3 
CARBOPLATIN +6 22.7±0.7* 
 
Figure 6.10 The effect of 6 (10 µM) combination with carboplatin (20 µM) and the agents singly 
on OVCAR 4 cells treated for 48h was assessed by Annexin V/PI staining, followed by flow 
cytometry analysis. The vehicle-treated cells were used as the control.  The results were 
expressed as a representative of three experiments. 
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Figure 6.11 The effect of 6 (10 µM) combined with carboplatin (20 µM), and the agents singly on 
Annexin V/PI staining on OVCAR 4 cells analysed by flow cytometry at 48h. A representation of 
the quantification of the early and late phase apoptotic cells is shown. The horizontal blue bars 
indicate the expected effect obtained from the bliss independent effect calculation comparing 
the effect of the combination and the single agents. * denotes that the result is significantly 
different (P<0.05, paired t-test) from the effect expected from the Bliss independence criterion.  
While *** denotes significant difference (P<0.01) from the control, one-way ANOVA. The results 
were expressed as mean ±SD, n=3. 
 
The results of the Annexin V/PI studies shown in Table 6.4 demonstrated significant 
synergism between 6 and carboplatin in the Annexin V/PI apoptosis assays. These results 
had huge significance at p<0.05, when compared with the calculated bliss expected effect. 
Also, this observation supports the inhibition observed in the TBA results (Figure 6.7 above). 
Similarly, these results demonstrate that 6 is an apoptosis inducer as seen from the 
significantly induced apoptosis in comparison with the control at P<0.01. These results 
further confirmed the observed apoptosis of the agent in the caspase 3/7 assay.  Again the 
demonstrated synergism between 6 and carboplatin in the cell growth assays and in the 
caspase 3/7 activity was again exhibited in the Annexin V/PI assay analysed by the flow 
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cytometer. Thus hypotheses a, b and c were tested. Further confirmation is seen from the 
morphological features of the cells monitored by light microscopy at 72h (Figure 6.12). 
 
 
Figure 6.12 The effects of 6 on cell viability of OVCAR 4 cells monitored by Light microscope 
(100 µm) at 72h after treatment. The Morphological changes observed in OVCAR 4 cells treated 
with 10 µM 6 and carboplatin (40 µM) (A), OVCAR 4 cells treated with 10 µM 6 (B), cells treated 
with carboplatin 40 µM (C), and vehicle-treated cells (D) respectively. These results are 
representative of three experiments. 
The observations from Figure 6.12 showed that 6 had significant cytotoxicity on OVCAR 4 
cells. This implies that the agent kills cancer cells and does not only inhibit the proliferation of 
the cells. Also, it could be seen that the compound synergises with carboplatin as shown in 
Figure 6.12(A). The characteristic features of apoptosis such as blebbing and shrinkage of 
cells were clearly observable in the pictures of the cell morphology (Figure 6.11). The finding 
from the caspase and the Annexin V/PI staining was consistent with the observed 
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morphological changes and indicative of apoptosis. These results strongly suggest that the 
route of cell killing exhibited by 6 is by apoptosis.  
A number of quinone-containing drugs are clinically used in chemotherapy for the treatment 
of cancers such as doxorubicin, mitomycin C and mitoxantrone. These agents have been 
shown to manifest several mechanism of action, MOA such as topoisomerase inhibition, 
(Tewey et al., 1984), redox-cycling properties with the generation of reactive oxygen species, 
ROS (Pelicano et al., 2004; Le et al., 2007) and DNA alkylation (Begleiter 1983; Li et al., 
1996). However, a complete elucidation of the MOA of quinone drugs has not been 
demonstrated as the drugs often exhibit multi-mechanisms.  An example is doxorubicin 
hydrochloride which is used in the treatment of ovarian cancer. The agent is both a DNA 
intercalating agent and a topoisomerase II inhibitor (Lu et al., 2005; Brayfield 2013). 
6.7 Conclusion 
An evaluation of the anti-cancer activities of TQ and twenty one of its analogues has been 
carried out. The existing literature of a SAR obtained from the investigation of the cytotoxicity 
of some synthesised TQ analogues on pancreatic cancer was employed in the design and 
synthesis of 11 analogues, while 10 additional analogues were procured. The aim of this 
research was to obtain more potent TQ analogues and derive a SAR for the anti-ovarian 
cancer activities of TQ analogues. 
The results of the study demonstrated that all the TQ analogues possess antiproliferative 
activities on the A2780, OVCAR 8 and CIS-A2780 ovarian cancer cell lines screened. 
Further findings, showed that compound 16 of the procured analogues and compound 6 of 
the synthesised analogues had significant inhibitory activities that doubled that of TQ.  In 
total, eight analogues were more potent than parent TQ. 
The SAR investigation revealed that the isopropyl group or a similar group was relevant for 
cytotoxic activity. Also, less bulky substituents boosted activity, while bulky substituents on 
the ring resulted in diminished activity. 
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Further investigation of the twenty one analogues and TQ on HOE was undertaken. The SI 
for the analogues was obtained. The values compared well with the reported values for some 
clinically used drugs. Statistical evaluation for significance of the activity of compound 6 in 
comparison to TQ showed that, compound 6 was significantly more active than TQ at 
p<0.05.The results of the trypan blue assay (TBA) conducted for compound 6 correlated with 
the observed inhibition of this compound in the SRB assay 
Drug combination studies were carried using two clinically used first-line ovarian cancer 
drugs: Carboplatin and paclitaxel. The CI showed statistically significant synergism between 
6 and both drugs in the cell growth assays. 
The route of cell killing exhibited by 6 was investigated by caspase3/7 experiments, with the 
results indicative of apoptosis as the route of cell death. The results of this experiment 
demonstrated a very significant synergism between 6 and paclitaxel, at a p<0.001 value with 
a p<0.05 significance recorded for the combination of 6 and carboplatin. 
Further investigation of the apoptosis of 6 was carried out by Annexin V/PI labelling of the 
cancer cells pre-treated with this agent singly and in combination with carboplatin followed by 
flow cytometry analysis. The obtained results confirmed that 6 is an apoptosis inducing 
compound. The results further observed a significant synergism between 6 and carboplatin, 
greater at p<0.05.  
In conclusion, 6 is a more potent analogue than parent TQ, with a two-fold increase in 
potency. Apoptotic studies carried out demonstrated that the compound induces apoptosis 
and showed significant synergism with two clinically used ovarian cancer drugs: carboplatin 
and paclitaxel in both the two cell growth assays and in the apoptosis assays. Further 
investigations of the mechanism of action of 6 are relevant. 
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Chapter Seven  
Stable Isotope Dilution Gas Chromatography−Mass Spectrometry 
for Quantification of Thymoquinone in Black Cumin Seed Oil 
7.1 Introduction 
Black cumin seed (Nigella sativa L.) is a widely used spice in Mediterranean countries, 
Pakistan, and India (Ramadan et al., 2002; Kiralan 2012). It is also used as a traditional 
medicine for the treatment of a range of diseases, such as diabetes, hypertension, fever, 
arthritis, inflammation, gastrointestinal disturbances, and cancer (Padhye et al., 2008). The 
black cumin seed oil is a highly sought after medicinal product which have resulted in the 
establishment of numerous botanical/phytochemical-based pharmaceutical firms. Many 
commercially available brands of the black cumin seed oils abound in the Mediterranean 
countries and in parts of Europe. Studies into the biological activities of this plant have 
revealed that the volatile essential oil components, predominantly thymoquinone (1) (Figure 
7.1) (El-Dakhakhny et al., 1963) possess anti-oxidant(Burits et al., 2000) anti-inflammatory 
(Hajhashemi et al., 2004), anti-diabetic (El-Mahmoudy et al., 2005), 
immunomodulatory(Salem 2005), and anti-tumor (Worthen et al., 1998; Sethi et al., 
2008;Woo et al., 2011) activities. There is the possibility that the amount of thymoquinone 
contained in the black cumin seed oil may vary based on the source and this may affect the 
pharmacological activities of the oil.  
Aim of Study 
Thymoquinone was previously quantitated by means of high performance liquid 
chromatography (HPLC) (Ghosheh et al., 1999; Hadad et al., 2012), high-performance thin-
layer chromatography (HPTLC) (Velho-Pereira et al., 2011) and a differential pulse 
polarographic method (Michelitsch et al., 2003). These methods could achieve high 
sensitivities and reproducibility, but they often need multi-steps of sample preparation and 
external calibrations; thus, the results could be influenced by complex matrices. Gas 
chromatography (GC) and/or gas chromatography−mass spectrometry (GC−MS) are 
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preferred techniques for the analysis of volatile and semi-volatile compounds and have also 
been used for the quantification of thymoquinone (Houghton et al., 1995) and identification of 
the composition of black cumin seed oil (Burits et al., 2000; Liu et al., 2012). 
 A stable isotope dilution assay/analysis (SIDA) should overcome the problem of the matrix 
effects, such as compound discrimination during extraction, chromatographic separation, and 
ultraviolet (UV)/mass spectrometry (MS)/electrochemical detection (Stanford et al., 2007; 
Allen et al., 1994) when a deuterated thymoquinone is used as an internal standard. Stable 
isotope dilution coupled with GC−MS (SID GC−MS) has widely been used for determination 
of various compounds, e.g., methoxypyrazines in red wines (Allen et al., 1994), dietary 
lignans in food (Penalvo et al., 2005), natural estrogens in vegetables and fruits (Lu et al., 
2012, 2013), and alkypyrazines in coffee (Pickard et al., 2013). 
The aim of this research is to synthesis stable deuterium (D or 2H)-labelled thymoquinone 
(Figure 7.1) for the first time, and apply this compound as an internal standard for the 
quantification of thymoquinone in black cumin seed oil by means of SID GC-MS. 
7.2 Materials and Methods 
Thymoquinone (99%), D2-sulfuric acid (D2SO4, 99.5%), deuterated water [deuterium oxide 
(D2O), 99.5%], sodium hydrosulphite (Na2S2O4), and chromium trioxide (CrO3) were 
purchased from Sigma-Aldrich. Hexane (analytical grade) was purchased from Fisher-
Scientific, U.K. The following black cumin seed oils were purchased from Amazon: Manako 
black cumin oil, CEBRANigella sativa oil, Avena black cumin oil, Iman VERGIN black cumin 
oil, and This Health black seed oil. 
1H NMR Spectroscopy  
1H NMR spectra were recorded on a Bruker DPX 300 MHz spectrometer using CDCl3 as the 
solvent. Chemical shifts are quoted on the δ scale in parts per million (ppm) using CDCl3 as 
the internal standard. NMR data were analyzed using ACD/Laboratories 12 software. 
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Multiplicities of signals are described as singlet (s), doublet (d), triplet (t), quadruplet (q), and 
multiplet (m).  
GC−MS  
The GC−MS system consisted of an Agilent 7890A GC system with split injection (250 °C; 
1:10), coupled to an Agilent MS model 5975C mass selective detector (MSD) with a triple 
axis detector (Agilent Technologies, Santa Clara, CA). A 30 m HP5-MS column [(5% phenyl)-
methylpolysiloxane, 0.25 mm inner diameter, film thickness (df) = 0.25 μm, Agilent 
Technologies, Santa Clara, CA] was used for the quantification of thymoquinone. The GC 
heating program was as follows: initially at 80°C, raised to 160 °C at 20 °C/min, then raised 
to 300 °C at 50 °C/min, and finally held at 300 °C for 3.2 min under a constant helium 
pressure (10 psi). MS was fitted with an EI source operating at an electron energy of 70 eV 
held at a temperature of 230 °C. Mass spectra and selected ion monitoring (SIM) were 
acquired using MSD ChemStation (Agilent Technologies, Santa Clara, CA). Full-scanmode 
was used to identify thymoquinone in the black cumin oil and characterize the synthetic 
compounds 2, [2H2]−2 and [
2H2]−1. After observation of the major ions for thymoquinone (1) 
and doubly deuterated thymoquinone ([2H2]-1), SIM mode (m/z 164.1 for compound 1 and 
m/z 166.1 for deuterium-labelled compound [2H2]-1) was performed for quantification of 
thymoquinone using SID GC−MS analysis. SIM mode (three selected ions at m/z 164.1, 
149.1, and 136.1 for compound 1) was applied for the quantification of thymoquinone using 
SIM GC−MS with standard addition and external calibration methods. 
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7.2.1 Synthesis 
The doubly deuterated thymoquinone ([2H2]-1) (Figure 7.1) was prepared and purified 
according to a similar method for preparation of deuterated 1, 4-benzoquinones (Charney et 
al., 1965; Lu et al., 2010) with modification. 
 
Figure 7.1 Scheme for synthesis of [
2
H2]-thymoquinone ([[
2
H2]-1).  i) Na2S2O4 in H2O/MeOH, RT, 
2 h; ii) a) 3.4 M D2SO4 in D2O, reflux 48h; b) Cool down to room temperature and work-up with 
H2O;  iii) CrO3 in 60 % HOAc in H2O, at -4 °C for 2h. 
2-Isopropyl-5-methyl-1, 4-benenediol (2). A solution of sodium hydrosulphite (348 mg, 
2.0mmol) in 2.0 mL of water was added to a solution of thymoquinone (164 mg, 1.0 mmol) in 
2.0 mL of methanol. The mixture was stirred for 2h at room temperature. The methanol was 
evaporated, and the resultant solution was extracted with ethyl acetate (3 × 10 mL). The 
combined organic phase was washed with water (3 × 10 mL) and then dried over sodium 
sulphate. After evaporation of ethyl acetate, 2-isopropyl-5-methyl-1, 4-benenediol 
(thymohydroquinone, 2, 70 mg, yield of 42%) was obtained. MS [electron ionization (EI)] m/z 
(relative intensity, %): 166.1 (43) [M]•+, 151.1 (100) [M − CH3]
•+, 137 (4), 123.1 (11), 95.1 (10), 
77.1 (10), 53.0 (3). Proton nuclear magnetic resonance (1H NMR) (300 MHz, CDCl3) δ: 6.56 
(s, 1H), 6.47 (s, 1H), 3.06 (m, 1H), 2.10 (s, 3H), 1.14 (d, 6H, J = 7.2 Hz, −CH(CH3)2).  
2-Isopropyl-5-methyl-1, 4-dideuterobenenediol ([2H2]-2). 2-Isopropyl-5-methyl-1,4-benenediol 
(2, 68 mg, 0.40 mmol) was refluxed for 48h in 3.4 M D2-sulfuric acid (D2SO4, 0.9 mL) in 
deuterated water (D2O, 4.2 mL). After cooling to room temperature, water (H2O, 10 mL) was 
added and the mixture was extracted with ethyl acetate (3 × 10 mL). The ethyl acetate 
extract was washed with water (H2O, 3 × 10 mL) and then dried over sodium sulphate. After 
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evaporation of the solvent, 2-isopropyl-5-methyl-1, 4-dideuterobenenediol ([2H2]-2, 45 mg) 
was obtained. MS (EI) m/z (relative intensity, %): 168.1 (44) [M]•+, 153.1 (100) [M − CH3]
•+, 
139.1 (3), 125.1 (11), 97.0 (10), 79.1 (8), 55.0 (3). 
2-Isopropyl-5-methyl-1, 4-dideuterobenzoquinone ([2H2]-thymoquinone ([
2H2]-1). 2-Isopropyl-
5-methyl-1, 4-dideuterobenenediol ([2H2]-2, 42 mg, 0.25 mmol) was dissolved in 60% acetic 
acid (2 mL) at −4 °C. Chromium trioxide (150 mg, 1.5 mmol) in 0.5 mL of 30% acetic acid 
was added, and the mixture was stirred at −4 °C for 2h. Water (10 mL) was then added to the 
mixture, followed by extraction with ethyl acetate (2 × 10 mL). After drying over sodium 
sulphate, the solvent was removed under vacuum to give crude doubly deuterated 
thymoquinone, which was sublimed to give pure 2- isopropyl-5-methyl-1, 4-
dideuterobenzoquinone ([2H2]-thymoquinone, [
2H2]-1, 28.0 mg, 43% overall yield based on 
thymohydroquinone (2)). The purity of compound [2H2]-1 was determined to be 97.7% by 
GC−MS using full-scan mode (Figure 7.2). 
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Figure 7.2 Full EI mass spectrum of thymoquinone (1) (A) and the doubly-deuterated 
thymoquinone ([2H2]-1) (B). 
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Figure 7.3 Possible electron impact fragmentation pathways for thymoquinone (1) (A) and for 
the doubly-deuterated thymoquinone ([
2
H2]-1) (B). 
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Figure 7.4
1
H -NMR spectra (300 MHz; CDCl3) of thymoquinone (1) (A) and [
2
H2]-thymoquinone 
([
2
H2]-1) (B) 
The disappearance of the signals at 6.52 and 6.45 ppm for H-3 and H-6 in the spectrum of 
[2H2]-1 indicates > 93% double substitution of deuterium for the two protiums of 1. The extent 
of double deuteration according to 1H NMR (Figure 7.4) and MS (see Figure 7.2) was greater 
than 93%. MS [electron ionization (EI)] m/z (relative intensity, %): 166.1 (100) [M]•+, 151 (54) 
[M − CH3]
•+, 138.1 (62) [M − CO]•+, 123.1 (73) [M − CH3CHCH3]
•+, 110.1 (19), 95.1 (63), 79.1 
(19), 69.1 (22), 54.1 (27) (see Figures 7.2 and 7.3). 1H NMR (300 MHz, CDCl3) δ: 3.06 (m, 
1H, −CH(CH3)2), 2.10 (s, 3H, CH3), 1.10 (d, 6H, −CH(CH3)2) (Figure 7.2B). 
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7.2.2 Development of a SID GC−MS Method for Quantification of 
Thymoquinone 
Calibration  
The analyte thymoquinone (1) and the internal standard [2H2]-thymoquinone ([
2H2]-1) were 
mixed in six ratios from 0.1 to 10 (5−500 μg/mL in hexane) and analyzed by means of 
GC−MS in triplicate. Calibration solutions were kept at 4 °C until analysis. The ratios of the 
area under the curve (AUC) of ion m/z 164.1 (AUC164) for compound 1 to the AUC of ion 
m/z 166.1 (AUC166) for compound [2H2]-1 were plotted against the concentration ratio of 
compound 1 to compound [2H2]-1 (Figure 7.5). The linearity of the calibration regression line 
was R2 = 0.99. The equation obtained was y = 0.843x+ 0.2297 (1/[2H2]-1). The limit of 
detection (LOD) was 0.16 μg/mL with a signal-to-noise ratio of 3:1, and the limit of 
quantification (LOQ) (10:1)26 was 0.50 μg/mL respectively. When using splitless injection 
mode, LOD and LOQ for thymoquinone were 0.04 and 0.16μg/mL, respectively. 
 
Figure 7.5 Calibration curve for the SID GC-MS method (Inset shows the mass spectrum of the 
selected ion at m/z: 166.1 and 164.1 for 1 and [
2
H2]-1, respectively). Results are the means ± SD 
for n = 3 independent experiments. 
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Quantification of Thymoquinone in the Black Cumin Seed Oils by SID GC−MS 
 A sample of black cumin seed oil (50 μL) was added to a 10 mL volumetric flask, and 
hexane was added to the mark. Aliquots of the diluted oil (200-fold) in hexane (980 μL) was 
spiked and mixed with a solution of compound [2H2]-1 in hexane (20 μL, 1.0 mg/mL). A total 
of 1 μL of sample was injected into the GC−MS instrument. Each black cumin seed oil 
sample was prepared 3 times and analysed with three replicates. 
Method Validation 
 Recovery experiments were performed with a sample of Manako black cumin seed oil. An 
aliquot of the diluted Manako oil (200-fold) in hexane (920 μL) was spiked with an increasing 
amount (20, 40, and 60 μL) of compound 1 dissolved in hexane (1.0 mg/mL) and mixed with 
20 μL of compound [2H2]-1 in hexane (1.0 mg/mL). Finally, hexane was added to give 1.0 mL 
of black cumin seed oil solution. Aliquots (1 μL) of the diluted oils were analyzed using the 
SID GC−MS method described above. Three replicates were performed. To study the intra- 
and inter-day imprecisions of the SID GC−MS method, diluted Manako oil in hexane (200-
fold) was analyzed. Relative standard deviations (RSDs) were determined for intra- and inter-
day variations based on a set of 9 (in 1 day) and 15 (on 5 different days) measurements SIM  
GC−MS Analysis of Thymoquinone Using Standard Addition and 
External Calibration 
Standard Addition 
An aliquot of the diluted (200-fold) Manako and Avena oil (800 μL) was added with an 
increasing amount of compound 1 in hexane to make oil solutions (1.0 mL) that contained an 
additional 40, 60, 80, 100, 120,140, and 160 μg/mL of compound 1. Linear calibration curves 
(R2>0.99) were obtained by plotting the AUC for the three selected ions (m/z 164.1, 149.1, 
and 136.1) versus the concentration. Each measurement was repeated in triplicate. 
217 
 
 
 
Figure 7.6 External calibration curve for thymoquinone (1) using SIM GC-MS method (Inset 
shows the mass spectrum of the selected ions for 1 at m/z 166.1, 149.1, and 136.1). Results are 
the means ± SD for n = 3 independent experiments. 
External Calibration 
Quantification of thymoquinone using external calibration was carried out by comparing the 
AUC for the three selected ions (m/z = 164.1, 149.1, and 136.1) of compound 1 in the diluted 
oil samples to those defined standard solutions of compound 1 dissolved in hexane. A 
sample of oil (50 μL) was diluted with hexane (10 mL) in a 10 mL volumetric flask, and an 
aliquot (1μL) of the diluted samples were analyzed via SIM GC−MS. Each measurement was 
performed in triplicate. The quantity of thymoquinone was determined using a five-point 
response curve based on the analysis of standard solutions. Those solutions contained the 
defined amount of thymoquinone in different concentrations ranging from 5 to 80μg/mL. The 
calibration curve (Figure 7.6) obtained was y = 2.2852x − 6.5186 (R2 =0.99), where y is the 
AUC/103 and x is the concentration of thymoquinone (μg/mL). The LOD was 0.10 μg/mL  
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with a signal-to noise ratio of 3:1, and the LOQ (10:1) was 0.31 μg/mL. When using splitless 
injection mode, LOD and LOQ were 0.02 and 0.08 μg/mL, respectively. 
7.3 RESULTS AND DISCUSSION 
Synthesis of a Stable Isotope-Labelled Thymoquinone  
The scheme of synthesis of the doubly deuterated thymoquinone ([2H2]-1) is shown in Figure 
7.1. Thymoquinone (1) was first reduced to thymohydroquinone (2) by sodium hydrosulphite. 
The two protiums (H-3 and H-6) of compound 2 were then exchanged by deuterium in 3.4 M 
D2SO4 in D2O under refluxing for 48h. After cooling to room temperature, the deuterated 
thymohydroquinone ([2H2]-2) was obtained after workup with H2O rather than expensive D2O. 
Finally, compound [2H2]-2 was oxidized with CrO3 in 60% HOAc to yield compound [
2H2]-1 
(17% overall yield). GC−MS shows a single peak with high purity (97.7%) based on GC−MS 
(Figure 7.2) and 1H NMR (Figure 7.4) for compound [2H2]-1. A comparison of the EI−MS 
spectrum of thymoquinone (1) to that of compound [2H2]-1 (Figures 7.2 A and 7.2 B) showed 
that a mass increase of the molecule ion m/z 164.1 by two deuterium atoms to m/z 166.1, 
which confirmed [2H2]-1 was the predominant isotopologue. The electron impact 
fragmentation pathways for compounds 1 and [2H2]-1 are very similar because of the 
substitution of H-3 and 6 of compound 1 by two deuteriums (Figure 7.3). The isotopic 
distribution of compound [2H2]-1 detected by GC−MS was found to be 2.0% natural [
2H] 
abundant compound 1, 5.0% compound [2H1]-1, and 93.0% compound [2H2]-1. Further 
comparison of the 1H NMR of compound 1 (Figure 7.4 A) to that of compound [2H2]-1 (Figure 
7.4 B) shows the disappearance of peaks for H-3 and H-6 because of the protium/deuterium 
exchange, again confirming the presence and position of two deuterium atoms in 2-isopropyl-
5-methyl-1,4-dideuterobenzoquinone ([2H2]-1). It shows only minor protium abundance of 
4.0% at position C-3 and 4.0% at position C-6 of compound [2H2]-1 (Figure 7.4), which is 
consistent with a high degree of double deuteration of compound [2H2]-1 found by GC−MS 
(Figure 7.2). Because only 2.0% natural [2H] abundant compound 1 was present in the 
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synthetic compound [2H2]-1 and less than 2.0% of the third isotopic peak of compound 1 (m/z 
166.1) was detected, the ratios of the AUC for ion m/z 164.1 for compound 1 to the AUC for 
ion m/z 166.1 for compound [2H2]-1 were used for the calibration and quantification of 
thymoquinone (1) using the SID GC−MS method. Compound [2H2]-1 was found to be stable 
in hexane for more than 6 months in the dark and, therefore, is suitable to be used as an 
internal standard for the SIDA. 
Establishment of a SID GC−MS Method 
The conditions for gas chromatographic separation were optimized to quantify thymoquinone 
(1) in black cumin seed oil within only 10 min (Figure 7.6). Figure 7.6A shows a typical total 
ion current (TIC) gas chromatogram of the Manako oil sample spiked with compound [2H2]-1 
using full-scan mode. A number of compounds can be detected. SIM (m/z 164.1 and 166.1 
for compounds 1 and [2H2]-1, respectively) mode was used to quantify compound 1 in the oil 
using SID GC−MS (chromatogram not shown). Panels B and C of Figure 7.7 shows the 
reconstructed ion chromatograms of compounds 1 (m/z 164.1) and [2H2]-1 (m/z 166.1) in the 
Manako black cumin seed oil. Compounds 1 and internal [2H2]-1 were co-eluted at 4.81 min. 
A calibration graph (Figure 7.6) was plotted from a mixture of known mass ratios of 
compounds 1 and [2H2]-1 and their corresponding peak area ratios in GC−MS by linear 
regression analysis. This calibration curve showing a linear response (R2 =0.99) could 
enable the determination of the quantity of thymoquinone in the samples based on their 
measured ion intensities. 
Recovery experiments were performed to check the trueness of the SIDA method. Specified 
quantities of thymoquinone (1) were added to the diluted Manako oil sample in three different 
concentrations before using SID GC−MS analysis. The quantity of compound 1 was 
measured and compared to those found in the blank diluted Manako oil sample as the 
control (Table 7.1). The mean recovery rate was determined to be 99.1 ± 1.1% RSD based 
on the amount of compound 1 added to the diluted oil sample. These results demonstrated 
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that the developed SID GC−MS is a reliable, rapid, and accurate method for quantification of 
compound 1. Thymoquinone in five marketed oil products was quantified, and their results 
are listed in Table 7.2. The concentration of thymoquinone ranged from 3.34 to 10.8 mg/mL. 
Manako oil has the highest content of thymoquinone, while CEBRA oil has the lowest content 
of thymoquinone. 
Table 7-1 The Recovery Rates for the Quantification of Thymoquinone in Black Cumin Seed Oil 
(Manako) Determined by a SID GC-MS Method (Data were expressed as the Mean±RSD, n=3) 
Amount of 1 
added [µg/mL] 
Conc. 
Calculated 
[µg/mL] 
Conc. 
Determined 
[µg/mL] 
Recovery [%] Average 
Recovery [%] 
  50.6±0.64   
20.0 70.6±0.64 71.6±0.98 101.4±1.7  
40.0 90.6±0.64 85.2±0.59 94.5±0.93 96.8±2.1 
60.0 110±0.64 104.7±0.51 94.7±0.7  
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Figure 7.7 Typical total ion current chromatogram (A) and reconstructed ion chromatograms of 
thymoquinone (1) (B) and deuterium-labelled thymoquinone ([
2
H2]-1) (C) in Manako black cumin 
seed oil spiked with [
2
H2]-1. 
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Table 7-2 Quantification of Thymoquinone in Black cumin Seed Oils Via SIDA GC-MS, External 
Calibration, and Standard Addition Methods (Data were expressed as the Mean± RSD, n-=3). 
Black cumin 
seed oil 
 
SIDA GC-MS 
Concentration (mg/mL) 
(n=3) 
External calibration 
 
Standard 
addition 
Manako 10.78±0.14 8.95±0.03 10.60±0.45 
Avena 7.27±0.14 7.33±0.08 7.17±0.13 
CEBRA 3.34±0.07 2.96±0.18 * 
Iman 7.23±0.05 6.02±0.09 * 
This Health 7.74±11 7.03±0.10 * 
* Concentration not determined. 
 
Cross-Validation of the SID GC−MS Method 
The standard addition method can also overcome the matrix effects and is often used for the 
validation of the SIDA method (Stanford et al., 2007; Stark et al., 2011). 
To validate the SID GC−MS method developed above, the data obtained using SID GC−MS 
were compared to those found using standard addition and external calibration (Table 7.2). 
Three characteristic ions (m/z 164.1, 149.1, and 136.1) for compound 1 were selected for the 
quantification of thymoquinone using standard addition and external calibration. An external 
calibration curve with a linear response (R2 = 0.99) (Figure 7.6) was attained by linear 
regression analysis of the AUC versus the concentration. Quantification based on the 
standard addition and external calibration showed 98.1 ± 1.2 and 82.9 ± 0.3% of compound 1 
in Manako oil and 98.6 ± 0.4 and 100.8 ± 1.1% of compound 1 in Avena oil (calculated from 
data in Table 7.2) when compared to the results obtained by means of SID GC−MS, 
respectively. 
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The standard addition and SID GC−MS results revealed very similar concentrations of 
compound 1 in Manako and Avena oils (differences are less than 2%), therefore validating 
the accuracy and advantage of the SIDA method. The concentrations of thymoquinone in all 
five oils determined by external calibration generally agreed with those determined from 
SIDA and/or standard addition methods (differences range between 1 and 17%). The slight 
discrepancies are probably due to matrix effects from the different preparations of these 
black cumin seed oils (Stanford et al., 2007). The intraday precision of the SID GC−MS 
method for compound 1 showed a RSD of ±1.3% (n = 9) by analysing diluted Manako oil in 
hexane in nine independent measurements in 1 day. Inter-day precision studies with diluted 
Manako oil revealed a RSD of ±5.9% (n = 15) in three independent measurements in each 
day for 5 days. These data again demonstrate that the SID GC−MS method is a reliable, 
rapid, and accurate analytic means for thymoquinone in black cumin seed oils. 
In previous reports, thymoquinone was quantified by several other analytical techniques 
(Houghton et al., 1995; Ghosheh et al., 1999; Michelitsch et al., 2003; Velho-Pereira et al., 
2011; Hadad et al., 2012). HPLC was used for quantification of thymoquinone in commercial 
black cumin seed oil (Ghosheh et al., 1999) and in different phytopharmaceuticals with a 
LOD of 0.006 μg/mL (10 μL of injection volume, ∼60 pg), (Hadad et al., 2012). Quantification 
of thymoquinone in herbal extracts and oil was also achieved using HPTLC with LOD of 50 
ng/spot (Velho-Pereira et al., 2011). A differential pulse polarographic method was 
developed for the determination of thymoquinone in black seed oil, where LOD was found to 
be 0.05 μg/mL (10 mL of volume, ∼500 ng) (Michelitsch et al., 2003). The content of 
thymoquinone in black cumin seed oils was also found to be in the range of 0.13−0.17% 
(w/v) of the oil by GC (Houghton et al., 1995). In our GC−MS methods, where split injection 
mode (1:10) was used to avoid overloading samples, LODs of thymoquinone for SIM 
GC−MS and SID GC−MS were found to be 0.10 and 0.16 μg/mL (1 μL of injection volume, 
∼100 and 160 pg), respectively. However, for trace analysis of thymoquinone, LODs can be 
further improved using splitless injection mode and range from 0.02 to 0.04 μg/mL (1 μL of 
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injection volume, ∼20−40 pg). Therefore, the sensitivities of GC−MS methods are 
comparable to that of HPLC and are higher than those of HPTLC and differential pulse 
polarographic methods. Furthermore, GC−MS and/or SID GC−MS methods have 
advantages of identifying analytes and overcoming matrix effects over other analytical 
methods (Allen et al., 1994; Stanford et al., 2007). 
In summary, synthesis of a highly pure deuterated thymoquinone has been achieved for the 
first time, which enables us to develop a SIDA of the biologically important thymoquinone in 
black cumin seed oil using GC−MS. Cross validation using standard addition confirms the 
accuracy and reliability of the SIDA method, which can quantify a large number of black 
cumin seed oil products for their quality control in high-throughput means. Synthetic 
deuterated thymoquinone and the SID GC-MS method should also be useful in the studies 
on the mechanism of binding thymoquinone to proteins, (Charney et al., 1965; MacDougall et 
al., 1980; Li et al., 2005, 2006; Lu et al., 2010; El-Najjar et al., 2011; Stark et al., 2011) in 
vitro and in vivo pharmacokinetics of thymoquinone, which are ongoing in our laboratory (Li 
et al., 2013). 
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Chapter Eight  
General Discussions, Conclusions and Outlook 
Significant Findings 
This research work on ‘Identification, Semi-synthesis and Evaluation of Anti-Ovarian cancer 
Compounds from Plants used in Traditional Medicines’ have been carried out. Two 
approaches were employed in the research: Investigation of the anti-ovarian cancer activities 
of three selected medicinal plants and semi-synthesised TQ analogues. The study reported 
the presence of a number of anti-cancer compounds, some of which have previously being 
identified. The synthesis of two novel anti-cancer compounds; 2-Ethylamino-6-isopropyl -3-
methyl- 1,4-benzoquinone (compound 4) and 2-(4’-Fluoroanilinyl)-5-methyl-p-benzoquinone 
(compound 8) were achieved in this research. While the anti-cancer activities of two 
previously synthesised compounds; 6-Isopropyl-2-methylamino-3-methyl-1,4-benzoquinone 
(compound 3) and  2-Dimethylamino-5-methyl-1,4-benzoquinone (compound 6) were 
reported for the first time in this research work. Evaluation of the cytotoxicities of the 
bioactives compounds obtained in this studies showed that palmatine, securinine and 6 were 
the most potent compounds with potentials as monotherapeutic agents and in combination 
with carboplatin or paclitaxel. Other likely drug candidates which also possess 
chemopreventive potentials identified include; lauryl gallate (which is more potent than 
carboplatin), betulinic acid and gallic acid. Three potentially chemopreventive compounds 
were also identified; Urs-12-en-24-oic acid, 3-oxo-, methyl ester, cis-Catechin and cis-
Gallocatechin. The anti-cancer activities of two of the medicinal plants (M. discoidea and R. 
parviflora) investigated is being reported for the first time. Also, the findings of this study 
support the traditional use of A. wilkesiana for the treatment of cancer. Importantly, the 
research on R. parviflora is the first time report about the phytochemical and pharmacological 
investigations of a specie of the genus; Rutidea. Thus, this work is a ground-breaking 
research into the investigations of the genus; Rutidea. 
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Limitations of the study 
The main limitation of this study was the insufficient amounts of the plant fractions, which 
limited the possibility of identifying other bioactive compounds. It was expected that 1kg of 
pulverized plant materials would be adequate for the research work. However, this was not 
the case. 
Secondly, the fractionation of the aqueous extracts and highly polar fractions could not be 
undertaken as more intricate and advanced techniques such as extractions with buffers, ion 
exchange chromatography, gel filtration and desalting would be required inorder to achieve a 
separation of the constituents (Shimizu et al., 2006), which due to time and resources 
constraints were not deemed feasible. 
Other challenges encountered in this research were time and resources constraints. For 
instance, some of the LC-MScompound peaks obtained from the bioactive hplcsubfractions 
of R. parviflora couldnot be unequivocally identified or authenticated with standard 
compounds. 
Future Work 
Further phytochemical studies would be carried out on Rutideaparviflora in order to establish 
the presence of the un-identified compounds in the plant. Other species of the Rutidea genus 
would be investigated for potential bioactivities. Similarly, other un-researched species of 
Margaritaria and Acalypha would be investigated for potential bioactivities 
Semi-synthesis of more potent thymoquinone analogues would be carried out. The aim of 
this study would be the conjugation of some bioactive compounds with thymoquinone. The 
gallic acid pharmacophore would be exploited in semi-synthesis.  
The in vivo investigation of the anti-cancer activities of the identified bioactive compounds in 
this research would be carried out. 
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Prospects and Outlook 
“Life is Green” is a popular term, which emphasizes the pivotal role played by plants in the 
existence of mankind. Plants are an integral part of the human race, and is the principal 
source of the three basic necessities of life; food, shelter and clothing, without which the 
continued existence of the human race on planet earth may be questionable.  A fourth need 
of man has been identified as the need for medicine which cannot be over-emphasised. 
Historical records of 2600 BC, documented in clay tablets showed that plants have been 
used as medicine. Examples of such plants were papaver somniferum, commiphora species 
and glycyrrhiza glabra, which are still being used as remedies in modern times (Newman et 
al., 2000). 
Further documentation has also shown that diverse ethnic groups have employed medicinal 
plants in the treatment of ailments, for instance, the ancient civilizations of China, Egypt, 
India and Greek also had written evidences of the use of natural products as remedies for 
disease conditions. An inventory, such as, “Ebers Papyrus”, an Egyptian record, dated 1500 
BC, documented more than 700 drugs. Also, the Chinese “Materia Medica” dated 1100 BC, 
recorded over 600 medicinal plants (Cragg et al., 1997). But the isolation of active 
constituents from natural products began with the isolation of morphine from Papaver 
somniferum in 1806 by Friedrich Serturner (Cragg et al., 2005).  
These available documentations of medicinal plants have been beneficial in the isolation of 
pharmacologically important compounds, such as artemisinin, which have contributed to the 
decrease in the death toll from malaria. Even more the medicinal plants have provided a vast 
number of leads for the pharmaceutical industries in the development of chemotherapy. 
Paclitaxel, camptothecin and the Vinca alkaloids are some of plant leads with many synthetic 
analogues.  
Literature has shown that less than 20% of the 15% taxonomically classified plants (which is 
about 500,000 species) have been investigated for biological activities. Nearly 200,000 
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secondary metabolites obtained from plants have been documented in the Natural products 
dictionary (Kinghorn et al., 2011). These research efforts have yielded 170,000 diverse 
structures.  This is an indication that plant-based drug discovery is very relevant. Despite the 
availability of this rich archive of plant-derived structures, clinical trials have utilised just 15% 
of this number and a greater majority (close to 60%) (CHEMnetBASE, 2013) of the drugs 
used were obtained from just 10 taxonomically classified families, with 235 trials conducted 
for anti-cancer activities (Sharma et al., 2013). This situation may be a lack of compelling 
evidence of the pharmacological activities of some of the plant-derived structures. This 
underscores the invaluable contributions of pharmacological studies in harnessing the 
potentials of medicinal plants. Another possibility is the reluctance of the scientific community 
to probe other genuses within a family, once some pharmacological compounds have been 
obtained from a particular genus in the family. Researchers, tends to focus on a genus that 
have been shown to hold some promise at the expense of the seemingly irrelevant genuses. 
A true case scenario is the Phyllanthaceae family. Much of the pharmacological 
investigations were carried out on species of the genus Phyllanthus. This is evident from the 
reviews and textbooks on the Phyllanthus genus (Calixto et al., 1998; Patel et al., 2011; 
Kuttan et al., 2012). Whereas other genuses, such as Martretia, and Meineckia scarcely 
have any mention in literature.  Margaritaria, one of the genus in the Phyllanthaceae family, 
was not investigated for anti-cancer activities until this present research work demonstrated 
the anti-cancer potentials of M. discoidea; one of the thirteen species of this genus. Given 
the above-mentionedpercentage of researched plants, it is very likely that there exist a vast 
majority of plant families and genuses (for instance, the genus; Rutidea, whose specie R. 
parviflora was investigated in this research) that have not been brought to the search light of 
the scientific community. This class of un-researched plants could be latent sources of 
desirable pharmacological activities.  
Ethnopharmacological database is a viable means of discovering medicinal plants. Most 
successful plant-based Investigations have relied on the traditional medicine information of 
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indigenous communities, for instance, the medicinal uses of the cinchona bark from which 
quinine was derived were first discovered by the Quechua people of Bolivia and Peru, who 
used the plant in the treatment of fever, before its anti-malarial properties were, validated 
(Motley 2010). Similarly, Artemisia annua, from which artemisinin, a renowned anti-malarial 
drug which has recently been shown to possess anti-cancer activity, has been in use in the 
traditional Chinese medicines (TCM) for a very long time (Tu1981). Again, a comparison of 
the Ethnopharmacological uses and research-validated activities of plant-derived drugs 
showed that 80% of 122 drugs had activities related to the traditional medicinal uses of the 
plants (Fabricant et al., 2001). 
In this present research, the documented traditional use of Acalypha wilkesiana was 
employed in the selection of the plant for anti-ovarian cancer activity, with the aim of finding 
the bioactive compound responsible for this anti-cancer activity.  It is worthy to note, that 
most ethnopharmacological information are undocumented in many developing countries, 
but keen researchers, could collaborate with other researchers in such countries and obtain 
these important ethnopharmacological clues. It may be said that tropical and sub-tropical 
climates are key locations for medicinal plants, given the body of existing knowledge of 
medicinal plants from these regions. Studies have also shown that the tropical rainforests 
have been the most harnessed locations for the collection of medicinal plants, as a result of 
the rich and very diverse floral present in these areas. However, it is pertinent to note that the 
rainforests which are the habitats of most of the endemic species are threatened by rapid 
deforestation occasioned by population explosion in these regions (Burslem et al., 2001; 
Pitman et al., 2002). 
Regions such as parts of Africa, Asia, South and Central America need to be combed in 
search for un-researched plants, as some plants are known to be endemic to specific 
locations. This fact has been established in Africa. The documented record showed that a 
vast majority of African plants could be found solely in the continent (White 1983), of which 
Madagascar, an extensive island country situated off the southeast coast of Africa, is a 
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unique region for medicinal plants. 4,900 of the 12,000 identified plant species found in the 
unexplored rainforest regions on this island country are endemic to the country; with the 
percentage of endemism documented as 82% (McNeely et al., 1990). An interesting 
observation is that close to 90% of the animals on this island, such as lemurs and fossa are 
found only in Madagascar (Hobbes et al., 2008). The country has been classified as a 
‘biodiversity hotspot’ by Conservation International (Conservation International 2007). The 
uniqueness of Madagascar has made some ecologists refer to the island as the ‘eighth 
continent’ (Hillstrom et al., 2003).  A number of novel anti-ovarian cancer compounds were 
recently isolated from two Madagascar plants; Tarenna grevei (Drake) Homolle (Rubiaceae) 
and Tarenna Madagascariensis (Baill.) Homolle by two groups of researchers: Kingston, D. 
and co-workers in 2012 and the research team of Salmoun, M. in 2007 (Kingston et al., 
2012; Salmoun et al., 2007).    
Planned investigations of the anti-cancer activities of medicinal plants commenced about 60 
years ago, with the discovery of the vinca alkaloids (vinblastine and vincristine) in the 1950s 
(Cragg et al., 2005). Thus anti-cancer researches on plants are relatively recent, with fewer 
plants investigated, compared to studies on other bioactivities (Tan et al., 2006; Cragg et al., 
2009).  A compilation of the anti-cancer drugs in use from 1981-2006 showed that 47.1% of 
the 155 clinically approved oncological drugs were derived from natural products, either as 
unmodified compounds, or semi-synthesised analogues, or synthesised based on natural 
product leads (Cragg et al., 2007). A further 5 drugs were approved in 2010: romidepsin from 
the bacteria Chromobacterium violaceum and used in the treatment of T-cell Lymphomas 
and Peripheral T-cell lymphomas(NCI 2009); cabazitaxel a derivative of paclitaxel used in the 
treatment of prostate cancer(Sanofi-Aventis 2010); eribulin, a synthetic macrocyclic analogue 
of  halichondrin B which was obtained from species of Halichondria- a sea sponge and is 
used in the treatment of Breast cancer (Towle et al., 2001; Yu 2005);  mifamurtide, a 
synthetic derivative of muramyl dipeptide (MDP), isolated from Mycobacterium species used 
in the treatment of osteosarcoma (Bin et al., 2016); and vinflunine , a derivative of vinca 
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alkaloids used in the treatment of metastatic transitional cell cancer of the urothelial tract 
(Kruczynski et al., 1998). This underscores the importance of plants as sources of new 
cancer chemotherapeutic (Cragg et al., 2013).  
The role of chemical synthesis, in the drug discovery process, is of great importance. Most of 
the obtained plant-derived drugs were found in insufficient amounts in the wild. For instance, 
the stem barks of about 2,000- 3,000 trees were harvested to enable the isolation of 1 kg of 
Taxol (paclitaxel), (Runowicz et al., 1993; Suffness et al., 1995). The continued reliance on 
medicinal plants for the provision of paclitaxel for clinical use would have been 
unsustainable. But through semi-synthetic methods, paclitaxel is commercially produced. 
Secondly, the need to optimize the activity of the plant-derived compound is another 
compelling reason, why semi-synthesis is required. It could be observed that many synthetic 
analogues have been derived for paclitaxel, camptothecin and the Vinca alkaloids. The 
combination of natural product and chemical synthesis in the drug development process 
could be likened to the two sides of the same coin. 
In plant-derived compounds for anti-cancer research, much emphasis has been given to the 
discovery of novel or more potent compounds. An area, which should be explored, is the 
identification of chemopreventive compounds. Most studies target compounds with very low 
IC50s in the range of nanomolar- single digit micromolar. While this is commendable, as more 
potent drugs with less-side effects are required. Another strategy should be geared towards 
discovery or identification of chemopreventive compounds, which may be present in plants 
that have been used as food for generations. Chemopreventive compounds are necessary, 
as these compounds could be beneficial in the prevention of cancers. One such compound 
that has demonstrated chemopreventive activity is thymoquinone, which is a popular 
mediterranean herb that has served both culinary and medicinal uses. The agent was shown 
to inhibit the development of pancreatic cancer by researchers at the Kimmel Cancer Centre 
at Jefferson, USA (Kimmel Cancer Centre 2009).  
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Gallic acid is another compound with potentials for chemoprevention. The compound is 
found in many fruits and vegetables. The cytotoxicity of gallic acid has been evaluated in a 
panel of cancer cell lines and in this present study. The compound showed moderate 
activities, and warrants further investigations.  
Also, the gallic acid pharmacophore is another entity for exploration in semi-synthesis, this is 
because several studies including this present study have shown that some gallic acid 
analogues such as laurylgallate, demonstrated enhanced activity on cancer cells, with IC50 in 
the nanomolar-single digit micromolar range. Thus the synthesis of more bioactive 
compounds with the gallic acid pharmacophore is potentially a noble pursuit. 
Drug combination is a new approach to disease treatment, which is been explored in the 
treatment and management of cancer. Currently, cancer regimens often employ a 
combination of two or more drugs, to improve therapeutic outcomes and minimize side 
effects. A significant drawback of clinically used cancer drugs is the very serious side effects, 
such as heart damage, myelosuppression, hair loss, nausea and vomiting (Tacaret al., 
2013), unusual bleeding, painful joints and vomiting (Ozcelik et al., 2010). A key goal of drug 
combination studies is to discover new agents which could sensitize cancer cells to clinically 
used drugs, thus result in a reduction of the drug dosage and an attenuation of side effects. 
A number of moderately active compounds reported in literature and from this study would 
be suitable candidates for this desired synergism. Agents such as securinine, palmatine, 2-
dimethylamino-5-methyl-1,4-benzoquinone, and betulinic acid, warrants further 
pharmacological investigations and elucidation of their mechanism of action, as these 
compounds possess potentials as drug combination candidates and also as monotherapeutic 
agents. 
It is pertinent to note that medicinal plant researches are not without some challenges. An 
often cited disadvantage has been the repeated isolation of previously known compounds 
and the isolation of bioactive compounds in minute quantities. These observations and 
233 
 
experiences should not hinder plant-based research, as seen in this present study. The 
discovery of new sources of a previously identified compound is also a novel achievement, 
as this new finding adds to the existing body of literature about the compound. Also, an 
alternative source of a bioactive compound has been discovered, which may be beneficial for 
further studies. The isolation of minute amounts of bioactive compounds is another obstacle 
in plant-based research. However, these challenges present the opportunities for 
collaborative research, which could help resolve most of these issues. 
Finally, this research work has undertaken the anti-cancer investigations of two plant 
genuses; Margaritaria and Rutidea. Most of the Rutidea species are endemic to Africa and 
there are no documented phytochemical or pharmacological data until this present study, 
which have brought the genus into the pharmacological spotlight of the scientific community. 
It is hoped that similar studies of previously unknown medicinal plants would be embarked 
on, as it is glaring from this study that medicinal plant researches are merited. Thus, a 
scientific expedition into the vast reserves of plants is very relevant and timely in unlocking 
the tremendous potentials yet untapped. 
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